Final Programme

Transcript

Final Programme

Under the patronage of
Comune
di Firenze
Final Programme
E
M
O
C
BE ISGE
ANRTIFIED NER
CE ACTITIO
PR
00 NTS
1
Y
L
ON RTICIPA
PA MITTED
AD
NEUROENDOCRINOLOGY
AND
FEMALE
REPRODUCTION
VENEZIA ITALY, 28-30 October 2010
2ND TRAINING COURSE
IN GYNECOLOGICAL ENDOCRINOLOGY OF THE
INTERNATIONAL SCHOOL OF GYNECOLOGICAL
AND REPRODUCTIVE ENDOCRINOLOGY
NEUROENDOCRINE DISEASES
AND MENSTRUAL CYCLE CONTROL
NEUROENDCRINE CHANGES
FROM 40 YEARS ON
THERAPEUTIC USE OF
ESTRO-PROGESTINS DURING FERTILE AGE
THE MENOPAUSAL WOMAN’S PATHOPHYSIOLOGY
THE MENOPAUSAL WOMAN’S CLINICAL
MANAGEMENT
Speakers D Archer, B Benedetto, S Berga, J Bitzer,
P Bouchard, M Brincat, G Creatsas, BC Fauser,
JM Foidart, M Gambacciani, U Gaspard,
AD Genazzani, AR Genazzani, A Graziottin,
P Kenemans, M Lachowsky, A Milewicz, RE Nappi,
S Palacios, N Panay, R Pasquali, F Petraglia,
A Schindler, D Serfaty, T Simoncini, J Stevenson, J Studd
List of contents
Welcome note
4
The International Society
of Gynecological Endocrinology
5
Gynendo News
6
The International Federation of the
Societies of Gynecological Endocrinology 7
Congress Area Map
8
Registration and Secretariats
10
Scientific Secretariat - Organizing Secretariat
Congress Secretariat Desk - Registration Fees
General information
12
Lunch points - Coffee - Official languages
Insurance - Certificate of Attendance
Customer Satisfaction - Personal Data Protection
Social Events
13
Scientific information
Congress on-line - Computer Projection
Preview Rooms - Oral Presentations
Poster Session - Poster awards
14
List of the abstracts winners
of the under 34 competition
15
Sponsors and exhibitors Exhibition Area Map, Company profiles
20
Continuous medical education
UEMS, AMA, ECM, AMB, SGGG
28
Boards & assemblies
29
II Congresso Nazionale ISGE Italia
Introduzione, Isge Italia, Segreterie,
Programma scientifico, Crediti ECM
31
Bollettino
di Ginecologia Endocrinologica
34
Scientific programme
Programme at a glance
Wednesday March 3rd
Thursday March 4th
Friday March 5th
Saturday March 6th
Sunday March 7th
37
38
40
43
59
75
86
Posters
93
14th world congress of Gynecological Endocrinology
Firenze, 4-7 March 2010
4
Welcome in the awesome city of Florence,
the centre of all Arts and Sciences, the city of
Leonardo da Vinci and Lorenzo il Magnifico… And the World capital of Gynecological Endocrinology! The 14th World Congress
of Gynecological Endocrinology has doubled
the number of submitted abstracts. We have
here 100 brilliant and young scientists from
all over the World that won a tight scientific
competition being granted free registration
and hospitality. We will diffuse the scientific
sessions real-time with a unique Congress-online service, so that every participant will be
heard in the farthest areas of the World with
an impact that was not imaginable a few years
ago. Plus, we have an effective e-mail bulletin, GynEndo News, that will be sent out
every day from the Congress, with interviews,
opinions and scientific contents, to make sure
that all the subscribers that did not make it to
Florence will have a share. But this was not
enough. A new creature has seen the light,
the International School of Gynecological
and Reproductive Endocrinology. The School
is devoted to develop education and to help
clinicians to master the art of gynecological
endocrinology. The first International course
will be held in Florence, and it will open a
series of itinerant courses that will bring education to everyone in the World. Our Society
is thus lively and vibrant, and I am glad to
welcome you here in this unique, fantastic
city, to enjoy one of the best scientific events
in our area...
Andrea R. Genazzani
President of the International Society of
Gynecological Endocrinology
ISGE Executive Committee
(2008-2012)
President
A.R. Genazzani
Pisa, Italy
Treasurer
B. Lunenfeld
Tel-Aviv, Israel
Executive Secretary
T. Simoncini
Pisa, Italy
Members
F. Al-Azzawi, Leicester, UK
S. Berga, Atlanta, USA
M. Birkhaeuser, Bern, Switzerland
P. Bouchard, Paris, France
M. Brincat, Malta
N. De Melo, Sao Paulo, Brazil
L. Devoto, Santiago, Chile
J.M. Foidart, Liege, Belgium
P. Kenemans, Amsterdam, Netherlands
T. Maruo, Kobe, Japan
M. Mendelsohn, Boston, USA
A. Milewicz, Wroclaw, Poland
F. Naftolin, New York, USA
E.H.Y. Ng, Hong Kong, China
F. Petraglia, Siena, Italy
A.E. Schindler, Essen, Germany
C. Simon, Valencia, Spain
E. Simpson, Clayton, Australia
N. Siseles, Buenos Aires, Argentina
V. Smetnik, Moscow, Russia
B. Tarlatzis, Thessaloniki, Greece
B. von Schoultz, Stockholm, Sweden
of Gynecological Endocrinology (ISGE)
About the society
of Gynecological Endocrinology
is a non-profit organisation
established in 1986 for the
purposes of promoting science
and research into all aspects
of gynecological endocrinology
and communication between
scientists interested in these subjects.
The Society operates through the
monthly Journal of Gynecological
Endocrinology, the monthly
newsletter GynEndo News
and the biannual World Congress,
a major scientific event which
allows a perfect integration
of renowned faculty members
with talented young scientists
presenting innovative research.
VOLUME
BER
26 NUM
ISHED
1 � PUBL
MONTHLY
ARY 2010
� JANU
-3590
0951
� ISSN:
GYNECOLO
12/21/09
8:57 PM
CRIN
GICAL ENDO
xd
DGYE_I_26_02_COVER.q
Page 1
LOGICAGLY
GYNECCO
INOLO
R
O
D
EN
Y 2010
MONTHLY � FEBRUAR
2 � PUBLISHED
VOLUME 26 NUMBER
OLOGY
VOLUME
ENDOCRINOLOGY
GYNECOLOGICAL
IETY
AL SOC
ERNATION
THE INT
GY
RINOLO
RNAL OF
L ENDOC
ICIAL JOU
LOGICA
THE OFF
GYNECO
0
� ISSN: 0951-359
OF
26
No. 1
GYNECOLOGICAL
ENDOCRINOLOGY
Y OF
ATIONAL SOCIET
AL OF THE INTERN
THE OFFICIAL JOURN
ENDOCRINOLOGY
GYNECOLOGICAL
Now you are an ISGE Member
Welcome to the International Society of Gynecological Endocrinology. Registering to the World Congress you have automatically become a member of the Society for 2 years. In order to formalize your registration please come to the ISGE
stand in the Exhibition Area for confirmation or go online on
www.gynecologicalendocrinology.org and insert the access code
that you received together with the congress badge.
Confirming for free your registration you
receive
A password for free on line access to the
Gynecological Endocrinology Journal.
Free access to the Congress On Line (see page n.12
for more information).
GynEndo News, our monthly newsletter.
Access to information and news related to the Society’s
activities through our website www.gynecological
endocrinology.org.
The Gynecological Endocrinology Journal
Registering to the World Congress, and confirming for free
your ISGE membership at the ISGE Stand ( 19 , 20 , 21 ) or on
www. gynecologicalendocrinology.org you have been granted,
for private use, the online access to the electronic edition of the
Gynecological Endocrinology Journal (2 years).
You are kindly requested to collect your access code at the ISGE
stand.
Gynecological Endocrinology, the official journal of ISGE, covers
all experimental, clinical and therapeutic aspects of this ever more
important discipline. It includes, amongst others, papers related
to the control and function of the different endocrine glands in
females, the effects of reproductive events on the endocrine system, the consequences of endocrine disorders on reproduction.
2010
VOLUME 26
JANUARY
No. 2
FEBRUARY 2010
If you are interested in receiving the Print edition of the journal
you can subscribe at the following prices:
€95 one year (2010)
€170 two year (2010 and 2011)
Please contact our staff at the ISGE stand in the Exhibition Area;
for all further information please contact the ISGE Secretariat at
[email protected]
5
GynEndo News
www.gynendonews.com
6
GynEndo News is the friendly e-mail bulletin of the
International Society of Gynecological Endocrinology.
The bulletin is sent monthly to a growing list of currently more than 30.000 subscribers. It is the voice of the
Society and it carries in your mailbox opinions and news
in Gynecological and Reproductive Endocrinology.
After more than 40 issues, the bulletin is a lively forum, where the subscribers find cutting edge editorials
from members of the ISGE Board, special editorials,
freely available sessions of International Congresses,
access to selected contents of our Journal, Gynecological Endocrinology, as well as news from the
International scientific press and congress and course
announcements in the broader area of Gynecological
Endocrinology. It is thus the best tool to keep abreast
of the speedy developments in our field and to be
updated with science and clinical practice.
The special GynEndo Daily that will be sent out every
day from the ISGE Congress, with interviews, opinions
summaries and scientific contents, will be a special
event to ensure that all subscribers that did not make it
to Florence will share a taste of this unique event.
ER.qxd
DGYE_I_26_02_COV
12/21/09
8:57 PM
Page 1
MONTHLY
2 � PUBLISHED
VOLUME 26 NUMBER
� FEBRUARY 2010
But GynEndo News is changing. After the biannual congress, from April 2010, GynEndo News will
have a totally renewed editorial strategy, providing all
those who select to receive it with special educational
contents developed from the Board of the teachers of
the School of Gynecological and Reproductive Endocrinology. The new bulletin will therefore blend much
more that before science with clinical practice, trying
to provide the readers with cutting edge advances that
have an impact on their daily clinical activity.
So watch out for this new twist of this powerful electronic tool!
If you already receive the bulletin look into your
mailbox every month for this exciting series of new
contents, and if you don’t, go visit now
www.gynendonews.com and subscribe to GynEndo
News. It’s absolutely free and will be your invaluable
source of update in Gynecological Endocrinology
from now on…
� ISSN: 0951-3590
GYNECOLOGICA
GY
L ENDOCRINOLO
GYNECOLOGICAL
ENDOCRINOLOGY
OF
ONAL SOCIETY
OF THE INTERNATI
THE OFFICIAL JOURNAL GICAL ENDOCRINOLOGY
GYNECOLO
VOLUME 26
No. 2
FEBRUARY 2010
News in science and clinical practice
Abstracts from Gynecological
Endocrinology
Video lectures from the last congresses
Last editorials published
on GynEndo News.com
2010
Placental Hormones and identification of
jan
pregnancy at risk
Michela Torricelli and Felice Petraglia
dec 2009
Progesterone, Thyroid Hormone and Relaxin
in the Regulation of the Invasive Potential of
Extravillous Trophoblasts in Early Placental
Development
Takeshi Maruo
2009
Post hoc MRI’s cannot justify the conclusions of
WHIMS
Frederick Naftolin, Jennifer King, and John H. Morrison
nov
oct
2009
Endometrial progesterone receptors and
Levonorgestrel as emergency contraceptive
Alberto Palomino and Luigi Devoto
2009
Special Issues Daily from the 8th congress of the
European Society of Gynecology
with interviews, articles and lectures from the congress
sept
The International
Federation
of the Societies
of Gynecological
Endocrinology
(FISGE)
In occasion of the 12th World
Congress of Gynecological
Endocrinology held in Florence, Italy, on 2-5
March 2006, The International Federation of the
Societies of Gynecological Endocrinology (FISGE)
has been established.
The Federation is open to national societies
of gynecological endocrinology as well as to focus
groups of gynecological endocrinology of national
or international societies of gynecology, obstetrics
and/or endocrinology.
The main purpose of the Federation is to unite
all the societies of gynecological endocrinology
and/or the above-mentioned focus groups interested
in the study and the research of all aspects of
gynecological endocrinology, aiming to improve
the communication and the exchange of information
related to the activities of each society, to promote
the development of common scientific projects and
to advance the interchange of young and senior
researchers between those centres devoted
to gynecological endocrinology all over the world.
For all further information
Palazzo
dei Congressi
13
0 Ground Floor
7
Entrance9to
Congressi
13 GynEndo news
7 Hall Onice
www.gynecologicalendocrinology.org
or contact the ISGE Secretariat
T. +39 050503985 F. +39 0502207028
[email protected]
7
8
Congress Area Map
Limonaia
L
da
alfon
Via V
Congress Venue
Firenze Fiera
Piazza Adua, 1 50123 Firenze, Italy
T. +39 05549721
F. +39 0554973237
[email protected]
www.firenzefiera.it
Main Entrance
Piazza Adua
3
9
1
0
25
Palazzo affari
9
Floor
Palazzo dei congressi
and Auditorium
10
3
3
Services
0
W
PR
L
B
22
8
Conference Halls
1
2
3
4
4b
5
6
7
8
PR
2
2
4
16
17
18
19
20
B
1
21
1
12
13
7
Entrance
to P.Affari
Entrance to
Hall Affari4
0
14
15
Entrance to
Congressi
0
B
11
Hall Affari 1
Hall Affari 2
Hall Affari 3
Hall Affari 4
Hall Affari 5
Poster area
Hall Auditorium
Hall Onice
Hall Verde
Dedicated Rooms
9
4b
Secretariat
Internet Point
Preview Room
Lunch point
Bar
12
13
14
15
16
17
18
19
20
21
22
Il Bollettino
di Ginecologia
Endocrinologica
Presidential Room
GynEndo News
Press room
Open Curtesy room
Private meeting room
Private meeting room
ESG/SEG Board room
IMS Board room
Biomedical room
Faculty room
Hall Belvedere
Exhibition Area
5
10
11
PR
6
-1
11
11
W
Palazzo Affari
Palazzo Congressi
10
Registration and Secretariats
Congress website
www.isge2010.com
Scientific secretariat
Angiolo Gadducci, Paolo Artini, Vito Cela,
Franca Fruzzetti, Marco Gambacciani,
Carlo Luchi, Patrizia Monteleone,
Nicola Pluchino, Valeria Valentino
Dept. of Reproductive Medicine and Child
Development Division of Gynecology and
Obstetrics “P. Fioretti” University of Pisa
Via Roma 35 - 56126 Pisa, Italy
T +39 050503985
F +39 0502207028
[email protected]
Organizing secretariat
Biomedical Technologies srl
www.biomedicaltechnologies.com
Main Office and Accounting
Via P. Cugia 1 - 09129 Cagliari, Italy
T +39 070340293
F +39 070307727
[email protected]
Marketing and Communication
Via Metauro 19 - 00198 Rome, Italy
T +39 068546198
F +39 0685389063
[email protected]
Co-organizing secretariat
Advanced Medical Education
and Conventions S.A.
Via alla Ramogna 12 - P. O. Box 845 - 6601
Locarno 1, Switzerland
T +41 917521305
F +41 917519867
E-mail: [email protected]
www.ameducational.com
Congress secretariat desk
The Congress Secretariat is located on the
ground floor of Palazzo Affari. The Secretariat
observes the following opening hours
Pre-congress courses
Wednesday March 3rd
08.00 - 09.30 participants only
10.00 - 19.30
Thursday March 4th
07.30 - 13.00
14.00 - 19.00
Friday March 5th
08.30 - 13.00
14.00 - 19.00
Saturday March 6th 08.30 - 13.00
14.00 - 19.00
Sunday March 7th
08.00 - 13.00
Registration fees on site
(20% VAT included)
Delegate €650
Developing countries and East Europe €450
Residents, nurses and technicians €300
Accompanying persons €120
Daily registration €180
Registration for Office Operative Hysteroscopy
“see and treat” Practical activities (P.82) €50
Registration fee for the delegates
includes
Opening Ceremony
and Welcome Reception
Closing Ceremony
Access to all sessions and exhibition area
Congress kit
Abstract Book (in CD version)
CME credits and/or ECM Credits
Coffee and lunches
Lunch
Ticket 2
Lunch
Ticket 1
Friday March th
5
13.10/14.10
Thursday March 4th
13.10/14.10
Please collect with this ticket
1 Congress Bag
at the Bags Desk
highly purified
hFSH
for follicular
stimulation
IBSA’s whole in-house manufacturing cycle,
based on a patented purification process,
provides a full range of highly purified,
human-derived gonadotrophins
(hFSH, hMG and hCG).
Fostimon, IBSA’s HP-hFSH, is available
in vials of 75 IU and 150 IU
for subcutaneous administration.
Please, check availability and specifications of
marketing authorisation in your country.
For further details see full prescribing information.
IBSA Institut Biochimique SA
Via del Piano, P.O. Box 266,
6915 Pambio-Noranco, Lugano, Switzerland
Telephone +41 58 360 10 00 Fax +41 58 360 16 47
www.ibsa-international.com, [email protected]
Fostimon
11
12
ance
General Information
3
1
0
25
Limonaia
L
Palazzo affari
Lunch points
9
10
Floor
Personal Data
and Auditorium
Protection
Law no. 196/2003
Lunch bags will be distributed in the Limonaia.
You will22
3
3
find luch tickets in your congress
kit.
Personal data collected directly and/or
through third parties by controller and processor
Biomedical Technologies. Main Office
8
Coffee
in Cagliari Via Cugia 1, are processed in
Get free coffee or hot drinks at any time during the printed, computing and telematic form for
PR
congress from the automatic beverage dispensers locat- fulfilling contractual and lawful obligations
as well as for the effective handing of busi2
ed around the congress venue.
2
ness relations. The email addresses provided
may be used by Biomedical Technologies to
4
Official Language
send advertising
materials on events similar
16 17 18 19
20
Official language of the Congress is English. Italian is to those subject of the present business relathe official language of the 2nd Congress of the Italian tions. The non-submittal of data, where no
compulsory, will be evaluated from case to
B
Society of Gynecological Endocrinology.
case by the controller
and the resulting deci21
1
sions to be made will take into account the
1
importance of the required data in respect
Insurance 4b
business
relations, management. Data
The Congress Organizers cannot accept liability12for 13 of the
14
7
be disclosed in Italy and/or abroad,
personal injuries, loss or damage to property belong- may
strictly in accordance with the above-menEntrance
ing to Congress delegates
ffari their accompanying
tioned purposes, and consequently procto P.A(or
in15relation to the mentioned
persons), either during or as a result of the Congress essed,Enonly
trance to
ressiother persons: professionals and
ngby
Co
purpose,
to
e
nc Florence.
or during their stay
Entrain
0
0
Hall Affari4
as well as by persons allowed to
It is therefore recommended that delegates arrange their consultants
access to your personal data according to Naown personal health, accident and travel insurance.
tional or Community regulations. If necesB for the above-mentioned reasons, your
sary,
data may be disclosed to third parties. For the
Badges
11
reasons, our partners and/or employees
All registrants including registered accompanying per- same
may process your data in their capacity of exsons will receive a badge. 5Your personal badge allows ecutors or processors. The persons concerned
you access to all Sessions, Exhibition Area and Social PR may exercise all the rights set forth in art. 7 of
Events. Please remember to always wear your badge, L.6n. 196/2003 (including the rights of data
-1
corrections, updating, objects to data
also during social events. If you have lost your badge,
a access,
11
11
processing and cancellation).
The processor
new one can be purchased at the Congress Secretariat. “pro tempore” is the legal representative of
theW company.
Certificate of attendance
You will find your certificate of attendance together
with your badge. Please check it and in case you need
any change come from Friday 5th 14.00 to the “New
Registrations Desk”.
Customer Satisfaction
Inside your congress bag you will find the Customer
Satisfaction Form. Please do not ignore it.
It is a Compulsory Service as Biomedical Technologies is Quality Certified and moreover you help us to
improve our services. Please hand it back to the CME
Certificate desk.
2
2
4
16
a
fond
Social Events
17
18
19
20
13
B
1
21
1
4b
12
13
14
7
Entrance
to P.Affari
Entrance to
Hall Affari4
0
15
Entrance to
Congressi
0
Thursday March 4th
B
Opening ceremony
and aperitif in the exhibition area.
Drinks and snacks in the exhibition area
Main Entrance
in Palazzo dei Congressi.
11
5
PR
6
-1
11
11
Piazza Adua
W
Friday March 5th Social Evening “Arts in florence”
Guided visit and cocktail at the Bargello museum.
Please come to the Social Events desk to get your ticket
with entrance and tour time.
Only registered participants and registered accompanying persons may ask for the tickets. For organization
and safety reasons please tick to the time assigned to
you. No entrance will be allowed without tickets.
social evening
ce
Arts in Floren
Guided visit
the
and cocktail in
eum
Bargello mus
Saturday March 6th
Wine and cheese Poster Session in the poster area.
Scopone wines, cheeses and salami welcome you
together with the posters’ authors. Don’t miss!
Speaker’s dinner upon invitation
LID
NOT VATRANCE
FOR EN
rance ticket
Collect the ent
e from
with visiting tim
nts desk
the social eve
on “first come
Scheduling time
.
first take” basis
tes
ps every 15 minu
grou
in
Entrance
until 9.00 PM
from 7.00 PM
Palazzo Affari
5
0 Ground Floor
-1 Floor
5
5 Poster Area
da
alfon
Via V
B
14
1
Scientific information
21
1
4b
12
13
14
7
Entrance
to P.Affari
Entrance to
Hall Affari4
15
Entrance to
Congressi
0
0
1
Congress on-line
da
alfon
Via V
The 14th World Congress of Gynecological Endocrinology will be totally available
in multimedia format through the web on
Main Entrance
www.isge2010.com and www.gynecologicalendocrinology.org.
It consists in recorded
Piazza Adua
presentations of the Congress enjoyable
through the web. Typing in your personal
password, that will be given to you at the moment of the registration, you can access the
scientific sessions and view the sequence of
the slides of the presentations while hearing
the speaker’s voice; it will be possible to stop,
to go back, or see again what you consider
more interesting at any time.
Key Note
To enter the Congress online
you need the access code
included in the congress kit.
B
Preview rooms
Speakers of hall Auditorium, hall Onice and
hall Verde are Limonaia
kindly requested 5to hand
over
Palazzo affari
their Powerpoint persentation at the slide
center near hall Auditorium.
-1
L
Speakers of hall Affari 1, 2, 3, 4 are kindly requested to hand over their Powerpoint persentation at the slide center located on second
floor of Palazzo Affari.
Presentations must be brought at least one
hour before their session. Speakers presenting
4
in the early morning sessions should ensure
that they have handed over their slides during
the previous afternoon.
Oral presentations
11
25
9
10
3
Floor
Palazzo d
and Audit
PR
63
22
11
11
W
PR
2
2
16
17
B
1
1
4b
Oral Presentations will last about 8 minutes
each plus 2 minutes discussion. The presenters are kindly requested to respect the time
Entrance to
allotted for each presentation.
Hall Affari4
12
0
0
Poster session
The Poster Session will take place on Saturday
March 6th from 17.10 to 19.30. During the
The following contents will be available:
Poster Session, Poster Authors should stand by
Plenary Lectures
their Posters for presentation and discussion.
Plenary Sessions
Main Entrance
Posters must be set up on Saturday March 6th
Sponsored Symposia
Piazza Adua
from 13.00 to 16.00 and dismantled the same
Oral Presentations
day from 19.30 to 20.00.
The maximum size of the posters must be
Computer projection
Computer projection is provided in all con- 90cm x 90cm.
ference rooms via direct link with the preview The organizers cannot be held responsible for
room. No projection through own computers posters not removed on time.
is allowed. Kindly bring your presentation on
a multimedia support (CD-Rom, Pen Drive) Poster award
as a PowerPoint file. Please remember that the Three posters will be awarded each with a free
first slide of your presentation has to show registration to the 15th ISGE World Congress
your photo along with the name underneath. (Firenze, March 8-11 2012) including a free
No other software is accepted. No Slide Pro- accommodation for one person (overnight
jector is provided.
stay in a 3 stars hotel, double room). The
awards will be given during the Closing Ceremony on Sunday March 7th.
13
Entrance
to P.Affari
Palazzo affari
0 Floor
5
5
-1 Floor
5
PR
-1
11
5 Poster Area
1
List of the abstracts winners
of the under 34 competition
2010 marks a new strategic effort of ISGE aimed at promoting education and participation where it is most
needed…
The Scientific Contest held for the first time this year has allowed 100 excellent young scientist of under 34
years to be supported by the Society to join us in Florence, by providing free registration and accomodation.
The contest has been extremely tight, and although the scientific committee could select only 100 winners, the
scientific level was so high that ISGE decided to support anyway those who did not get through, by providing a
reduced registration rate to the congress. This is the first of a series of moves to help the young and the brightest
to contribute to ISGE and to its lively Congress.
the best
5 abstracts
Plenary Session
Winners under 34 Competition Symposium
4 march 2010, 16.30/18.30, hall Affari 3
Anti-Mullerian Hormone in the prediction of
menopausal transition or menopause; a follow-up
study
Broer Simone L, van Rooij I, Scheffer G, Eijkemans
M, Fauser BC, Broekmans FJ, (NL)
Characterisation of early ovarian cancer
biomarkers
Meehan Katie, Rainczuk A, Fairweather N, Stephens A
(AUS)
The Effects of Menstrual Cycle Phase & Stress
on Cognitive Flexibility
Sundermann Erin E, Mordecai K, Rubin LH, Eatough E, Savarese A, Maki PM (USA)
Magnetic Resonance Elastography Allows
Quantitative Assessment of Uterine Leiomyomas
Taran Andrei F, Stewart EA, Chen J, Gostout BS,
Woodrum DA, Felmlee J, Ehman DRL (USA)
ER17p, a peptide corresponding to the
regulatory platform P295-T311 of ER-alpha:
role in actin cytoskeleton, migration and
apoptosis
Pelekanou Vassiliki, Kampa M, Gallo D, Notas G,
Jacquot Y, Castanas E, Leclercq G, (B)
100 winning abstracts
Swab Test and Transperineal Ultrasound in the
evaluation of the Urinary Incontinence. Alvarez
Nieto Jenny Maria (VE)
Quality of life in menopause: outcomes derived
from adhering to a monitorized physical exercise
programme Andrés Patricia C, Godoy-Izquierdo D,
Vélez M, Pérez-Fortis A, Mendoza N, Salamanca A,
de Teresa C, Godoy JF (E)
Thyroid function and postpartum mood
disturbances in Greek women Armeni Eleni,
Lambrinoudaki I, Rizos D, Pliatsika P, Leonardou
A, Sygelou A, Argeitis J, Spentzou G, Hasiakos D,
Zervas I, Papadias C (GR)
Plasma homocysteine levels in woman with
polycystic ovary syndrome Atanasova Elena
Atanasova A, Dimitrov GI (FYROM)
Differences in characteristics of dysfunctional
uterine bleeding in patients with immaturity of
the hypothalamic-pituitary-ovarian (hpo) axis
and polycystic ovarian syndrome Athanasopoulos
Nikolaos, Tismaris P, Deligeoroglou E (GR)
Human chorionic gonadotropin auc as a new
parameter to predict the success of single-dose
methotrexate in the treatment of ectopic pregnancy
Aybatli Aysun, Balkanli Kaplan P, Sut N, Yuce MA,
Cenk Sayin N, Varol FG (TR)
Psycho emotional impact of women with provoked
vestibulodynia Balasko Bridgette, Hall M, Lee
M,Ventolini G (USA)
Premenstrual syndrome in women with cushing
syndrome Barac Marija M, Ivovic M, Tancic M,
Marina L, Ivanisevic M, Arizanovic Z, Vujovic SZ (RS)
15
16
Effects of glucosamine alone and in association with
chondroitin sulphate in epiphyseal growth plate on
ovariectomized rats Bastos Wolff Roberta, Teixeira
Gomes RC, Simões MJ, dos Santos Simões R, Ferraz
Carbonel AA, Verna C, Chada Baracat E, Soares
Júnior JM (BR)
Aldosterone and renin plasma levels in young patients
with Polycystic Ovary Syndrome. Benelli Elena,
Bernini GP, Rinaldi E, Del Ghianda S, Cionini R,
Burelli A, Monteleone P, Vitti P, Pucci E (I)
Regulation of cyclin G2 degradation in ovarian cancer
cells Bernaudo Stefanie, Rosman D, Peng C (CA)
hCG: a pregnancy-related hormone stimulating
angiogenesis and pericyte recruitment. Berndt
Sarah, Blacher S, Perrier d’Hauterive S, Thiry M,
Tsampalas M, Cruz A, Péqueux C, Lorquet S,
Munaut C, Noël A, Foidart JM (B)
Level of total testosterone (TT) and wide spectrum
of steroids measured by mass spectrometry in
adolescent girls with hirsutism and polycystic ovarian
morphology Bogdanova Polina S, Kareva MA (RUS)
Insulin resistance is associated with
hyperandogenism and oligo-anovulation, but not
with the ultrasonographic features of the ovaries, in
the woman with polycistic ovary syndrome (PCOS)
Bonin Cecilia, Tosi F, Di Sarra D, Spiazzi G,
Bettinazzi F, Signori C, Forner S, Moghetti P (I)
Expression of mRNA for placental growth factor
(PlGF) and hypoxia inducible factor (HIF1α) in
placental tissues during early pregnancy in sheep.
Borowicz Pawel P, Grazul-Bilska AT, Johnson ML,
Redmer DA, Reynolds LP (USA)
WWP1, TGFβ and KLF gene expression levels as
prognostic factors in cervical oncogenesis Botezatu
Anca, Socolov D, Goia CD, Iancu IV, Huica I, Plesa
A, Anton G (RO)
Two and Three-dimensional ultrasound evaluation
of adenomyosis: correlation of sonographic findings
to histology Brienza Letizia, Amoroso C, Di
Giovanni A, Romeo V, Exacoustos C, Arduini D (I)
Could SP cells be an indicator of progression to
hormone non-responsive breast cancer? Britton
Kelly, Harvey IJ, Stemke-Hale K, Lennard TWJ,
Meeson AP (UL)
Anti-Mullerian Hormone in the prediction of
menopausal transition or menopause; a follow-up
study Broer Simone L, van Rooij I, Scheffer G,
Eijkemans M, Fauser BC, Broekmans FJ, (NL)
The Role of Tumour Necrosis Factor Alpha in Early
Pregnancy Calleja-Agius Jean, Muttukrishna S,
Brincat M, Jauniaux E (M)
The levels of placental hsp27, a modulator of
intracellular estrogen availability, are reduced in
deliveries of small fetuses. Cañete Patricia, Monllor
A, Pineda A, Cano A (E)
Alternatively Spliced Progesterone Receptor (PR)
Expression in Breast Cancer Cork David MW,
Lennard TWJ, Tyson-Capper AJ (UK)
Brain-derived neurotrophic factor levels in patients
with Turner syndrome. Czyzyk Adam ,Casarosa
E, Luisi M, Podfigurna-Stopa A, Meczekalski B,
Genazzani AR (PL)
Characterisation of Osteopontin Function in the
Human Endometrium. De Mello Natalie, Gonzalez
D, Joels L, Conlan S, White J (UK)
Development of postmenopausal hypertension in
a rat model of diet-induced obesity: a link between
cardiac endocrine function and fat mass. De Oliveira
Belo Najara, Nery de Andrade E, Kelle Neves
Gonçalves G, Caldeira de Oliveira TH, Silva Santos
C, Leal Silva e Souza C, Mendes de Magalhães AC,
de Jesus Soares T (BR)
Characterisation of Mutations and Sequence
Variants in Breast Cancer Susceptibility Gene 2
(BRCA2) in a Group of Breast Cancer Patients
in Sri Lanka De Silva Sumadee, Tennekoon KH,
Karunanayake EH, De Silva JWN, Amarasinghe I,
Angunawala P (LK)
Analysis of left ventricular systolic and diastolic
function in patients with polycistic ovary syndrome:
an echocardiographic study. Del Ghianda Scilla,
Pucci A, Talini E, Giannini C, Benelli E, Burelli A,
Rinaldi E, Vitti P, Pucci E, Di Bello V (I)
Impact of increased body mass index on IVF
outcomes Devesa Marta, Chueca A, Tur R,
Rodriguez I, Coroleu B, Barri PN (E)
Three-dimensional Coded Contrast Imaging : a new
approach for automated sonographic tubal patency
evaluation. Di Giovanni Alessandra, Exacoustos C,
Szabolcs B, Romanini ME, Amoroso C, Romeo V,
Zupi E, Arduini D (I)
Pregnancy and Epilepsy. Diaz Linder , Zambrano B,
Chacon G (VE)
Polycystic ovarian disease does not enhance rescue
of corpus luteum by administration of recombinant
(r)hCG on the first day of the menses Domingues
Thaís , Serafini P, Monteiro Rocha A, Leme Alves
da Motta E, Yadid I, Coslovsky M, Fettback P,
Domingues T, Homem de Mello Bianchi P, Carrilho
E, Chada Baracat E (BR)
Effects of metformin with or without folate
supplementation on homocysteine levels and
vascular endothelium of women with polycystic
ovary syndrome Falbo Angela, Materazzo C, Rocca
M, Russo T, Zullo F, Palomba S (I)
Effect of glucocorticoid treatment for foetal lung
maturation on maternal capillary glycemia and
ketonemia. Firquet Anne, Degée S, Pintiaux A,
Foidart JM (B)
The human endometrial Ishikawa cell line as model
for detecting tissue-specific estrogenic effects Fischer
Lara, Deppert WR, Nöthling C, Austermann-Hesse
H, Zahradnik HP, Schäfer WR (D)
Heparin and low molecular weight heparins modulate
the decidualization of human endometrial stromal
cells Fluhr Herbert, Spratte J, Zygmunt M, (NL)
Wii Fit: the new generation tool for improving
balance, health and well-being for women? Fu
Stephanie, Kuys S, Isles R, Nitz J (AUS)
A multigenic combination of polymorphisms
within ESR1, ESR2, FSHR, CYP19A1, NRIP1
and BMP15 genes are associated with the duration
of fertility age in a Spanish population. Galliano
Daniela, González I, Mendoza N, Eloy Ruíz J,
Sánchez-Borrego R, Salamanca A, Malde J, Godoy
D, Vélez M (E)
Hemodynamic evaluation of healthy young women
during use of an oral contraceptive containing 20
mcg of ethinyl estradiol plus 3mg of drospirenone
Galvão Giribela Cassiana R, de Melo NR,
Nieselbaum M, Guerra GM, Baracat EC, Marciano
Consolim-Colombo F (BR)
The endocannabinoid system controls endometrial
plasticity Gentilini Davide, Besana A, Vigano P,
Vignali M, Melandri M, Di Blasio AM, Busacca M (I)
Expansion of trophoblastic spheroids is promoted
by coculture with decidualized endometrial stromal
cells and enhanced by HB-EGF and IL-1ß González
Marina, Reimann K, Bamberger AM, Gellersen B (D)
Duration of fertility age and multigenic
combination of estrogen related genes: a propotional
hazard model González Pérez Inmaculada, Mendoza
N, Galiano D, Eloy Ruíz J, Marín L, Quereda F,
Pérez-Fortis A, Mozas J, Sánchez-Borrego R (E)
Nuclear factor-kappaB p65 and RelB peptides
expression in human endometrium across the
menstrual cycle González-Ramos Reinaldo, Rojas C,
Rocco J, Poch A, Sovino H, Kohen P, Devoto L (RCH)
Effect of lifestyle on vascular function and
metabolism in post menopausal hypertensive and
obese women. Gorlato Giulia, Nuzzo A, Chiurlia
E, Origliani G, Battistini NC, Fantini G, Rossi R,
Modena MG (I)
Conception and altered semen parameters:
retrospective analysis of 453 pregnancies. Grande
Giuseppe, Milardi D, Bianchi A, Giampietro A,
Pompa G, Merola AM, Astorri AL, Pontecorvi A,
Lanzone A, De Marinis L, Marana R (I)
Apoptotic Machinery in aging: gene expression
profiles in oocytes and in cumulus cells by High
Throughput Real Time PCR Guglielmino Maria
Rosa, Vento M, Borzì P, Santonocito M, Ragusa M,
Barbagallo D, De Palma A, Garofalo MR, Minutolo
E, Scollo P, Di Pietro C, Purrello MV (I)
Effects of human chorionic gonadotropin
administration on follicular growth and ovulation
in ob/ob and db/db mice. Habay Nathalie, Alvarez
Gonzalez ML, Monget P, Foidart JM, Pintiaux A (B)
Adipocyte fatty acid-binding protein as a novel
prognostic factor in obese breast cancer patients
Hancke Katharina, Grubeck D, Hauser N,
Kreienberg R, Weiss JM (D)
Higher frequency of anti-thyroid antibodies in
patients with recurrent spontaneous abortion
may stem from impaired vitamin D3 metabolism
Hedayat Zeinab , Mohammadzade V, Javadi H,
Sadeghi MR, Akhondi MM, Sadeghitabar A,
Zarnani AH (IND)
Disturbed estrogen metabolism in endometrial
cancer Hevir Neli, Smuc T, Vouk K, Sinkovec
J,Lanisnik Rizner T (SI)
The effects of oestrogen on alternative splicing
regulators in breast cancer cells Hong Elaine, Elliott
D, Tyson-Capper A (UK)
Thyroid stimulating hormone receptor and thyroid
hormone receptor alpha expression in the uterus of
cynomolgus macaques: effects of steroid hormone
treatment Hulchiy Mariana , Lindén Hirschberg A,
Cline JM, Sahlin L (SI)
Effects of chlormadinone acetate (CMA)-containing
oral contraceptive on premenstrual depressive mood
Iozza Irene, Andò A, Ciotta L, Giunta G, Iemmola
A, Rubbino G, Palumbo M (I)
Premature ovarian failure and bone density Ivanisevic
Maja, Barac M, Sljivancanin D, Vujovic S (RS)
Insulin-Like Growth Factor (IGF)-I , IGF
Binding Protein-1 and Dinucleotide (CT) Repeat
Polymorphism of the intron 2 of IGF-I Gene and
Their Association with Birth Indices Jayanthiny
Poopalapillai , Tennekoon KH, Karunanayake EH,
Kumarasiri JM, Wijesundere APDeS (LK)
The combined use of Anti-Mullerian Hormone and
age to predict the ovarian response to controlled
ovarian hyper stimulation in poor responders Jeve
Yadava Bapurao, Fleming R (UK)
17
18
Receptor mediated agglutination of human
spermatozoa by spermagglutinating factor isolated
from Staphylococcus aureus Kaur Siftjit, Prabha V,
Shukla G, Sarwal A (IND)
Overweight and oligomenorrhea in adolescence
- a preliminary study Kedikova Sesil, Sirakov M,
Pavlova E, Boyadzhieva M (BG)
Effect of Androgenic Activity of Zingiber officinale
on Serum FSH, LH, Testosterone hormone and
Spermatogenesis in Rat Khaki Arash (IR)
Obstetric complications cluster in women with
endometriosis among IVF pregnancies KuivasaariPirinen Paula , Hippeläinen M, Heinonen S (FIN)
Metformin administration restores allopregnanolone
response to ACTH stimulation in overweight
hyperinsulinemic PCOS patients Lanzoni Chiara,
Chierchia E, Rattighieri E, Santagni S, Campedelli
A, Casarosa E, Luisi M, Genazzani AD (I)
Silencing of the JNK pathway maintains
progesterone receptor activity in decidualizing
human endometrial stromal cells exposed to
oxidative stress signals Leitao Beatriz Belchior, Jones
MC, Fusi L, Higham J, Lee Y, Takano M, Goto T,
Christian M, Lam EWF, Brosens JJ (UK)
The assessment of fetal heart failure with respect to the
severity of fetal anaemia Luterek Katarzyna, Wielgos
M, Szymusik I, Bartkowiak R, Filipiak KJ (PL)
Obesity related lipid profile and altered insulin
incretion in adolescent with PCOS Magnini
Roberta, Fulghesu AM, Portoghese E, Angioni S,
Minerba, Melis GB (I)
Transferrin Receptor 1 protein expression and
localization in human Intrauterine Growth
Restriction placentas Mandò Chiara, Tabano S,
Colapietro P, MarinoA, Pileri P, Parisi F, Avagliano
L, Bulfamante G, Miozzo M, Cetin I (I)
Maternal and placental pathology as main predictors
in the quality of umbilical cord stem cells and the
success of sampling and cryopreservation Marin
Jan Andi, Calomfirescu M, Bohiltea R, Horhoianu
I, Horhoianu V, Russu M, Nastasia S, IonescuTirgoviste C (RO)
Potent AhR agonist from sauerkraut modulates the
ER pathway Medjakovic Svjetlana, Zoechling A,
Vollmer G, Zierau O, Kretzschmar G, Moeller F,
Kolba S, Papke A, Opietnik M, Kosma P, Rosenau
T, Jungbauer A, (A)
Characterisation of early ovarian cancer biomarkers
Meehan Katie, Rainczuk A, Fairweather N, Stephens A (AUS)
Sexual function is impaired in patients with endometriosis
Melis Irene, Arena I, Melis GB, Angioni S (I)
Female sexual dysfunction in young people at a
public university in northern Peru Mezones-Holguín
E, Escajadillo-Vargas N, Castro-Castro J, CórdovaMarcelo W, Blumel JE (PE)
Expression of ghrelin and its receptor in endometriotic
lesions Milewski Lukasz , Wojtowicz K, Roszkowski P,
Kaminski P, Barcz E, Malejczyk J (PL)
Detection of different kind of human papillomavirus
in normal pregnancy and in pregnant women
with insulin dependent diabetes mellitus. Mohseni
Meybodi Anahita, Haratian K, Zari Moradi S,
Mansouri Z (IR)
Aging plays a detrimental role on cardiovascular
protection by estrogen Novensà Casas Laura,
Novella S, Castillo N, Medina P, Segarra G,
Hermenegildo C, Dantas AP (E)
Colposuspension versus tension free vaginal tape
during laparoscopic sacralcolpopexy: a retrospective
study. Oppedisano Rosamaria , Venturella R,
Materazzo C, Rocca M, Palomba S, Zullo F (I)
Acaciaside-B-enriched fraction of Acacia
auriculiformis possesses spermicidal as well as antiHIV activity with wide margin of safety Pal Durba ,
Sabde S, Ray H, Pal BC, Mitra D, Kabir SN (IND)
Serum androgens are increased in the presence
of MTHFR ala222val polymorphism in healthy
postmenopausal women. Papadimitriou Dimitra,
Kaparos G, Rizos D, Armeni E, Christantoni
E, Tsakonas E, Creatsa M, Alexandrou A,
Christodoulakos G, Lambrinoudaki I (GR)
Exposure of rat pups to medical intensity ultrasound
waves Pečlin Polona, Rozman J (SI)
ER17p, a peptide corresponding to the regulatory
platform P295-T311 of er-alpha: role in actin
cytoskeleton, migration and apoptosis Pelekanou
Vassiliki , Kampa M, Gallo D, Notas G, Jacquot Y,
Castanas E, Leclercq G (B)
Vaginal estriol to overcome side effects of aromatase
inhibitors in adjuvant treated breast cancer patients
Pfeiler Georg, Glatz C, Königsberg R, Geisendorfer
T, Fink-Retter A, Kubista E, Singer C, Seifert M, (A)
Serum kisspeptin concentrations in patients with
functional hypothalamic amenorrhea Podfigurna-Stopa
Agnieszka, Luisi S, Petraglia F, Meczekalski B (PL)
Analysis of candidate genes for primary ovarian
insufficiency in a large cohort of women with
primary or secondary amenorrhea Rossetti Raffaella,
Cacciatore C, Marozzi A, Persani L, NIDO (Network
Italiano per lo studio dei Difetti Ovarici) (I)
Puerarin, a selective estrogen receptor modulator,
disrupts embryo-uterine communication and inhibits
implantation in rats Saha Piyali , Pal BC, Kabir SN (IM)
The effect of soy isoflavones over mood and
menopausal symptoms in mid-aged women with
increased body mass index San Miguel Glenda ,
Schwager G, Chedraui P (EC)
Polymerization of Insulin-like Growth Factor
Binding Protein-1 (IGFBP-1) Potentiates IGF-I
Actions in Placenta Shibuya Hiromi, Keiji S,
Mitsutoshi I (JP)
Epigenetic Response of the Human Breast to
Environmental Estrogens Snider Kara E , Huang Y,
Zhou Y, Russo IH, Russo J, Fernandez SV (USA)
Heparin modulates effects of TNF-a in human
endometrial stromal cells by interference with NFkB Spratte Julia, Fluhr H, Zygmunt M (D)
Laparoscopic modification of colpopexy technique
performed with LSH, TLH, and after open
hysterectomy. Stangel-Wójcikiewicz Klaudia , Wojtyś
A, Migdał M (PL)
In vitro assays for assessing anti-inflammatory
effects of chlormadinone acetate in dysmenorrhoea
Stuckenschneider Johanna (D)
The Effects of Menstrual Cycle Phase & Stress on
Cognitive Flexibility Sundermann Erin E., Mordecai
K, Rubin LH, Eatough E, Savarese A, Maki PM (USA)
Activation and action of ezrin protein during the
endometrial cycle and its potential role in embryo
implantation Tan Orkun, Ornek T, Fadiel A,
Naftolin F (USA)
Magnetic Resonance Elastography Allows
Quantitative Assessment of Uterine Leiomyomas
Taran Andrei F, Stewart EA, Chen J, Gostout BS,
Woodrum DA, Felmlee J, Ehman DRL (USA)
Amenorrhea in schizophrenic women - Correlation
with the pharmacodynamic particularities of both
“typical” and “atypical” antipsychotics Tica Oana
Sorina, Chirita A, Tica A, Barbu M, Berceanu C (RO)
Increased kit ligand levels in human polycystic
ovaries Tuck Astrud, Tilley W, Hickey T (AUS)
Are We Missing Out Evaluation of Paternal
Chromosomal Abnormality In Recurrent
Miscarriage ? Varicocele and Sperm FISH Turp
Ahmet (TR)
Glutathione S-transferase M1 and T1
Polymorphisms and the Risk of Recurrent Early
Pregnancy Loss in Women with High Perceived
Stress. Tutchenko Tetyana N. Tatarchuk TF,
Gorovenko NG, Podolskaya SV, Shakalo IN (UA)
Exercise and quality of life in menopause:
comparisons between long-term active, initiaters,
non-adhering and sedentary women. Vélez Mercedes
Godoy-Izquierdo D, Andrés CP, Pérez-Fortis A,
Mendoza N, Salamanca A, de Teresa C, Godoy JF (E)
In PCOS preconceptional HOMA index identifies
women at risk for gestational diabetes Veltman
Susanne M van Haeften TW, Eijkemans MJC, de
Valk HW, Fauser BCJM, Goverde AJ, (NL)
The Sexual Life of German Medical Students:
Investigation of the prevalence of sexual dysfunction
and the impact of contraception Wallwiener Lisa
Maria Wallwiener CW, Seeger H, Mueck AO, Bitzer
J, Wallwiener M (D)
Eventual proapoptotic or anti-apoptotic impact of
aberrantly expressed Cx43 and Cx26 can depend
on ER-alpha overexpression in endometrioid
adenocarcinoma. Wincewicz Andrzej Sulkowska M,
Kanczuga-Koda L, Koda M, Sulkowski S (PL)
Breast cancer and pregnancy:theories and guidelines
Zampetaki Charisti Delimpalta C (GR)
Cardiac autonomic neuropathy in diabetic
postmenopausal women Zelenina Tatiana A
Vorokhobina N, Mamontov O (RUS)
FIRENZE, ITALY
MARCH 8-11 2012
UNDER 34 COMPETITION
FREE 100 REGISTRATIONS WITH ACCOMMODATION
Participants must be under the age of 34 by March 8th 2012 and
must submit a maximum of 2 abstracts as first author on any of the
Congress’ topics by November 21st, 2011 using the online form and
checking the apposite box.
The first authors of the accepted abstracts will pay the registration
to the Congress €180 (instead of €600). The Scientific Committee
will evaluate the abstracts and select the 100 better works whose
first authors will receive a voucher for free registration and accommodation in a 3 stars hotel, double room.
19
20
Sponsor and Exhibitors
Auditorium
(Palazzo dei congressi)
Opening hours
Thursday March 4th 08.30 - 19.00
Friday March 5th 08.30 - 19.00
31
30
29
1
25
24
2
28
23
22
21
3
12
27
4
5
13
20
6
7
19
18
26
17
34
35
16
15
33
38
36
Palazzo Affari, 3rd floor
9
32
10
11
37
Opening hours
Thursday March 4th 08.30 - 19.00
Friday March 5th 08.30 - 19.00
8
14
2
Exhibition
Area
1
Hall
Affari3
3
Hall
Affari3
Company Profiles
List of exhibitors
Alfa Wassermann Spa
21
18
99, 5 - 40133 bologna italy
t.+39 0516489511 f. +39 051388593
www.alfawassermann.it
[email protected]
Founded in 1948, Alfa Wassermann S.p.A. holds a
prominent position in the Italian pharmaceutical market. Its activities include research, production and commercialisation of prescription drugs and selfmedication
products. The head office and research laboratories are
located in the company’s historical headquarters in
Bologna, while the modern production plant located
in Alanno (Pescara) also carries out contract manufacturing. The International Division is headquartered in
Milan. The company, which employs over 670 people
in Italy and over 1,200 worldwide, ended 2008 with a
turnover of 273 million Euro and a 10.6% growth.
The fact that over 60% of the company’s turnover is
generated by its own products constitutes one of the
strengths of Alfa Wassermann S.p.A. These products are
the result of internal research and include several leading drugs in their relative market segments.
via ragazzi del
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
23
24
25
26
27
Esaote
Hra
Hra
Bracco
Zambon
System Biologie
System Biologie
Angelini
Ethicon Women’s
Health&Urology
Johnson&Johnson
Ferring
Solvay
Schering Plough
Grunenthal
General Electric
Bruno Farmaceutici
Velates
Alfa Wassermann
Besins
Rottapharm
Rottapharm
Wyeth - Pfizer
Bayer Schering
List of exhibitors
1
2
3
Menarini
Guidotti
Finderm
28
29
30
31
34
Ibsa
Theramex
Laboratoire Theramex
Laboratoire Theramex
Nuskin Enterprises
booksellers
32 Wisepress
33 Cic
35 Informa
36 Editrice Universo
38 Wichtig Editore
scientific societies
19 ISGE
20 ISGE
21 ISGE
22 IMS
37 ESG/SEG
Amgen
(in collaboration with GSK)
Amgen Europe GmbH
Dammstrasse 23, Opus 105 6301 Zug, Switzerland
t. +41 0413690495 cell +41 0787507331
Amgen, Inc. - Amgen, a biotechnology pioneer, discovers, develops and delivers innovative human therapeutics. Our medicines have helped millions of patients
in the fight against cancer, kidney disease, rheumatoid
arthritis and other serious illnesses
GlaxoSmithKline – one of the world’s leading researchbased pharmaceutical and healthcare companies – is
committed to improving the quality of human life by
enabling people to do more, feel better and live longer.
For further information please visit www.gsk.com.
22
ACRAF s.p.a.
8
Viale Amelia, 70 – 00181 Roma
t. +39 06910451 f. +39 0678332385
[email protected] - www.angelini.it
Angelini is an Italian privately own Company committed
in developing, manufacturing and marketing pharmaceutical and wellbeing products worldwide. It is directly
present in Italy, Spain, Portugal and Central-Eastern Europe and its products are being distributed worldwide,
thanks to a network of partners and licencees.
Angelini has discovered and developed benzydamine,
an anti-inflammatory agent; Trazodone, an antidepressant agent and prulifloxacin, an antibacterial agent. The
R&D pipeline currently includes projects in the fields
of pain and inflammation.
In the area of prescription drugs, Angelini operates in
pain therapy, CNS, gynaecology, disinfection, cold&flu.
In Italy the company is leader in self-medication and
healthcare and is among the top five pharmaceutical
companies. Angelini Group: 3.000 people. Turnover
2008: 1.2 billion euro.
Bayer Schering Pharma AG
27
Müllerstr. 178, D-13342 Berlin, Germany
t. +49 304681111 - f. +49 3046818074
www.bayerscheringpharma.de
Bayer Schering Pharma is a worldwide leading specialty
pharmaceutical company. Our research and business
activities are focused on the following areas:
Women’s Healthcare, Diagnostic Imaging, General
Medicine and Specialty Medicine. With innovative
products Bayer Schering Pharma aims for leading positions in specialized markets worldwide.
We would like to make a contribution to medical
progress and strives to improve the quality of life.
Building on almost 100 years of expertise Bayer Schering Pharma is today the leading provider in Women’s
Healthcare.
We focus on three key areas: Female Contraception,
Menopause Management and Gynecological Therapy.
Bayer s.p.a.
Viale Certosa 130 - 20156 Milano, Italia
t. +39 02.39781
www.bayerscheringpharma.it
Besins Healthcare SA
23
Avenue Louise, 287 - 1050 Brussels – Belgium
+32 (0)2 649 43 00 – f. +32 (0)2 629 43 14
[email protected]
www.Besins-healthcare.com
Besins Healthcare is a pharmaceutical company specialised in the development and worldwide diffusion of innovative drugs and food supplements for the well-being
of men and women throughout their life. The company
has established a strong reputation in gynaecology over
the last 30 years and is a renowned actor in hormonal therapies for women and men. Besins Healthcare
has its own manufacturing facilities, specialising in the
production of innovative products in the fields of gynaecology, fertility & obstetrics, men’s health and nutrition. We would like to invite you to visit our site (www.
Besins-healthcare.com) to understand why Innovating
for well-being is our claim.
t.
Bracco s.p.a.
4
XXV Aprile, 4 20097 San Donato Milanese (MI)
t. +39 0221772284 - f. +39 0221772759
via
Bruno Farmaceutici
16
CIC Edizioni internazionali
33
Via delle Ande, 15 Roma -Italy
t. +39 066050601 - f. +39 0660506040
[email protected]
www.brunofarmaceutici.it
Bruno Farmaceutici is an Italian pharmaceutical company headquartered in Rome having well-established
products in various therapeutic areas .
Bruno is the Italian market leader in the oral and injectable corticosteroid segment and has also innovative
and unique products for pain management and in the
area of the cardiovascular system.
Further therapeutic targets are respiratory tract infections where Bruno markets a 4th generation injectable
cephalosporin and external otitis having a ciprofloxacin
containing product in an ear-drop formulation.
Corso Trieste 42, 00198 Roma, Italy
+39 068412673 - f. +39 068412688
[email protected] - www.gruppocic.it
For several decades CIC Edizioni Internazionali has
been a leading publishing house in the different specialties on medicine and surgery. We publish both books
and periodicals, and in particular we are specialized in
the publication of books and congress proceedings regarding Gynecology and Obstetrics.
t.
Eli lilly & Company
Lilly Corporate Center - Faris Campus - 520 South
Meridian Street Indianapolis, IN 46225
t. +1-317-276-2000 - www.lilly.com
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products
by applying the latest research from its own worldwide
laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis,
Ind., Lilly provides answers – through medicines and
information - for some of the world’s most urgent medical needs. Additional information about Lilly is available at www.lilly.com.
Esaote s.p.a.
1
Ethicon Women’s Health&Urology
10
Via Siffredi 58, 16153 Genova, Italy
t. +39 010 65471 - f. +39 010 6547275
[email protected] - www.esaote.com
Esaote is a global leader in research, production and
marketing of medical diagnostic equipment and related
services, focused on solving the medical needs of customers worldwide.
More than 60,000 Esaote ultrasound, MRI and electromedical diagnostic systems have been installed worldwide since the company was founded in the1980’s.
Via del mare 56, 00040 Pratica di Mare-Roma
06-91194210 - Fax 06-91194246
www.gynecare.com
Among the Johnson&Johnson family of Companies,
Ethicon Women’s Health&Urology is global leader in
Incontinence’s treatment with TVT family of product and Pelvic Floor repair with recently launched
Prolift+M mesh kit.
Specifically to Minimally Invasive Gynaecology,
EWH&U provides a wide range of solution for Uterine
Disorders treatment withThermachoice Uterine Balloon System for endometrial ablation, Versapoint Bipolar System and Versascope Hysteroscopy System for
See&Treat approach of intracavitary patologies as well
as state-of-the-art Morcellator device for laparoscopic
tissue morcellation.
t.
Ferring Pharmaceuticals
11
Via Senigallia 18/2 – 20161 Milano, Italy
t. +39 02 64000143 - F. +39 02 64000155
Ferring Pharmaceuticals is a research-driven biopharmaceutical company devoted to identifying, developing and marketing innovative products in the fields of
infertility, obstetrics, urology, gastroenterology, endocrinology and osteoarthritis.Ferring’s marketing, medi-
cal services and sales teams, led by corporate headquarters in Saint-Prex, Switzerland, operate from more than
40 countries and employ over 3000 people throughout
the world, while treatments are available in more than
70 countries. Ferring is committed to a future where it
will continue to provide new
and innovative medicines by utilising existing and acquired skills and the development of pioneering technologies and, where necessary, through partnerships
with academic institutes and other companies.
Finderm farmaceutici srl
3
GE Healthcare
15
Via A. De Gasperi, 165/B - 95127 Catania
t. 095 371122-370292 - f. 095 384539
[email protected] - www.finderm.it
Finderm farmaceutici, based in Catania, was established in 1995 pursuant the brilliant intuition of its
founder, Fabio Scaccia, who leads it to become one of
the leading companies in the gynecological field in a
very short time. Now, fifteen years after its foundation,
with a turnover of more than ten million euro, it ranks
among the first Italian companies. With its products
– drugs, medical devices, cosmetics and food supplements – Finderm Farmaceutici takes care of the woman
during all her life, from the adolescence to the menopause, without neglecting any of the daily problems
and staying close to her during the pregnancy.
Via Galeno, 36 - 20126 Milano
t. 02 26001111
http://www.gehealthcare.com/eueu/contact/
contact_addresses.html
www.gehealthcare.com
GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient
care. Our expertise in medical imaging and information
technologies, medical diagnostics, patient monitoring
systems, performance improvement, drug discovery, and
biopharmaceutical manufacturing technologies is helping clinicians around the world re-imagine new ways to
predict, diagnose, inform, treat and monitor disease, so
patients can live their lives to the fullest.
GE Healthcare’s broad range of products and services
enable healthcare providers to better diagnose and treat
cancer, heart disease, neurological diseases and other conditions earlier. Our vision for the future is to enable a new
“early health” model of care focused on earlier diagnosis,
pre-symptomatic disease detection and disease prevention.
Products At GE Healthcare, we believe an innovative
idea can achieve transformational results. We focus on
Ultrasound applications that will create new clinical
23
24
value for you and your patients. Then, we bring them to
life through annual breakthroughs within our LOGIQ®,
Vivid® and Voluson® product families.
It’s all about giving you the freedom to see Ultrasound
in brand new ways. Volume ultrasound. Compact ultrasound. Powerful IT solutions. All the latest technologies
from GE -- designed just for you. Imagine the effect.
OUR Committment At GE Healthcare, we strive to see
life more clearly. We help predict, diagnose, inform, and
treat, so that every individual can live life to the fullest.
GE Healthcare is committed to serve the communities
where we do business to provide our customers with innovative, high-quality products and services and to protect the health of our workers and our environment.
Grünenthal Italia
14
Via Robert Koch 1/2 - 20152 Milano
tel. 02 43051 - fax 02 430555
[email protected] - www.grunenthal.it
Grünenthal GmbH is an independent, research-based
and global pharmaceutical company. We specialised in
the field of pain therapy, contraception and innovative
formulations for established active substances. Grünenthal products are available in more than 100 countries, most of it are prescription medicines.. Together
with highly specialised partners we are pressing on with
the research and development of new active substances.
For this we are concentrating on selected indications
and the latest technological developments. We are intensively searching for innovative ways of improving
pain, pain relief and reducing side-effects.
IBSA Institut Biochimique SA
23
Via del Piano, P.O. Box 266, 6915 PambioNoranco, Lugano, Switzerland
t. +41 58 360 10 00 - f.+41 58 360 16 47
[email protected] - www.ibsa-international.com
IBSA is an international pharmaceutical company headquartered in Lugano, Switzerland, delivering different
therapeutic solutions for follicular stimulation and luteal
support. IBSA’s unique, whole in-house manufacturing
cycle provides a full range of highly purified, human-type
gonadotrophins: hFSH (Fostimon), hMG and hCG.
Other company’s franchises include osteoarthritis, painmanagement, dermatology and thyroid diseases.
Informa Healthcare - Clinical Medicine
35
Johnson & Johnson Medical
10
A. Menarini
1
52 Vanderbilt Avenue
New York, NY 10017
t. 212-520-2710 - f. 212-520-2705
www.informahealthcare.com
Informa Healthcare is the proud publisher Gynecological Endocrinology, the official journal of the International Society of Gynecological Endocrinology. The
Journal covers the experimental, clinical and therapeutic
aspects of this important discipline. Visit our booth for
more information, and pick up your free sample issue.
Informa Healthcare provides authoritative research and
analysis, up-to-the-minute news, comment and debate
for life science and medical markets. This dynamic publishing group offers a unique range of groundbreaking
books and journals from leading authors in the fields of
obstetrics, gynecology and reproductive medicine.
Via del Mare 56 – 00040 - Pratica di Mare,
Pomezia (Roma)
t. +39 06911941 - f. +39 0691194290
www.jnjmedical.it
Johnson & Johnson Medical is in Italy the most comprehensive company in the healthcare sector for the
commercialization of medical devices and diagnostic
under the following brands:
Depuy
Ethicon Endo-Surgery
Ethicon
Cordis
Ortho-clinical Diagnostic
Johnson & Johnson Vision Care
Lifescan
Biosense Webster
Johnson & Johnson Medical has two sites in Italy in
Pomezia and in Milan, for a total of 1.000 employees.
Via sette Santi, 3 50131 Firenze (ITALY)
t. +39 05556801 f. +39 055582771
www.menarini.com
Menarini was founded in 1886.
In 1915 its headquarters were established in Florence.
Menarini was born in 1886 in the small laboratory of the
Farmacia Internazionale of Naples. In 1915 it was transferred to Florence, where its headquarters still reside.
In 1964 the process of internationalization commences
with the creation of Laboratorios Menarini in Barcelona, Spain.
Scientific research at a qualitative international level
starts in 1978 (with the implementation of patent for
medicines in Italy too. Menarini gave a significant contribution to this implementation).
Menarini is present overall in 105 countries, directly in
54 countries worldwide and through agents-licenses in
other 51 countries worldwide.
Ranking of Menarini in the World among 4.641
companies: 36th Position
Ranking of Menarini in Europe among 2.311 companies: 20th Position
Laboratori Guidotti SpA
2
Via Livornese 897, 56122 La Vettola (Pisa), Italy
t. +39 0509710392 - f. +39 0509710336
[email protected] - www.labguidotti.it
Laboratori Guidotti S.p.A. is an italian pharmaceutical
Company founded in 1914 in Pisa.
Correct medical scientific information (carried out by
forty hundreds and twenty reps and thirty-three area
managers), continuosus development of scientific portfolio through clinical trials and research of new drugs
are the keywords that today distinguish Laboratori
Guidotti, a company whose objective is to constitute a
permanent point of reference for the medical class.
Guidotti develops two differents therapeutic areas: cardiology area and diabetes to and uses the term “Mission” to define its commitment in this way.
Laboratoire HRA Pharma
3
15 rue Béranger- 75003 Paris – France
t. +33 1 40 33 11 30 f.+33 1 40 33 12 31
[email protected] - www.hra-pharma.com
HRA Pharma is an emerging, privately-held European
pharmaceutical company that designs products, devices
and supporting services in niche areas of health and
makes them available to doctors and patients worldwide. The company targets therapeutic gaps in the areas of reproductive health and endocrinology, and uses
innovative marketing solutions and socially-conscious
programs, such as contraception education in developing countries, to promote healthy management of
drugs and diseases.
A pioneer in emergency contraception, its product
NorLevo was the first emergency contraceptive based
on one type of progesterone to be approved for sale by
health authorities. The company’s other product in this
field includes ellaOne®, the first compound of a new
generation in emergency contraception to be taken
within five days of unprotected sexual intercourse or
contraceptive failure.
Headquartered in Paris, France and with local offices in
Germany, the United Kingdom, Italy and Spain, HRA
Pharma has built a strong network of R&D, manufac-
turing, distribution and NGO partners which enables
it to satisfy critical patient needs and improve patient
health in over 50 countries across the globe. Visit www.
hra-pharma.com for more information.
Laboratoire Théramex - Merck Serono
30 31
6 Avenue Albert II BP 59 98007 MONACO CEDEX
t. 00 377 92050808 - f. 00 377 92057000
www.merckserono.fr - www.merckserono.com
Merck Serono is the division for innovative prescription
pharmaceuticals of Merck, a global pharmaceutical and
chemical group. Merck Serono discovers, develops, manufactures and markets innovative small molecules and biopharmaceuticals to help patients with unmet medical needs.
Headquartered in Geneva, Switzerland, Merck Serono is
active on all continents.
Merck Serono has leading brands serving patients with
cancer, multiple sclerosis, infertility, endocrine and metabolic disorders as well as cardio metabolic diseases.
Théramex, a company of the Merck Serono division, has
built a solid image in women’s health thanks to its expertise
in gynecology. Théramex offers a large range of products
for menopause and osteoporosis. New international perspectives will soon open to Théramex with contraception.
Merck Serono Spa 29
Via Casilina 125 00176 ROMA
t. 06 703841 - f. 06 70384643
www.merckserono.it
Merck Serono is the division for innovative prescription pharmaceuticals of Merck, a global pharmaceutical
and chemical group.
Headquartered in Geneva, Switzerland, Merck Serono
discovers, develops, manufactures and markets innovative small molecules and biopharmaceuticals to help patients with unmet medical needs in specialists focused
therapeutic areas, including neurodegenerative diseases,
oncology, fertility, endocrinology and autoimmune
and inflammatory diseases.
Merck Serono has a strong presence in Italy: the Italian
affiliate Merck Serono S.p.A. has about 630 employees working in three separate sites: the headquarters in
Rome, the R&D site in Guidonia Montecelio (RM),
and the production site in Bari.
25
26
Max Mairhofer Consulting & Marketing Pfizer Italia S.R.L.
Via Valbondione, 113 – 00188 Roma
Independent Distributor Nu Skin
34 T. +39 0633182 - www.pfizer.it
Enterprises
Donau-Schwaben-Strasse 9, D 94036 Passau
t. +43 676 43 72720 - f. +43 2235 42928
[email protected]
www.maximizedbeauty.com
Since its founding in 1984, Nu Skin has demonstrated
a distinctively different approach to business. We began
with an innovative concept of premium quality products and a uniquely compelling global business opportunity. This helped NU SKIN expand into a global
anti-aging beauty and wellness company.
“All of the good and none of the bad” was our ambition
from the beginning. The result is that the remarkable
Nu Skin personal care range includes some of the most
scientifically advanced products in the world of antiaging beauty. With nearly $1,3 billion in annual sales
in 49 international markets, we are reaching our goals
and setting the industry standard.
Our Mission is to be a force for good throughout the
world by empowering people to improve lives with rewarding business opportunities, innovative products,
and an enriching and uplifting culture.
Pantarhei Bioscience BV (PRB)
PO Box 464, 3700 AL Zeist, The Netherlands
t. +31 306985028 f. +31 306985021
[email protected] - www.pantarheibio.com
PRB develops patent protectable new drugs and treatment concepts based on existing compounds (drugs or
endogenous human molecules) up to proof-of-concept
(phase II) in the human. PRB is specialised in the area
of Women’s and Men’s Health including hormonal
contraception, hormone replacement therapy (HRT),
infertility, osteoporosis, osteoarthritis and cancer of reproductive organs such as the breast, the ovary and the
prostate.
PRB has currently prioritised the following projects:
1. Estetrol (E4 project): a fetal estrogen, suitable for
oral contraception, HRT, including HRT in women
with breast cancer and bone disease
2. Androgen Restored Contraception (ARC project):
restoring testosterone levels in women using oral
contraception
3. Zona Pellucida (ZP project): active immunization
with zona pellucida antigens for the treatment of
ovarian granulosa cell cancer
26 Pfizer: Working together for a healthier world
At Pfizer, we apply science and our global resources to
improve health and well-being at every stage of life. We
strive to set the standard for quality, safety and value
in the discovery, development and manufacturing of
medicines for people and animals. Our diversified global health care portfolio includes human and animal
biologic and small molecule medicines and vaccines, as
well as nutritional products and many of the world’s
best-known consumer products. Every day, Pfizer colleagues work across developed and emerging markets to
advance wellness, prevention, treatments and cures that
challenge the most feared diseases of our time. Consistent with our responsibility as the world’s leading biopharmaceutical company, we also collaborate with health
care providers, governments and local communities to
support and expand access to reliable, affordable health
care around the world. For more than 150 years, Pfizer
has worked to make a difference for all who rely on us.
Rottapharm Spa
24
Valosa di Sopra 9, 20052 Monza Italy
- [email protected]
www.rottapharm.com - www.rottapharm.it
Established in 1961, Rottapharm|Madaus is a pharmaceutical group headquartered in Monza with branches
in more than 85 countries worldwide.
In 2007, with the acquisition of the German pharmaceutical company Madaus Pharma, Rottapharm’s
expertise in the genito-urinary area has been strongly
improved: important synergies have been identified in
this area, where the group is benefiting not only the
ongoing clinical research activities but also the presence
on the market of Madaus leading products.
Rottapharm|Madaus R&D activities are currently
focused on gynecology (with prescription drugs for
HRT), urology (with URIVESC), personal care (with
Saugella, leading brand for intimate hygiene) and nutraceutical segment (Estromineral line for the treatment
of menopausal symptoms).
via
t.+39.039.7390.1
Schering Plough s.p.a.
13
Centro Direzionale Milano Due
Palazzo Borromin Via Fratelli Cervi snc - 20090
Segrate (MI) - ITALY
t. +39 02 21018.1 - www.schering-plough.it
Schering-Plough is an innovation-driven, sciencecentered global health care company. Through its own
biopharmaceutical research and collaborations with
partners, Schering-Plough creates therapies that help
save and improve lives around the world. The company
applies its research-and-development platform to human prescription and consumer products as well as to
animal health products.
Schering-Plough products reach patients and caregivers in more than 140 countries. In human prescription
pharmaceuticals, our core therapeutic areas include cardiovascular care, respiratory care, immunology and infectious diseases, oncology, women’s health, and central
nervous system therapies.
Solvay Pharmaceuticals Marketing&Licensing AG
12
Hegenheimermattweg 127 4123 Alschwil Switzerland
+49 511 8570 - f. +49 511 8573120
www.Solvay.de
Solvay has built an extensive expertise in hormone
therapy, most of it relieving menstrual or menopausal
symptoms in women. DUPHASTON® (dydrogesterone) is one of the leading progestogens worldwide. It is
prescribed for a wide range of gynaecological conditions
caused by progesterone deficiency, such as endometriosis, premenstrual syndrome and irregular or absent menstruation, but is also used by women struggling with infertility and habitual abortion.
The FEMOSTON® (17beta estradiol/dydrogesterone)
family with sequential and continuous combined regimens is an ideal choice for hormone replacement therapy due to the pure side effect profile of dydrogesterone
leading to pure estrogenic action relieving menopausal
complaints and due to several strengths on the market
leading to individualilsation of therapy according to each
patient’s need. It is marketed in over 60 countries worldwide. Solvay is worldwide number 2 in hormone replacement therapy.
ANDROGEL® provides testosterone therapy to men
whose bodies do not make enough testosterone.
It is the first testosterone gel approved by the U.S. Food
and Drug Administration for therapy in men for conditions associated with absent or low testosterone. With
the testosterone gel ANDROGEL® Solvay introduced its
first transdermal hormone therapy for men in the United
States.For more information visit www.androgel.com
t.
System Biologie AG
6
t.
+1 305 604 8980 - f. +1 305 604 8986
- www.system-biologie.com
System Biologie AG Laboratories is a Swiss based company working in research and development with low
molecular compounds, specializing in Organic Engineering and systems biology. Main focus is prevention
of cell damage, chronic illnesses and cancer. With locations and collaboration worldwide, we also work on
cancer treatment with organic substances. We filed several patents for syntheses and drug targeting.
[email protected]
Wisepress Medical Bookshop
32
Zambon Group s.p.a.
5
The Old Lamp Works 25 High Path Merton Abbey
London SW19 2JL UK
t. +44 20 8715 1812 f. +44 20 8715 1722
[email protected] - www.wisepress.com
Wisepress.com, Europe’s leading conference bookseller,
has a complete range of books and journals relevant to
the themes of the meeting. Books can be purchased at
the stand or, if you would rather not carry them, posted
to you – Wisepress will deliver worldwide.
Via Lillo del Duca 10 20091 Bresso (Milan) Italy
t. +39 02 665241 - f. +39 02 66501492
[email protected]
www.zamboncompany.com
Zambon is a leading pharmaceutical and chemical multinational with a reputation for inventive and innovative thinking, flexibility and customer focus. Operating
directly on three continents - Europe, North & South
America and Asia - with 2500 employees in 14 countries.
Headquartered in Bresso and originally founded in Vicenza in 1906
Zambon Company S.p.A. is the holding company of the
Zambon’s group , consisting of fine chemicals company
ZaCh System, pharmaceuticals multinational Zambon
S.p.A. and corporate venture specialist Z-Cube the corporate venture arm of the group Zambon, has achieved
the launch of the three start-ups companies PharmEste
s.r.l., SuppreMol GmbH and ProtAffin Biotechnologie
AG based on highly innovative medicine projects.
27
28
Continuous medical education
21 credits
UEMS Credits (Europe)
The European Accreditation Council for CME is an
official body of the European Association of Medical
Specialists (UEMS) being established by the UEMS
Management Council meeting in October 1999.
The UEMS (European Union of Medical Specialists)
has assigned to the 14th World Congress of the Gynecological Endocrinology n.21 Continuous Medical Education European (CME) credits. These credits are valid
for all European Community Countries and are recognized by the American Medical Association toward the
Physician’s Recognition Award (AMA) for Canada and
North American Countries.
Certificate
Certificates will be distributed at the ECM/UEMS
certificate desk on Saturday morning from 10.00am
onwards. All information will be available at the CME/
Certificates Desk. The handback of the Customer Satisfaction Form is compulsory to recieve the UEMS certificate and ECM.
AMA conversion
Physicians may apply to convert European credit into
AMA credit by completing and returning the EACCME application, along with the appropriate application
processing fee and documentation of the meeting Physicians have attended. Please check the UEMS website
(www.uems.net) to ensure the activity attended is listed
and marked as “Approved” before submitting the application. The credits are one-to-one
14 credits
ECM Credits (italian delegates)
Congress has been certified with 14 ECM credits.
The course “Le varie età della donna: aspetti
clinico-terapeutici nell’ambulatorio del ginecologo”
has obtained 2 ECM credits.
The course “Confronti clinici in contraccezione
ormonale” has obtained 2 ECM credits.
The course “Sindrome metabolica ed insulinoresistenza nella donna” has obtained 2 ECM credits.
Pre-congress courses have been accredited with 4
ECM credits.
The ECM accreditation of the “14th World Congress of
Gynecological Endocrinology” and the courses has been
requested for Physicians specialized in Gynecology and
Obstetrics, Endocrinology and General Medicine.
The scientific sessions with credits are highlighted on
the Scientific Programme with the ECM sign ( ECM).
In order to obtain credits from the Continuous Medical
Education Programme the following steps are mandatory
Attend a number of daily ECM sessions that cover
the whole congress day for the entire duration the
congress;
Fill in the ECM Questionnaire that you will find
at the ECM Desk of the Congress Secretariat; the
Questionnaire is structured per scientific session,
we kindly ask you to answer the questions related
to the sessions you have attended;
Fill in the Evaluation Form.
Key note
Kindly remember that the Questionnaire
together with the Evaluation Form will have
to be handed back to the ECM Desk before the
end of the Congress.
The Questionnaire has validity only when
accompanied by the completed Evaluation Form.
The ECM certificate will be sent to the
participants, via post or email, after evaluation
of the answers.
Boards
& assemblies
5 credits
Brazilian Medical Association (AMB)
The Brazilian Medical Association (AMB) credits 5
points to the attendees to the Congress; in order to obtain the credits the certificate of attendance should be
presented to the AMB.
28 credits
Swiss Society of Obstetrics
and Gynaecology (SGGG)
Swiss Society of Obstetrics and Gynaecology (SGGG)
credits 28 points for the International Congress and 8
credits for the pre-congress courses.
For information please contact the Swiss Society of
Obstetrics and Gynaecology (SGGG) www.sggg.ch.
ESG/SEG Executive Board
Wednesday 3 - 14.45 - 16.30
Room 18, Palazzo dei congressi
ISGE Executive Board
Wednesday 3 - 17.00 - 19.30
Room 16, Palazzo dei Congressi
ISGE Italia Executive Board
Friday 5 - 07.45 - 09.00
Gynecological Endocrinology
Editorial Board
Friday 5 - 09.00 - 10.15
ISGE General Assembly
Friday 5 - 19.20 - 20.00
Hall Affari 1
AGUI Executive Board
Saturday 6 - 11.00 - 13.00
Hall Belvedere
ISGE Italia General Assembly
Saturday 6 - 12.40 - 13.10
Hall Affari 3
IMS Executive Board
Sunday 7 - 09.00 - 17.00
Hotel Baglioni
29
Cod. ZI.09.014
Essere subito
disponibile
può fare
la differenza.
Depositato presso AIFA in data 1/04/2009
30
Prefolic è la forma fisiologica
di trasporto dell’acido folico nel
plasma, dove rappresenta la quasi
totalità dei folati circolanti.1
Il pronto assorbimento nel tratto
digestivo, la completa distribuzione
tissutale e l’utilizzo come tale senza
necessità di biotrasformazione ne
consentono l’impiego in tutte le
forme di carenza di folati.1
Bibliografia
1) Prefolic®. Riassunto delle caratteristiche del prodotto
Il folato nella forma biologica attiva
31
II Congresso Nazionale
Associazione Italiana
Firenze, 4-7 Marzo 2010
32
Cari amici
Benvenuti al secondo congresso della nostra
associazione. L’endocrinologia ginecologica
ha avuto in questi ultimi due anni un ulteriore
sviluppo sia nella ricerca di base e clinica che
nelle applicazioni diagnostico terapeutiche.
Sempre più la nostra disciplina pervade l’area
della medicina di genere e come tale rivela
risvolti sempre più incisivi nella quotidianità
del vivere al femminile. Dall’adolescenza alla
menopausa, dallo stress alla sindrome metabolica, dall’acquisizione del picco di massa ossea all’osteoporosi, dall’ovariectomia precoce
al rischio di Alzheimer, negli ultimi due anni
si sono scritte pagine importanti e il nostro
bollettino è stato un mezzo prezioso per i
nostri soci ed i nostri amici lettori che in così
gran numero lo hanno scaricato dal nostro
sito www.isgeitalia.it.
Il congresso quest’anno è articolato sui corsi di aggiornamento in lingua italiana, e
sull’insieme delle sessioni sviluppate dalla società internazionale. La nostra seduta amministrativa ci permetterà di tracciare i piani di
sviluppo del prossimo biennio per sviluppare
il nostro ruolo di ginecologi endocrinologi
per tutti gli aspetti della salute della donna.
Con un caloroso benvenuto auguro a tutti di
ritrovare nelle sale del nostro congresso quei
contenuti che come nella precedente edizione
hanno sempre caratterizzato il grande ruolo
della endocrinologia ginecologica italiana.
Un caro saluto, vostro
Andrea R. Genazzani
Presidente
ISGE Italia
Consiglio Direttivo
Presidente A.R. Genazzani (Pisa)
G. D’Ambrogio (Lecce)
V. De Leo (Siena)
A. D. Genazzani (Modena)
S. Lello (Roma)
C. Nappi (Napoli)
R.E. Nappi (Pavia)
M. Palumbo (Catania)
T. Simoncini (Pisa)
H. Valensise (Roma)
Segreteria di Direzione
[email protected]
T. 050503985
Segreteria scientifica
Tommaso Simoncini
[email protected]
Divisione di Ginecologia
e Ostetricia Universitaria 1°
“P. Fioretti” via Roma 67 - 56126 Pisa
T. 050503985 F. 0502207028
Segreteria organizzativa
Biomedical Technologies srl
Sede legale e amministrativa
Via P. Cugia 1 - 09129 Cagliari, Italy
T +39 070340293
F +39 070307727
[email protected]
Ufficio Marketing e comunicazione
Via Metauro 19 - 00198 Rome, Italy
T +39 068546198
F +39 0685389063
[email protected]
II Congresso nazionale ISGE Italia
14 crediti
programma scientifico
Il programma scientifico del II Congresso
Nazionale della Associazione Italiana di Ginecologia Endocrinologica si inserisce all’interno del più ampio programma scientifico del
14th World Congress of Gynecological Endocrinology. Gli iscritti a quest’ultimo potranno
indistintamente scegliere se partecipare alle
sessioni in lingua italiana qui presentate o alle
altre sessioni del programma scientifico internazionale in lingua inglese.
In particolare le sessioni in italiano saranno:
hall affari 3
Venerdì 5 Marzo
08.30/10.30 - 11.00/13.00
Corso educazionale - BAYER ITALIA
CONFRONTI CLINICI
IN CONTRACCEZIONE ORMONALE
15.00/19.00
Corso educazionale - WYETH/PFIZER
CONTROVERSIE CLINICOTERAPEUTICHE NELL’AMBULATORIO
DEL GINECOLOGO
Sabato 6 Marzo
8.30/12.30
Corso educazionale - GUIDOTTI
SINDROME METABOLICA ED
INSULINO-RESISTENZA NELLA DONNA
12.40/13.10
ASSEMBLEA GENERALE ISGE ITALIA
Domenica 7 Marzo
8.30/10.30 Simposio organizzato da FIOG
SOMMINISTRAZIONE DI
ESTROPROGESTINICI CONTROVERSIE
E CLINICAL EVIDENCE
Crediti ECM
Il Congresso ha ottenuto 14 crediti ECM.
Il corso “Controversie clinico-terapeutiche nell’ambulatorio
del ginecologo” ha ottenuto 2 crediti ECM.
Il corso “Confronti clinici in contraccezione ormonale” ha
ottenuto 2 crediti ECM.
Il corso “Sindrome metabolica ed insulino-resistenza nella
donna” ha ottenuto 2 crediti ECM.
I corsi precongressuali hanno ottenuto 4 crediti ECM
ciascuno.
L’accreditamento ECM di “14th World Congress of the Gynecological Endocrinology” e dei corsi è stato richiesto per la categoria
del Medico chirurgo specialista in Ginecologia e ostetricia, Endocrinologia, Medicina generale. Le sessioni scientifiche accreditate
sono evidenziate nel Programma Scientifico con il simbolo ECM.
Per ottenere i crediti del Programma Educazione Continua in
Medicina è obbligatorio
Frequentare un numero di sessioni giornaliere ECM che
coprano l’intera giornata congressuale per l’intera durata del
Congresso;
Compilare il Questionario ECM in distribuzione al Desk
ECM della Segreteria Congressuale (o all’esterno della sala
per quanto riguarda i corsi accreditati); il Questionario
è stato strutturato per sessioni scientifiche. Si prega di
rispondere alle domande relative alle sessioni frequentate;
Compilare la scheda di valutazione.
Nota bene
Il questionario ECM insieme alla Scheda di Valutazione,
dovrà essere riconsegnato al desk ECM entro la fine
del Congresso.
La mancata compilazione della Scheda di Valutazione
invalida il questionario.
L’attestato ECM verrà inviato agli iscritti dopo aver
valutato la verifica dell’apprendimento.
33
34
Il Bollettino
Il Bollettino di Ginecologia Endocrinologica è dal
2007 l’organo di informazione e formazione on-line
della Associazione Italiana di Ginecologica Endocrinologica, strettamente collegata alla International Society
for Gynecological Endocrinology (ISGE). Il Bollettino
con la sua cadenza bimestrale (6 numeri ogni anno)
offre l’opportunità a tutti coloro che lo visitano o che
ricevono le News Letters, di aggiornarsi e di arricchire
la propria raccolta bibliografica sia con gli abstracts dei
lavori più rilevanti appena usciti sulle riviste internazionali sia scaricando, gratuitamente, delle mini reviews.
Le mini reviews sono la grande attrattiva del Bollettino.
Scritte da esperti italiani, affrontano dalla A alla Z ogni
aspetto sia clinico che diagnostico che terapeutico relativamente alla problematica clinica oggetto della mini
review. Le mini reviews sono facilmente scaricabili dal
sito come files pdf, stampabili o salvabili sul proprio
PC, sempre pronte quindi per la consultazione e la let-
il bollettino è online su www.bollettinoginendo.it
e ti raggiunge ogni due mesi nella casella di posta
tura. Possono essere anche stampate per offrire informazione alle proprie pazienti, al fine di migliorare la
compliance e il gradimento delle scelte clinico-diagnostiche oltre che quelle terapeutiche.
Lo scopo delle mini reviews è quello di offrire in poche
pagine una overview clinico-pratica che possa essere di
aiuto per l’attività professionale del ginecologo ma anche della paziente.
I temi trattati sono sempre molto vari, spesso lontani
tra loro ma sempre destinati a focalizzare l’attenzione
sulla salute della donna, lungo tutto il percorso della
sua esistenza da quando è bimba fino a quando sarà
una anziana.
Il Bollettino e le sue mini reviews sono una iniziativa
che riteniamo possa essere sempre di grande gradimento ed utilità non solo per il ginecologo ma per tutti
medici che in qualche modo sono dediti alla cura e alla
salute della donna.
35
Le monografie pubblicate nel 2009
Endometriosi: trattamenti attuali
Approccio diagnostico e terapeutico della
amenorrea primaria e del ritardo puberale
Metella Dei, Gilda Di Paolo°, Vincenzina Bruni
e nuovi orizzonti terapeutici
M.Vignali, C. D’Amico, M. Busacca
PCOS e Diabete Mellito Tipo II
E. Chierchia, S. Santagni, E. Rattighieri, C. Lanzoni,
F. Ricchieri, A.D. Genazzani
Isteroscopia e infertilità
Stefano Angioni, Beatrice Vacca, Stefania Sanna,
Gian Benedetto Melis
Il deficit estrogenico come fattore di stress
infiammatorio: un’ipotesi patogenetica unificata
per l’aumentato rischio osteoporotico e
Management del diabete gestazionale
Herbert Valensise, Giulia Gagliardi,
Francesco Altomare
Aspetti endocrini, diagnostici e terapeutici
delle menometrorragie in età perimenopausale
Erika Rattighieri, Chiara Lanzoni, Susanna Santagni,
Elisa Chierchia, Anna Lisa Campedelli,
Valerio M. Jasonni, Alessandro D. Genazzani
Le monografie pubblicate nel 2010
Il carcinoma mammario: diagnostica e trattamento
cardiovascolare in postmenopausa
chirurgico nella donna tra età fertile e
Francesco S. Pansini, Carlo M. Bergamini
premenopausa.
Alberto Farinetti
Il trattamento ormonale conservativo
nelle pazienti giovani con iperplasia atipica
o carcinoma endometriale
Angiolo Gadducci, Roberta Tana, Giulia Zanca
Il clomifene citrato nel trattamento della
infertilità in ambulatorio: dalla scelta della
paziente allo schema di trattamento.
Paolo Giovanni Artini, Francesca Papini,
Maria Ruggiero, Olga Maria Di Berardino, Vito Cela
Bollettino di Ginecologia Endocrinologica
Vol 4:1-9, 2010
ica
Il carcinoma mammario: diagnost
o nella donna
chirurgic
rari e/o
e trattamento
tardivi possono essere la linfoadenopatia sovraclaveare,
la secrezione ematica o siero-ematicapausa.
e premeno dal capezzolo, l’aspetto
tra età fertile
eczematoso-ulcerato del capezzolo nel morbo di Paget, l’edema
Alberto Farinetti
il carcinoma mammario: diagnostica e trattamento chirurgico nella
donna tra età fertile e premenopausa.
todica non è tuttavia indicata come esame diagnostico esclusivo (eccettuati i casi predetti), né come esame di screening, a
causa dell’insoddisfacente sensibilità per le lesioni precliniche,
del braccio3.
cioè non palpabili (50% circa, quindi molto inferiore rispetFarinetti
LaAlberto
sensibilità diagnostica dell’esameChirurgiChe
clinico è relativa- to alla mammografia, anche nelle donne giovani);
Di Chirurgia generale e SpeCialità
può essere
Dipartimento integrato
mente
bassa (70%) per
i tumori aventi diametro < 2cm. (T1) fatta seguire alla mammografia
anche qualora i reperti clinicoDi moDena e reggio emilia
univerSità
e si riduce
considerevolmente per lesioni di diametro inferio- mammografici non
siano dubbi ed in questo caso l’associazione
re al centimetro (lesioni che, d’altra parte, rappresentano ben migliora
la sensibilità diagnostica globale, a scapito però della
il 30-50% delle forme diagnosticate mediante mammografia specificità2
. Inoltre questa metodica viene utilizzata come guinei programmi di screening2); anche la specificità non è mol- da per
diverse procedure interventistiche (reperimento preoto elevata. Di conseguenza, l’esame clinico da solo non con- peratorio,
prelievo citologico ed istologico, agoaspirazione di
sente assolutamente di escludere la presenza di un tumore e, linfonodi
ormoalla gravidanza ed all’allattamento: gli ascellari ecograficamente sospetti in modo da evitare,
oppuredicorrelate
d’altra parte, la presenza
un reperto
clinico sospetto
ovaio.
deve totalità,
in casodall’
di positività,
introduzione
l’exeresi del linfonodo sentinella).
prodotti, per la quasi
steroidei,
sessuali con
esseredelle
ulteriormente
morti niindagata
test complementari.
il 20%
gli magnetica è una tecnica impiegata
Peral- nella
Ladonna,
risonanza
esponsabile a livello globale di oltre
sessuali comprende,
come
Il gruppo degli
1
tro, giova ricordare
mam- l’importanza
dell’eormoni
carcinoma
same clinico inteso
come Leeventuale
normali cellule
integrazione della mammografia e/o della ecografia
per tumore nel sesso femminile , il autoesame
e gli androgeni.
il progesterone
inci- estrogeni,
dalla donna
tanto per praticato
su se stessa: ancoratutte
oggi,
no- molecole,
che sono
in particolare
qualora non si possa fare ricorso all’approccio
queste
mario è nella donna il primo tumorenostante
recettori per
crescentemammarie
diffusionehanno
dei programmi di principali
svi- di questa metodica, estremamente sensibinegli Stati Uniti illa triste
screening,promotori
dello
bioptico;
il limite
denza quanto per mortalità: soltanto
considerate i
da tempo
si
calcola che del
oltre iloramai
60% delle
donne scopra di avere siuncomportano
appannaggio
car- le (95-100%
come fattori
per il carcinoma infiltrante7) è la scarsa specifimammario;
primato concernente la mortalità è diventato cinoma mammario
carcinoma
luppo
le del
proprie
mani; anche alla luce
ascesa a seguito dell’af- con
nel
delle
forte
in
cità,
per
amplificano,
cui
tumore
il
suo
che
impiego
come primo esame in diagnostica
fattori
o
broncogeno,
carcinoma
o condizioni
gli eventi
di rischio
informazioni
che può
.
fornire (tempo di comparsa
tabagica2importanti
l’entitàsi dell’
senologica
tradurrebbe in un eccesso di falsi positivi, con
fermarsi, tra le donne, dell’abitudine
o dell’ intensità o di entrambe,
della duratanel
sensovolumetrica
della
lesione,
fattori
sua
crescita
diversi
tempo),
l’
e
dagli
conoscono
secuzione
si
solo
conseguente
non
richiesta
di successivi controlli e biopsie inutili e
Per il carcinoma mammario
sulla ghiandola mammaria
esercitata
più influenza
dell’autoesame
deve essere
fin d’ora che
raccomandata
dai medici
ricordareperiodica
. tempo
ruolo, 7un
di rischio: è nondimeno opportuno
anche dagli androgeni, il cuicostose
bensì
dinon
medicina
2
generale estrogeni,
e dai medici
è riconduspecialisti, che sono chiamati
. indicazioni sono8:
Le principali
recente rivalutato ed anzi enfatizzato
della metà dei casi di carcinoma mammarioad offriredal
è stato di
trascurato,
donne ogni
delucidazione
in merito alle modalità
a prescindere allesesso
I. screening delle donne a rischio genetico (mutazione
cibile ad alcun fattore di rischio noto,
di esecuzione.
2
sistematiUna rassegna
di BRCA 1 o BRCA 2)
femminile e dall’invecchiamento .
Tra dall’
tutteesame
le metodiche diagnostiche la mammografia è
aperta
II. ricerca di carcinoma primitivo metastatico, occulto
ca dei fattori di rischio viene generalmentequella che
presenta la maggiore sensibilità, in particolare per i
Il carcinoma mammario
ma di sospetta origine mammaria, allorchè gli esami
E
dei fattori demografici: sesso ed età.
tumori ilinrapporto
fase iniziale: per questo tipo diCLASSIFICAZION
lesioni la DELLA
femminile:
sensibilitàMAMMELLA
convenzionali siano negativi.
è appannaggio quasi assoluto del sesso
CARCINOMA
DEL
raggiunge
età la consente l’esplorazione in toto della mam- dei III.
riguardail l’94%6:
ciò che
ricerca della
carcinomi
di multicentricità, multifocalità, bilateralità,
istopatologica
femmina/maschio è pari a 150:13. Per
classificazione
mella ie25-30
permette
anni,di definire l’eastensione,
la mono odue
e
multifocadonne dopo
duttale
in caso
di carcinomi
già diagnosticati con le indagiistotipi principali,
neoplasia colpisce maggiormente le
prevede
mammella
litàpresenta
e l’eventuale
un anbilateralità; infine
3
presenta un’eccellente speciod infil- e candidati ad intervento chirurgico
in situ
ni tradizionali
salvo rarissime eccezioni . Il tasso d’incidenza
lobulare, ciascuno dei quali può essere
ficità,
tumori
98%6.
altri del
glicirca
di tutti
ed anatoconservativo.
più rari, con aspetti clinici
damento peculiare, diverso da quello
ed istotipièspeciali,
sensibilità adellatrante,
mammografia
riproduttivi:
particolarmente apormonali eLa
IV. monitoraggio delle lesioni mammarie trattate con
epiteliali non dipendenti da fattori
prezzabile nelle
tà mo-patologici
con l’edonne
sopra i 35-40 peculiari.
anni e nelle donne il
riveste la neoadiuvante (prechirurgica), specuisenza dubbio
chemioterapia
partire dai 25 anni, il tasso aumenta esponenzialmente
duttale è quello che
Il carcinoma
presenta
una significativa
perimenocomponente adiposa, tende alla forma di
periodo
fino al seno
gran lunga
cialmente
per quel che riguarda le dimensioni della
clinica, essendo
(come per gli altri tumori epiteliali)
importanza
maggiore
contrario
a
ridursi
6
questo
in
(fino
al
70%)
anni);
nel
53
caso
i
dei
e
cosiddetti
45
carcii
Il
“seni
.
tra
lesione residua, che a volte può non essere ben diffequella con la prognosi peggiore
pausale (compreso grosso modo
nonché
densi”6,
anzi più comune
che si riscontrano
e subisce
più spesso
nelle donne giovani: in
di crescere
renziabilenella
da aree fibrotiche o necrotiche.
intervallo temporale l’incidenza cessa
può, come il carcinoma lobulare, presentarsi
duttale
un nomava
casi,
mammografia
malacon
integrata
crescere,
aquesti
con altre metodiche,a seconda
che le cellule
V. follow
up della mammella sottoposta a chirurgia
una lieve diminuzione, per poi riprendere ecografia
4
forma invasiva o nella forma in situ
in primis.
.
basale deie/o radioterapia, in presenza di dubbio
conservativa
“rate” inferiore, dopo l’età della menopausa Gli esiti
abbiano o meno superato la membrana
neoplastiche
diagnostici della
mammografia
una percentuavengono classificacir- differenziale tra recidiva e cicatrice
nella diagnosi
infiltrato lo stroma fibro-adiposo
Esistono poi fattori di rischio genetici:
dotti 6e,
ti nelle mammarie
è classi
seguenti cinque
: di conseguenza,
neoplasie
nondi malignile compresa tra il 5% e il 10% delle
ciò che conferisce alla lesione il carattere risolto dagli esami tradizionali e non risolvibile
il costante,normale.
3
quadro mammografico
di sviluppare
Il rischio» R1:
si parla cito/istologico.
con il prelievo
strettamente legata a questi fattori .
allo sviluppo del carcinoma duttale
In riferimento
» R2:delle
quadro
parenti
benignotà.(nessun
provvedimento)
al numero
VI.l’evalutazione
pitelio duttale
di impianti protesici.
tappe:
più
a
carcinoma mammario è proporzionale
cancerogenesi
di
in di un processo
» R3: quadro
all’etàprobabilmente
benigno (valore predittivo
proporzionale
pro- cito-istologici in lesioni evidenziaVII. guida per prelievi
di primo grado affette ed inversamente 4
prima iperplastico, vale a dire abnormemente
diverrebbe
positivo
2%): richiede
specie <umana
un approfondimento
. Nella
diagnobiliA sua volta RM.
cui queste hanno sviluppato la malattia
poi displastico (iperplasia con atipie)2. solo con la
sticonelle
od unforme
controlloliferante,
ravvicinato.
implicati
relazione al
sono stati individuati almeno due geni
può essere lieve, moderata o grave in
displasia
» R4:
sospettola(VPP
nel braccio
sitoquadro
2-70%):
richiede il risconBRCA1,
parametri
dei della
Il peso
medicina nucleare nella diagnostica senolosulla base
familiari del carcinoma mammario:
grado di atipia delle cellule, stabilito
trobraccio
citologico
lungo
e/o istologico.
posto nel
gicadisidifferenziazione
è grandemente accresciuto in virtù dell’introduzione di
lungo del cromosoma 17 e BRCA2,
che indicano la perdita
anatomo-patologici
» R5:
della
quadro
positivo
cancro
o
maligno
di
(VPP
casi
>70%):
nurichiede
rarissimi
nei
due
rapporto
nuove tecniche di estrema utilità: lo studio del linfonodo
del
del cromosoma 13 e coinvolto
cellule (dedifferenziazione): aumento
riscontro
quasi delle
nella citologico
e/o istologico.
2
rischio ilsono
sentinella,
pleomorfismo
che viene individuato tramite l’uso di radioisotopi e
ipercromatismo nucleare,
mammella maschile . Altri fattori di
6
meccanismo endocrino, cleo-citoplasmatico,
. La
mitoticoradioguidata
localizzazione
delle lesioni occulte della mamnucleare, elevatolaindice
totalità riconducibili e coerenti con un
cellulare,
L’ecografia
è l’esame di
al controllo
elezionepleomorfismo
nelle donne giovani
deputati
sin- mella. in situ, vale a
mediato dagli ormoni fisiologicamente tomatiche regolazione
altro non è se non il carcinoma
inferiore grave
alla (donne di età displasia
a 35 anni, il cui seno, free
neoplastiche
Un ruolo
promettente
è poi svolto dalla scintigrafia mamdi cellule francamente
della ghiandola mammaria ed in particolare
una proliferazione
diresempre
quentemente
cicliche non
siano esse“denso”,
può essere indagato nel maria, che consiste nella somministrazione di
farmaci oncotrodelle sue modificazioni anatomo-funzionali,
migliore dei modi tramite la mammografia), in gravidanza e pi legati
al tecnezio radioattivo (radiomarcati) i quali si accudurante l’allattamento; l’ecografia integra inoltre la mammo- mulano
all‘interno della lesione neoplastica: questa metodica,
grafia in presenza di reperti mammografici dubbi (evenienza che consente
anche la visualizzazione di eventuali linfonodi
che, come detto, si verifica più spesso in caso di mammella con ascellari
{1}
positivi, è senz’altro promettente, ma rimane a tutt’ogcomponente adiposa modesta, “densa“ appunto). Questa me- gi un esame
integrativo, non convenzionale.
9
R
L
{3}
Bollettino di Ginecologia Endocrinologica
Vol 4:1-9, 2010
Palazzo affari
Piano 3
3
9 Il Bollettino di
Ginecologia
Endocrinologica
3 Hall Affari 3
36
Welcome
14th World congress
of Gynecological endocrinology
March 4–7, 2010 · Florence, Italy
Bayer Schering Pharma cordially invites
you to our symposia on menopause and
endometriosis management:
Young at Heart
March 5, 2010 . 15:00 –17:00
hall affari 1 (1st floor),
Palazzo affari
Innovation in Endometriosis Therapy
March 6, 2010 . 11:10 –13:10
hall auditorium (ground floor),
14th World Congress of gyneCologiCal endoCrinology
March 4 –7, 2010 . Florence, Italy
37
Scientific
Programme
Programme at a glance
Wednesday March 3rd
Thursday March 4th
Friday March 5th
Saturday March 6th
Sunday March 7th
38
40
43
59
75
86
38
wednesday 3 Hall Auditorium
09.30 -18.30
Hall Verde
thursday 4 Hall Auditorium
08.45 -10.15 New frontiers in art
Hall Verde
Stem cells
Hall Affari 1
Hyperandrogenisms and reproduction
(pre-congress course)
Hall Affari 1
Climacteric medicine
10.35 -11.05 Testosterone and the breast
Seamless healthcare for ageing patients Why is estrogen protective against
cardiovascular disease, but not against
stroke?
11.10 -13.10 Ibsa Fostimon, human type FSH; from New concepts on gonadotrophin
Hormonal contraception for woman’s
basic science to clinical practice
signaling
and man’s health
Premature ovarian failure
Hormonal regulation of cardiovascular
14.10 -16.10 Theramex Oral contraception: The
achievement of 50 years of Hormonal research
function
16.30 -18.30 Schering Plough Low–dose
Ovarian cancer
Obesity and gynecological
contraception: why, how and how much
endocrinology
18.30 -19.45 Opening Ceremony
and Opening lecture
19.45 - 20.45 Aperitif
friday 5
Hall Auditorium
08.30 -10.00 Association Française pour l’étude
de la menopause
When menopause comes too early
10.30 -11.00
11.10 -13.10
14.10 -15.00
15.00 -17.00
17.20 -19.20
Hall Verde
Johnson &
Johnson Medical
Live reproductive
surgery session
Estetrol: a fetal estrogen for clinical use Gyne surgery under
Theramex A woman’s journey: 3 main imaging conditions
periods of a woman’s life through 3
therapeutic areas
Should there be an international limit on Is there a role for
the number of fertilized oocytes that are metformin in the
implanted in a woman at one time?
treatment of PCOS
women?
Merck Serono The future of fertility:
Androgens
individualised therapy
in women
Follicular growth, oocyte quality, embrio Female sexuality
selection and endometrial receptivity:
an unsolved puzzle
Hall Belvedere
Roundtable
Discussion
The Hot Flush:
Benign Annoyance
or Predictor of
Neurological
Vulnerability?
19.20
Hall Affari 1
Academy of Human Reproduction
The future trends of induction of
ovulation - dedicated to the late
dr. Sheldon Segal
Fertility preservation in woman with breast
cancer: a need for a global strategy
Breast cancer
Diagnostic tools for menopausal
symptoms
Bayer Schering Pharma
Young at heart
From nature for menopause
Arts in Florence - visit to Bargello Museum
saturday 6
Hall Auditorium
08.30 -10.00 Esg/Seg Polycystic ovarian-metabolic
syndrome (pcos) from birth to postmenopause
10.30 - 11.00 Inflammation and endometriosis
11.10 - 13.10 Bayer Schering Pharma
Innovation in endometriosis therapy
14.10 - 15.00 Is pcos a disease or an adaptation?
15.10 - 17.10 50 Years of ovarian stimulation with
human gonadotropins
17.10 - 19.30 Poster session in Poster Area
sunday 7
Hall Auditorium
08.30 - 10.30
Hall Verde
Sobrage Health benefits of the
extended use of oral contraceptives
Hall Affari 1
IMS
Unanswered questions on HRT
Acupuncture in reproductive medicine
Dydrogesterone in HRT
New ultra - low dose regimen to come
Woman’s health through menopause
and ageing
Are estrogens neuroprotective?
Art: from basic science to clinical
application
Are progestins always needed to
counteract effects of estrogens after
menopause?
Progesterone and progestins: their
targets
11.00 - 13.00
Hall Affari 1
New mechanisms of steroid receptor
signaling
Testosterone and male sexual attitudes
and behaviours
Contraception in 2010
13.00 - 13.30
Closing Ceremony and Poster Awards
10.30 - 11.00
Hall Verde
Hormones and female brain ageing
wed
thur
Hall Affari 2
Hall Affari 2
Pathogenesis of preeclampsia: from
immunology to angiogenesis inhibition
Dydrogesterone - the missing link to
improved maternal blood flow
Current issues in preterm birth and
placental function regulation
Uterine fibroids: from the bench to the
bedside
New horizons in endometriosis
fri
Hall Affari 3
Hall Affari 4
Therapeutical use of hormonal contraception
(precongress course)
Hall Affari 3
Hall Affari 4
Targeting the endometrium with new
Premature ovarian
molecules: SPRMS and SARMS
insufficiency
Diagnosis and management of PCOS
from birth to senescence
Polycystic ovary syndrome
Sierr Oocyte quality in biology of
reproduction and human IVF
Winners under 34 competition symposium
Reproductive
neuroendocrinology
Androgens and
hyperandrogenisms
Breast cancer
Hall Onice
39
Hall Onice
Female sexual function
and dysfunction
Medically-assisted
procreation
Infertility
Regulation of the
endometrium
Hall Affari 2
Hall Affari 3
Sociedad Argentina De Endocrinologia Bayer Italia
Ginecologica Y Reproductiva
Confronti clinici in contraccezione ormonale
Ovarian ageing: impact for fertility
preservation
New aspects of OHSS
Hall Affari 4
Hall Onice
Polish group of G.E. Fertility and
Hot topics in
pregnancy in 2010
gynecological
endocrinology
Chronic anovulation
Hormones and
hormone receptors
Patophysiology of
PCOS
Advances in
contraception
Clinical and
therapeutical aspects
of PCOS
HRA PHARMA A new look at emergency Prevention of postmenopausal osteoporosis:
contraception
hormones or bisphosphonates?
sat
Endometriosis: from the bench to the
bedside
Endometrial hyperplasia and cancer
Wyeth/Pfizer
Controversie clinico-terapeutiche
nell’ambulatorio del ginecologo
Gynecological
cancers
Miscarriage and
abortion
Hall Affari 2
Ispog Psychosomatic Obstetrics and
Gynaecology at patient’s side
Hall Affari 3
Guidotti “Sindrome metabolica ed insulinoresistenza nella donna”
-
Post-menarchal disorders and reproductive
tract anomalies
Hall Affari 5 and 4 Hall Onice
Ethicon Women’s & Gynecological
Urology - Johnson & endocrinology and
Johnson medical infertility
Karl Storz
8.30/13.00 AFFARI 5
See and Treat
Frontiers in pregnancy
Theoretical Part
research
14.00/17.00 AFFARI 4
See and Treat
Practical activities
(special registration
Advances in imaging
needed)
and surgery
Hall Affari 2
Benign Gynecological disorders
Hall Affari 3
Fiog Somministrazione di estro progestinici:
controversie e clinical evidence
Hall Affari 4
Hall Onice
Menopause and
cardiovascular disease
Diseases of pregnancy
Early pregnancy diagnosis and treatment
Menopause, quality of
life and osteoporosis
Medical ethics – who writes the rules?
sun
SERMS
12.40-13.10
Assemblea generale isge italia
Amgen in collaboration with GSK
New concept for the treatment of
postmenopausal
Endocrine control of bone metabolism
Are progestins effective for threatened
abortion?
40
Wednesday March 3rd
Wednesday March 4th
Hall AFFARI 1
HYPERANDROGENISMS AND REPRODUCTION
09.30/18.30
SCHOOL OF GYNECOLOGICAL AND REPRODUCTIVE ENDOCRINOLOGY
Chairpersons: Lunenfeld Bruno (IL), Tarlatzis Basil (GR)
Genazzani Alessandro D (I)
Pathophysiology and hormonal screening
Battaglia Cesare (I)
Ultrasound imaging: use in diagnosis and follow-up
Lanzone Antonio (I)
Medical treatment and management
Tarlatzis Basil (GR)
Surgical and ART treatment
Devoto Luigi (RCH)
Hyperandrogenism at and after menopause
Kiesel Ludwig (D)
Clinical cases: hyperandrogenic woman with hyrsutism, acne and no will of pregnancy
Fauser Bart, (NL)
Clinical cases: overweight patient with hyperinsulinism and oligo-amenorrhea seeking
pregnancy
41
Hall AFFARI 3
THERAPEUTICAL USE OF HORMONAL
CONTRACEPTION
09.30/18.30
SCHOOL OF GYNECOLOGICAL AND REPRODUCTIVE ENDOCRINOLOGY
Chairpersons: Foidart Jean-Michel (B), Naftolin Frederick (USA)
Schindler Adolf (D)
How to select the contraceptive for each specific woman
Berga Sarah (USA)
Oligo and amenorrhea
Baird David (UK)
Dysfunctional uterine bleeding and dysmenorrhea
Nappi Rossella (I)
PMS, PMDD and catamenial disorders
Petraglia Felice (I)
Fibroids, endometriosis and functional ovarian cysts
Lobo Rogerio (USA)
Overcoming side effects
Bitzer Johannes (CH)
Clinical cases: Mood and sex in pill user
Vujovic Svetlana (SR)
Clinical cases: Irregular cycles and ovarian cysts
Wednesday March 4th
42
FIRENZE, ITALY MARCH 8-11 2012
Professional Congress Organizer
WWW.ISGE2012.COM
Thursday March 4
43
th
Hall Verde
Hall Affari 1
Stem cells
Climacteric medicine
10.35 -11.05 Testosterone and the breast
Seamless healthcare for ageing patients Why is estrogen protective against
cardiovascular disease, but not against
stroke?
11.10 -13.10 Ibsa Fostimon, human type FSH; from
New concepts on gonadotrophin
Hormonal contraception for woman’s
basic science to clinical practice
signaling
and man’s health
Premature ovarian failure
Hormonal regulation of cardiovascular
14.10 -16.10 Theramex Oral contraception: The
achievement of 50 years of Hormonal research
function
16.30 -18.30 Schering plough Low–dose
Ovarian cancer
Obesity and gynecological
contraception: why, how and how much
endocrinology
18.30 -19.45 Opening Ceremony
and Opening lecture
19.45 - 20.45 Aperitif
Hall Affari 2
Hall Affari 3
Hall Affari 4
08.45 -10.15 Pathogenesis of preeclampsia: from
immunology to angiogenesis inhibition
Targeting the endometrium with new Premature ovarian
molecules: SPRMS and SARMS
insufficiency
10.35 -11.05 Dydrogesterone - the missing link to
improved maternal blood flow
11.10 -13.10 Current issues in preterm birth and
placental function regulation
14.10 -16.10 Uterine fibroids: from the bench to the
bedside
16.30 -18.30 New horizons in endometriosis
Diagnosis and management of PCOS
from birth to senescence
Polycystic ovary syndrome
Reproductive
neuroendocrinology
Sierr Oocyte quality in biology of
Androgens and
reproduction and human IVF
hyperandrogenisms
Winners under 34 competition
Breast cancer
symposium
Today’s picks
Opening Ceremony
18.30 Hall Auditorium
Chairpersons: ANDREA R. Genazzani (I),
Palumbo Giuseppe (I), Maruo Takeshi (JP),
Lombardi Gaetano (I), Benedetto chiara (i),
Vittori Giorgio (I)
Mendelsohn Michael (USA)
The biology of estrogen receptor action in
cardiovascular health and disease
Hall Onice
Female sexual
function and
dysfunction
Medically-assisted
procreation
Infertility
Regulation of the
endometrium
Thursday March 4th
Hall Auditorium
08.45 -10.15 New frontiers in art
44
Thursday March 4th
Thursday March 4th
Hall Auditorium
NEW FRONTIERS IN ART
08.45/10.15
PLENARY SESSION
ECM
Chairpersons: Scarselli Gianfranco (I), Zygmunt Marek (D)
Devoto Luigi (RCH)
The physiological function of progesterone receptor in the human ovulatory process
Monteleone Patrizia (I)
Role of thyroid autoimmunity in female infertility
Fuji Haruko (JP)
Blastocyst attachment is regulated by Eph-ephrin A system
Chances for fertility preservation and ovulation induction in POF patients
10.35/11.05
PLENARY LECTURE
Kenemans Peter (NL)
Testosterone and the breast
ECM
Chairpersons: Ambrosini Antonio (I), von Schoultz Bo (S)
11.10/13.10
SPONSORED SYMPOSIUM - IBSA
FOSTIMON, HUMAN TYPE FSH: FROM BASIC SCIENCE
TO CLINICAL PRACTICE
Chairpersons: Revelli Alberto (I), Tarlatzis Basil (GR)
Filicori Marco (I)
FSH isoforms in human reproduction: an overview
Gürgan Timur (TR)
Highly glycosylated FSH: available clinical results and investigational issues
Ménézo Yves (F)
Effects of FSH stimulation regimens on the pattern of mRNA expression in human cumulus
cells
Aboulghar Mohamed (ET)
Efficacy and safety of FSH drug products for ART in PCOS
SPONSORED SYMPOSIUM - THERAMEX MERCK SERONO
45
ORAL CONTRACEPTION: THE ACHIEVEMENT OF 50 YEARS OF
HORMONAL RESEARCH
Chairpersons: Bouchard Philippe (F), Genazzani Andrea R (I)
Sitruk Ware Regine (USA)
Hormonal creativity in contraception
Bruni Vincenzina (I)
How nomegestrol acetate leads to estradiol in a monophasic regimen?
Jamin Christian (F)
Metabolic consequences from such evolution
Fruzzetti Franca (I)
Achieving lower impact on hemostasis parameters
16.30/18.30
SPONSORED SYMPOSIUM - SCHERING PLOUGH
LOW – DOSE CONTRACEPTION: WHY, HOW AND HOW MUCH
Chairpersons: De Melo Nilson Roberto (BR), Scarselli Gianfranco (I)
Nappi Rossella (I)
Counseling in contraception: fundamental to a tailored approach
Cagnacci Angelo (I)
The benefits of intravaginal administration of hormonal contraception
Nappi Rossella (I)
The tolerability of intravaginal administration of hormonal contraception
Benedetto Chiara (I)
To “E” or not to “E”: contraception without estrogen
18.30/19.45
OPENING CEREMONY
OPENING LECTURE
Chairpersons: Genazzani ANDREA R. (I), Palumbo Giuseppe (I),
Maruo Takeshi (JP), Lombardi Gaetano (I), Benedetto chiara (i),
Vittori Giorgio (I)
Mendelsohn Michael (USA)
The biology of estrogen receptor action in cardiovascular health and disease
Hall VERDE
STEM CELLS
08.45/10.15
PLENARY SESSION
ECM
Chairpersons: Huhtaniemi Ilpo (UK), Petraglia Felice (I)
Gil Sanchis Claudia (E)
What do we know about endometrial stem cells?
Enseñat Roberto (E)
Reprogramming as a new approach to obtain patient specific stem cells
Zhou Canquan (PRC)
The establishment of human parthenogenetic stem cell line and its DNA methylation
Eden John (AUS)
Breast cancer stem cells
Thursday March 4th
14.10/16.10
46
Thursday March 4th
10.35/11.05
PLENARY LECTURE
Naftolin Frederick (USA)
Seamless healthcare for ageing patients
11.10/13.10
PLENARY SESSION
NEW CONCEPTS ON GONADOTROPHIN SIGNALING
ECM
Chairpersons: Eden John (AUS), Rees Margaret (uk)
ECM
Chairpersons: Alviggi Carlo (I), Tempone Antonio (RA)
Huhtaniemi Ilpo (UK)
Novel molecular mechanisms of gonadotrophin action
Aittomaki Kristina (FIN)
Gonadotrophin receptors: functional insights from genetic variants
Zygmunt Marek (D)
Vascular actions of gonadotrophins
Sanchez Matias (RA)
Breast actions of gonadotrophins
Zaidi Mone (USA)
Actions of gonadotrophins on the bone
14.10/16.10
PLENARY SESSION
PREMATURE OVARIAN FAILURE
ECM
Chairpersons: MASSOBRIO MARCo (I), Smetnik Vera (RUS)
Massobrio Marco (I) - Revelli Alberto (I)
Genetics of premature ovarian failure
Tempone Antonio (RA)
Iatrogenic POF
Fauser Bart (NL)
Anti-Mullerian Hormone and other markers of residual ovarian potential
Castelo-Branco Camil (E)
Medical treatment for prevention of POF
Morfín Julio (MEX)
POF: definition, diagnosis and treatment
16.30/18.30
PLENARY SESSION
OVARIAN CANCER
Chairpersons: Franchi Massimo (I), Uzan Serge (F)
Pecorelli Sergio (I)
Hormones and ovarian cancer
Barri Pedro (E)
ART and ovarian cancer
Gadducci Angiolo (I)
Therapeutical approach to recurrent ovarian cancer
Prat Jaime (E)
Subclassification of ovarian cancer based on pathology and genetics
Metka Markus (A)
Antioxidative, anti-inflammatory and chemopreventive potency of phytosubstances:
the isoflavone resveratrol and epigallocatechin
ECM
Hall AFFARI 1
PLENARY SESSION
CLIMACTERIC MEDICINE
ECM
Chairpersons: Becorpi Angelamaria (I), Milewicz Andrzej (PL)
Lello Stefano (I)
Pharmacology of post-menopause and aging
Brincat Mark (M)
The ageing of connective tissues in women: the menopause crossing
Gambacciani Marco (I)
Personalized therapies in postmenopausal women
Rees Margaret (UK)
Managing the Menopause without oestrogen
ECM
10.35/11.05
PLENARY LECTURE
Lobo Rogerio (USA)
Why is estrogen protective against cardiovascular
disease, but not against stroke?
Chairpersons: Mendelsohn Michael (USA), Selvaggi Luigi (I)
ECM
11.10/13.10
PLENARY SESSION
HORMONAL CONTRACEPTION FOR WOMAN AND MAN’S HEALTH
Chairpersons: lello Stefano (I), Lobo Rogerio (USA)
Future perspectives for hormonal contraception and woman’s health
Blithe Diana (USA)
Current status of male contraceptive development
Maia Hugo (BR)
Hormonal contraception and the risk of cancer
Serfaty David (F)
Interest of LONG-acting reversible contraception
Skouby Sven (DK)
Metabolic actions of hormonal contraceptives
ECM
14.10/16.10
PLENARY SESSION
HORMONAL REGULATION OF CARDIOVASCULAR FUNCTION
Chairpersons: Angioli Roberto (I), Castelo-Branco Camil (E)
Siseles Nestor (RA)
HRT and CVS - an update
Karas Richard (USA)
Molecular mechanisms regulating rapid vascular dilation by estrogen receptors
Vaughan Douglas (USA)
Hormonal regulation of the renin-angiotensin-aldosterone system and endothelial
function in postmenopausal women
Rosano Giuseppe (I)
Metabolic therapy for the treatment of cardiovascular diseases in the Perimenopausal Woman
Lobo Rogerio (USA)
The future of clinical cardiovascular trials of HRT in menopausal medicine
Thursday March 4th
08.45/10.15
47
48
16.30/18.30
PLENARY SESSION
OBESITY AND GYNECOLOGICAL ENDOCRINOLOGY
ECM
Thursday March 4th
Chairpersons: Perino Antonio (I), Simpson Evan (AUS)
Hirschberg Angelica (S)
Hormones and the regulation of feeding behavior
Berg Gabriela (RA)
Abdominal adiposity, sex hormones and insulin resistance
Milewicz Andrzej (PL)
Polymorphisms of endocannabinoid receptors and serum adiponectin and obese
phenotype in postmenopausal women
Al-Azzawi Farook (UK)
Management of obesity in gynecological practice
Stevenson John (UK)
Should all menopausal women with metabolic syndrome receive HRT?
Hall AFFARI 2
08.45/10.15
PLENARY SESSION
PATHOGENESIS OF PREECLAMPSIA: FROM IMMUNOLOGY TO
ANGIOGENESIS INHIBITION
Chairpersons: Branconi Francesco (I), Chedraui Peter (EC)
Arck Petra (D)
Immunology and implantation
Lyall Fiona (UK)
Mechanisms underlying failed trophoblast invasion in preeclampsia
Redman Christopher (UK)
Preeclampsia and the long arm of the innate immune system
Foidart Jean-Michel (B)
The molecular mechanisms of action of sVEGFRs in preeclampsia
10.35/11.05
PLENARY LECTURE
Daya Salim (CDN)
Dydrogesterone - the missing link to improved
maternal blood flow
Chairpersons: Arck Petra (D), Caruso Alessandro (I)
PLENARY SESSION
CURRENT ISSUES IN PRETERM BIRTH AND PLACENTAL
FUNCTION REGULATION
ECM
Chairpersons: Redman Christopher (UK), Lyall fiona (UK)
Challis John (CDN)
Preterm birth and stress hormones
López Bernal Andrés (UK)
Prostaglandins and preterm birth
Torricelli Michela (I)
Preterm birth and neuropeptides
Iwashita Mitsutoshi (JP)
Regulation of placental function by insulin-like growth factor (IGF) and IGF-binding
proteins
Giles Warwick (AUS)
The management of major forms of placenta percreta
14.10/16.10
PLENARY SESSION
UTERINE FIBROIDS: FROM THE BENCH TO THE BEDSIDE
ECM
Chairpersons: Cicinelli Ettore (I), Clementi Wolfgang (a)
Morton Cynthia (USA)
Genetics of uterine fibroids
Chegini Nasser (USA)
MicroRNAs and fibroids
Maruo Takeshi (JP)
Nonsurgical treatments of fibroids: Selective progesterone receptor modulators
Sciarra John (USA)
Alternatives to hysterectomy
Ben-Rafael Zion (IL)
Uterine fibroids and ART – is there any Dilemma left?
16.30/18.30
PLENARY SESSION
NEW HORIZONS IN ENDOMETRIOSIS
Chairpersons: Busacca Mauro (I), Schenker Joseph (IL)
Caserta Donatella (I)
Environmental disruptors and endometriosis
Zondervan Krina (UK)
Genetics of endometriosis
Osuga Yutaka (JP)
Immune and inflammatory aspects of endometriosis
Bulun Serdar (USA)
Endometriosis and sex steroids
Endometriosis and peptides
49
Thursday March 4th
11.10/13.10
ECM
50
Hall AFFARI 3
TARGETING THE ENDOMETRIUM WITH NEW MOLECULES:
SPRMS AND SARMS
08.45/10.15
PLENARY SESSION
ECM
Thursday March 4th
Chairpersons: daya salim (CDN), Marchionni Mauro (I)
Bouchard Philippe (F)
The SPRMS and SARMS
Pintiaux Axelle (B)
The impact of SPRMS on endometrial vascularization
Marbaix Etienne (B)
Molecular mechanisms of SPRMS on endometrial gene expression
Williams Alistair (UK)
The endometrial response to progesterone receptor modulators
10.35/11.05
PLENARY LECTURE
Lunenfeld Bruno (IL)
Diagnosis and management of pcos from birth
to senescence
ECM
Chairpersons: Carmina Enrico (I), Messinis Ioannis (GR)
11.10/13.10
PLENARY SESSION
POLYCYSTIC OVARY SYNDROME
ECM
Chairpersons: Ibáñez Lourdes (E), Lanzone Antonio (I)
Dunaif Andrea (USA)
PCOS: from genes to pathophysiology
Hart Roger (AUS)
Prenatal influences on female reproduction
Palomba Stefano (I)
Infertility and pregnancy
Carmina Enrico (I)
Metabolic issues and lifetime risks
Messinis Ioannis (GR)
Control of LH secretion in PCOS
14.10/16.10
PLENARY SESSION ORGANIZED BY SOCIETÀ ITALIANA DI EMBRIOLOGIA RICERCA
E RIPRODUZIONE
OOCYTE QUALITY IN BIOLOGY OF REPRODUCTION AND
HUMAN IVF
Chairpersons: Coticchio Giovanni (I), Tatone Carla (I)
Zuccotti Maurizio (I)
Oocyte-derived regulators of early embryonic development
Ledda Sergio (I)
Cellular and biochemical criteria to assess oocyte quality
Chigioni Sara (I)
Domestic animal models as a tool to understand human oocyte maturation
Focarelli Riccardo (I)
A proteomic approach to the study of human oocyte microenvironment
16.30/18.30
PLENARY SESSION
WINNERS UNDER 34 COMPETITION SYMPOSIUM
Chairpersons: Naftolin Frederick (USA), Simoncini Tommaso (I)
Broer Simone L, Van Rooij I, Scheffer G, Eijkemans M, Fauser BC, Broekmans FJ,
(NL)
Anti-Müllerian Hormone in the prediction of menopausal transition or menopause; a
follow-up study
Meehan K, Rainczuk A, Fairweather N, Stephens A (AUS)
Characterisation of early ovarian cancer biomarkers
Sundermann Erin E, Mordecai K, Rubin LH, Eatough E, Savarese A, Maki PM (USA)
The Effects of Menstrual Cycle Phase & Stress on Cognitive Flexibility
Taran AF, Stewart EA, Chen J, Gostout BS, Woodrum DA, Felmlee J, Ehman DRL (USA)
Magnetic Resonance Elastography Allows Quantitative Assessment of Uterine Leiomyomas
Pelekanou V, Kampa M, Gallo D, Notas G, Jacquot Y, Castanas E, Leclercq G (B)
ER17p, a peptide corresponding to the regulatory platform P295-T311 of ER-alpha: role
in actin cytoskeleton, migration and apoptosis
Hall AFFARI 4
08.45/10.15
Oral Presentations
PREMATURE OVARIAN INSUFFICIENCY
Chairpersons: Aittomaki Kristina (FIN), Luisi Stefano (I)
Ayed W, Bouayed Abdelmoula N, Houiji D, Harzallah F, El Kamel Lebbi I, Zhioua F,
Abdelhak S, Amouri A (TN)
Clinical, Cytogenetic and Molecular Study in Premature Ovarian Failure. A Tunisian Study
Dragojević-Dikić S, Vujovic S, (SRB - MNE)
The influence of hormone replacement therapy(HRT) on fertility in premature ovarian
failure(POF) patients
Janse F, Knauff EAH, Niermeijer MF, Eijkemans MJ, Laven JSE, Lambalk CB, Fauser
BCJM, Goverde AJ, (NL)
Similar presentation of sporadic and familial premature ovarian failure (POF)
Lipovac M, Rudelstorfer G, Imhof M, (A)
AMH - an eligible marker of ovarian function for oncological patients undergoing ovarian
tissue banking
Moridi I, Fallahian M, Mahdian M, (IR)
Does ovarian drilling precede premature ovarian failure in Clomiphene resistant PCOD
patients?
Pellatt L, Dilaver N, Heshri A, Galea R, Brincat M, Rice S, Mason HD, (UK)
Mechanism of effects of raised AMH in anovulatory polycystic ovary syndrome
Russo L, Ferrarini E, Agretti P, Dimida A, De Marco G, Simoncini T, Vitti P, Pucci E,
Pinchera A, Tonacchera M, (I)
Premature ovarian insufficiency (POI)
Thursday March 4th
Paffoni Alessandro (I)
Parthenogenesis as a system to validate novel methodologies in human IVF
51
Signori B, Di Gangi E, Peruzzi E, Mannini L, Dei M, Bruni V, (I)
Bone mass in Primary Ovarian Insufficiency
52
Thursday March 4th
Takagi K, Kawahara K, Ide S, Satoh S, Sanai H, (JP)
Successful pregnancy after intermittent hormone replacement therapy in a patient with
premature ovarian failure
Vujovic S, Ivovic M, Tancic-Gajic M, Ivanisevic M, Barac M, Marina Lj, Stojanovic M,
(SRB - MNE)
Characteristics of women with “idiopathic” premature ovarian failure
11.10/13.10
Oral Presentations
REPRODUCTIVE NEUROENDOCRINOLOGY
Chairpersons: Genazzani Alessandro D (I), Meczekalski Blazej (PL)
Athanasopoulos N, Tismaris P, Deligeoroglou E, (GR)
Differences in characteristics of dysfunctional uterine bleeding in patients with immaturity
of the hypothalamic-pituitary-ovarian (HPO) axis and polycystic ovarian syndrome
Bacchi E, Zendrini G, Bonin C, Spiazzi G, De Cata AP, Moghetti P, (I)
Role of body weight and training profile in menstrual dysfunction of professional and
non-professional classical ballet dancers
Czyzyk A, Casarosa E, Luisi M, Podfigurna-Stopa A, Meczekalski B, Genazzani AR,
(PL)
Brain-derived neurotrophic factor levels in patients with Turner syndrome
Gambera A, Nicosia F, Bomba M, Bonini L, Scagliola P, Sartori E, Pecorelli S, (I)
Correlation between endocrine profile, heart rate variability and neuropsychiatric
parameters in adolescents with anorexia nervosa and functional hypotalamic amenorrhea
Maganhin CC, Rassi Mahamed R, Cavalcante Fonseca M, Rennó Guimarães C,
Mendes Akiau D, Gasparini Fernandes LH, da Silva Ferreira C, Santos Alves MM,
dos Santos Simões R, Haidar MA, Baracat EC, Soares Jr JM, (BR)
Ovarian gene expression after melatonin supplementation on the adult female rats
Malejczyk J, Jóźwiak J, Roszkowski P, Grzela T, Hyc A, (PL)
Changes of natural killer cell cytotoxic activity and immunoregulatory cytokine
production during menstrual cycle
Massart F, Gaspari L, Marini F, Brandi ML, Saggese G, (I)
No association between the TTTA repeats polymorphism of aromatase (CYP19) gene and
the precocious puberty development
Podfigurna-Stopa A, Luisi S, Petraglia F, Meczekalski B, (PL)
Serum kisspeptin concentrations in patients with functional hypothalamic amenorrhea
Spinelli C, Di Giacomo M, Cariati E, Messineo A, (I)
Ovarian lesions in children and adolescents: evaluation and management of 104 cases
Tessaris D, Matarazzo P, Repici M, Fiore L, Lala R, Einaudi S, (I)
Persistency of autonomous ovarian hyperfunction during adolescence and early adult
age in female with McCune-Albright syndrome
Tsampalas M, Berndt S, Gridelet V, Hagelstein MT, Charlet-Renard C, Munaut C,
Foidart JM, Geenen V, Perrier d’Hauterive S, (B)
The endometrial hCG/LH receptor: quantification throughout the menstrual cycle
Zektser V, Ilovayskaya IA, Keda UM, Zakharova EY, Pankov UA, Melnichenko GA,
Dedov II, (RUS)
Pathogenetic aspects of hypogonadotropic hypogonadism in women of reproductive age
14.10/16.10
Oral Presentations
ANDROGENS AND HYPERANDROGENISMS
Benelli E, Rinaldi E, Burelli A, Salvetti G, Del Ghianda S, Cionini R, Piaggi P,
Monteleone P, Vitti P, Pucci E, (I)
Dyslipidemia and polycistic ovary syndrome
Berguio Vidotti D, Schnabel B, Secco M, Dale Cotrim Guerreiro da Silva I, (BR)
Genetic analysis and cAMP measurement between lean and obese (ob/ob) anovulating mice
Boldrini França Fernandes J, Soares Wellington GM, de Paula Martins MF, Silva de
Sá Rui A, Ferriani RM, dos Reis C, Sales V, (BR)
Hormonal oral contraceptive alone or associated with metformin on cardiovascular risk
markers in polycystic ovary syndrome women
Bonin C, Tosi F, Di Sarra D, Spiazzi G, Bettinazzi F, Signori C, Forner S, Moghetti P, (I)
Insulin resistance is associated with hyperandogenism and oligo-anovulation, but not
with the ultrasonographic features of the ovaries, in the woman with polycistic ovary
syndrome (PCOS)
Khaki A (IR)
Effect of Androgenic Activity of Zingiber officinale on Serum FSH, LH, Testosterone
hormone and Spermatogenesis in Rat
Link K, Nordlöf H, Giwercman A, (S)
Circadian and menstrual cycle variation of serum androstenedione
Naessén S, Carlström K, Lindén Hirschberg A, (S)
So similar and so different: Androgen status in bulimic women
Papadimitriou D, Kaparos G, Rizos D, Armeni E, Christantoni E, Tsakonas E, Creatsa
M, Alexandrou A, Christodoulakos G, Lambrinoudaki I, (GR)
Serum androgens are increased in the presence of MTHFR ala222val polymorphism in
healthy postmenopausal women
Peruzzi E, Christopoulos P, Nannini S, Mannini L, Dei M, Bruni V, (I)
Flutamide hepatotoxicity: our experience over 176 patients
Rousset-Jablonski C, Plessier A, Lahlou N, Laromiguière M, Pichard C, Larger E,
Gompel A, (F)
Menstrual Cycle Disorders and Hormonal Alterations in Women with Vascular Liver Disease
Stomati M, Potì E, Casarosa E, Potì M, Luisi M, Genazzani AR, (I)
Low-dose oral deydroepiandrosterone (DHEA) supplementation in postmenopausal women
16.30/18.30
Oral Presentations
BREAST CANCER
Chairpersons: Biglia Nicoletta (I), Morfin Julio (ME)
Pelekanou V, Laios I, Kampa M, Castanas E, Leclercq G, Larsimont D, (B)
hERα36, a new variant of ERα: Expression and potential biological relevance in breast
cancer
Baumgärtner AK, Häusler A, Seifert-Klauss V, Schwarz-Boeger U, Kiechle M, (D)
Breast cancer outcome in peri- versus postmenopausal women with or without hormone
therapy prior to diagnosis
Britton K, Harvey IJ, Stemke-Hale K, Lennard TWJ, Meeson AP, (UK)
Could SP cells be an indicator of progression to hormone non-responsive breast cancer?
Thursday March 4th
Chairpersons: Berg Gabriela (RA), Palomba Stefano (I)
53
Capittini C, Bergamaschi P, Guarene M, Cremaschi AL, Marchesi A, Genovese V,
Romano B, Tinelli C, Cuccia M, Salvaneschi L, (I)
Birthweight and cord blood haematopoietic stem cell content: is there a connection for
cancer risk in adulthood?
54
Thursday March 4th
Goglia L, Sanchez AM, Flamini M, Giretti MS, Baldacci C, Garibaldi S, Genazzani AR,
Fu X, Simoncini T, (I)
Progesterone enhances breast cancer cell mobility by the nongenomic activation of focal
adhesion kinase
Kampa M, Pelekanou V, Notas G, Sanidas E, Alexaki VI, Castanas E, (GR)
Membrane acting androgens specifically modify early gene transcription in breast cancer cells
Mozdarani S, Shahidi M, Mozdarani H, (IR)
Repair kinetics of radiation induced DNA damages in leukocytes of breast cancer
patients as a measure of breast cancer susceptibility
Pfeiler G, Glatz C, Königsberg R, Vutuc C, Kubista E, Singer C, (A)
Influence of the dramatic fall of HRT prescription on postmenopausal breast cancer
incidence: the Austrian Data
Tosi V, Pisaneschi S, Goglia L, Genazzani AR, Simoncini T, (I)
Effect of dydrogesterone, dehydro-dydrogesterone, progesterone and
medroxyprogesterone acetate on T47D breast cancer cell migration and invasion
Hall ONICE
08.45/10.15
Oral Presentations
FEMALE SEXUAL FUNCTION AND DYSFUNCTION
Chairpersons: Nappi Rossella (I), Valentino Valeria (I)
Balasko B, Hall M, Lee M, Ventolini G, (USA)
Psycho emotional impact of women with provoked vestibulodynia
Chedraui P, Rodríguez MC, Pérez-López FR, Schwager G, Hidalgo L, (EC)
Assessment of sexuality after hysterectomy using the Female Sexual Function Index
Firquet A, Pintiaux A, Zimmerman XY, Foidart JM, Beliard A, Albert A, Minon JM,
Vincent C, Gerday C, Beekman L, Coelingh Bennink HJT, (B)
Androgen deficiency during combined oral contraceptives
Loto O, Adewuya A, Adewumi T, (WAN)
Pattern and Correlates of Premenstrual Symptoms (PMS) amongst Nigerian University
Students
Melis I, Arena I, Melis GB, Angioni S, (I)
Sexual function is impaired in patients with endometriosis
Mezones-Holguín E, Escajadillo-Vargas N, Castro-Castro J, Córdova-Marcelo W,
Blumel JE, (PE)
Female sexual dysfunction in young people at a public university in northern Peru
Moghasemi S, Ziaei S, Haidari Z, (IR)
Female sexual dysfunction in Iranian postmenopausal women
Wallwiener LM, Wallwiener CW, Seeger H, Mueck AO, Bitzer J, Wallwiener M, (D)
The Sexual Life of German Medical Students: Investigation of the prevalence of sexual
dysfunction and the impact of contraception
11.10/13.10
Oral Presentations
MEDICALLY-ASSISTED PROCREATION
Crha I, Ventruba P, Zakova J, Cadova K, Pohanka M, Huser M, (CZ)
Luteal-phase GnRH agonist administration in IVF/ICSI cycles stimulated with the long
GnRH agonist protocol
Devesa M, Chueca A, Tur R, Rodriguez I, Coroleu B, Barri PN, (E)
Impact of increased body mass index on IVF outcomes
Fettback P, Serafini P, Monteiro Rocha A, Leme Alves da Motta E, Homem de Mello
Bianchi P, Messias Gomes C, Domingues T, Carrilho E, Baracat EC, (BR)
Administration of recombinant (r)hCG on the first day of the menses produces age
independent rescue of the corpus luteum
Guglielmino MR, Vento M, Borzì P, Santonocito M, Ragusa M, Barbagallo D, De
Palma A, Garofalo MR, Minutolo E, Scollo P, Di Pietro C, Purrello M, (I)
Apoptotic Machinery in aging: gene expression profiles in oocytes and in cumulus cells
by High Throughput Real Time PCR
Inaudi P, Petrilli S, Bruni L, Boni C, Battista R, Zerbetto I, Quadrifoglio M, Petraglia F, (I)
Low-dose rFSH administration is effective and safe in PCOS women in IUI or IVF cycles
Jeve Yadava B, Fleming R, (UK)
The combined use of Anti-Mullerian Hormone and age to predict the ovarian response
to controlled ovarian hyper stimulation in poor responders
Kini S, Li HWR, Morrell D, Pickering S, Thong KJ, (UK)
Evaluation of Anti-Mullerian hormone in predicting cumulative pregnancy outcome
during assisted reproduction
Koloda YA, Podzolkova NM, Anshina MB, Shamugia NL, Smirnova AA, Abliaeva ES, (RUS)
Effect of overweight and obesity on assisted reproductive technology outcomes
Niu ZH, Feng Y, Zhang H, Zhang AJ, Sun Y, Lu X, (PRC)
Effects of exogenous luteinizing hormone on patients with relative LH deficiency after
pituitary down-regulation during controlled ovarian hyperstimulation
Santonocito M, Guglielmino MR, Vento M, Borzì P, Ragusa M, Barbagallo D, De
Palma A, Garofalo MR, Minutolo E, Scollo P, Purrello M, Di Pietro C, (I)
Identification and validation of molecular markers of human oocyte biological quality
after vitrification
Venetis CA, Kolibianakis EM, Toulis KA, Goulis DG, Papadimas I, Tarlatzis BC, (GR)
Addition of rLH in patients undergoing ovarian stimulation with rFSH and GnRH
analogues for IVF: a meta-analysis
Pelekanou V, Kampa M, Gallo D, Notas G, Jacquot Y, Castanas E, Leclercq G, (B)
ER17p, a peptide corresponding to the regulatory platform P295-T311 of ER-alpha: role
in actin cytoskeleton, migration and apoptosis
14.10/16.10
Oral Presentations
INFERTILITY
Chairpersons: Gurgan Timur (TR), Viana gersia (I)
Dinopoulou V, Stefanidis K, Makrinioti H, Mavromati D, Bletsa R, Loutradis D,
Antsaklis A, (GR)
Oct-4 expression in fetal cells recovered from the lower uterine pole
Thursday March 4th
Chairpersons: Enseñat Roberto (E), Monteleone Patrizia (I)
55
56
Dziadecki W, Radomska-Leśniewska M, Jankowska-Steifer E, Bablok L, Malejczyk J,
Barcz E, (PL)
The role of human neutrophil peptides 1-4 in pathogenesis of male genital tract inflammation
Thursday March 4th
Garzia E, Clauser R, Persani L, Borgato S, Bulfamante G, Avagliano L, Cetin I,
Marconi AM, (I)
Prolactin and pro-inflammatory cytokines expression at the feto-maternal interface in the
first trimester implantation failure
González Pérez I, Mendoza N, Galiano D, Eloy Ruíz J, Marín L, Quereda F, PérezFortis A, Mozas J, Sánchez-Borrego R, (E)
Duration of fertility age and multigenic combination of estrogen related genes: a
propotional hazard model
Grande G, Milardi D, Bianchi A, Giampietro A, Pompa G, Merola AM, Astorri AL,
Pontecorvi A, Lanzone A, De Marinis L, Marana R, (I)
Conception and altered semen parameters: retrospective analysis of 453 pregnancies
Kabir SN, Banerjee S, (IND)
The size of ovarian follicular reserve impacts the expression of GDF-9 and NOBOX, and
modulates the rate of follicular atresia
Kaur S, Prabha V, Shukla G, Sarwal A, (IND)
Receptor mediated agglutination of human spermatozoa by spermagglutinating factor
isolated from Staphylococcus aureus
Maragno L, Coppola F, Patria G, Pezzuto AC, Benegiamo A, Ferrari B, Nardelli GB, (I)
Endometrial function during ART
Papini F, Simi G, Di Berardino OM, Ruggiero M, Monteleone P, Cela V, Artini PG,
Genazzani AR, (I)
Fragmin administration in women undergoing program of assisted fertilization
Shamsi MB, Venkatesh S, Kumar K, Talwar P, Kumar R, Mittal S, Dada R, (IND)
ROS levels and DNA damage - association with poor sperm quality and Medically
Assisted Procreation failure
Viana G, Ruggiero M, Parisen Toldin MR, Valentino V, Papini F, Artini PG, Cela V,
Genazzani AR, (I)
Endometritis: hysteroscopic follow-up after antibiotic therapy in infertile patients
16.30/18.30
Oral Presentations
REGULATION OF THE ENDOMETRIUM
Chairpersons: Cela Vito (I), Pintiaux Axelle (F)
Asaturova AV, Mogirevskaya OA, Kondrikov NI, (RUS)
The efficacy of PTEN expression assessment in endometrial hyperplasia and other
possible markers for endometrial precancerous process identification and prediction
Botto de Barros Filho AM, Barbosa IC, Maia Jr H, Genes CC, Coutinho EM, (BR)
Effects of subdermal implants of estradiol and testosterone on the endometrium of
postmenopausal women
Fluhr H, Spratte J, Zygmunt M, (D)
Heparin and low molecular weight heparins modulate the decidualization of human
endometrial stromal cells
Fujiwara H, Fujii H, Takao Y, Horie A, Sato Y, Konishi I, (JP)
EphrinA1 induces cell attachment and intercellular dissociation in Ishikawa cells
Gentilini D, Besana A, Vigano P, Vignali M, Melandri M, Di Blasio AM, Busacca M, (I)
The endocannabinoid system controls endometrial plasticity
Hulchiy M, Lindén Hirschberg A, Cline JM, Sahlin L, (S)
Thyroid stimulating hormone receptor and thyroid hormone receptor alpha expression in
the uterus of cynomolgus macaques: effects of steroid hormone treatment
Kovalenko Y, Kubyshkin A, Litvinova S, (UA)
Role of nonspecific proteolytic enzymes and their inhibitors in endometrial hyperplasia
development
Malenkovic G, Mandic A, Popovic M, Zikic D, Rajovic J, Tesic O, (SRB - MNE)
Endometrial pathologies associated with Tamoxifen in breast cancer patients with
postmenopausal vaginal bleeding
Schaefer WR, Fischer L, Deppert W, Hanjalic-Beck A, Seebacher L, Stuckenschneider
J, Zahradnik HP, (D)
Effects of drugs and endocrine active chemicals on endometrial gene-expression
biomarkers in vitro
Singh M, Singh T, Singh H, (IND)
Endometrial Tuberculosis- Case for Differential Diagnosis in Abnormal Uterine Bleeding
In Late Reproductive Period
Tan O, Ornek T, Fadiel A, Naftolin F, (USA)
Activation and action of ezrin protein during the endometrial cycle and its potential role
in embryo implantation
Thursday March 4th
González-Ramos R, Rojas C, Rocco J, Poch A, Sovino H, Kohen P, Devoto L, (RCH)
Nuclear factor-kappaB p65 and RelB peptides expression in human endometrium across
the menstrual cycle
57
58
Roma, 8-11 June 2011
Menopause Renaissance
in the Eternal City:
preventive and therapeutic
strategies for healthy aging
www.imsroma2011.com
Friday March 5
59
th
10.30 -11.00 Estetrol: a fetal estrogen for clinical use
Hall Verde
Hall Belvedere
11.10 -13.10 Theramex A woman’s journey: 3 main
periods of a woman’s life through 3
therapeutic areas
14.10 -15.00 Should there be an international limit on Is there a role for
the number of fertilized oocytes that are metformin in the
implanted in a woman at one time?
treatment of PCOS
women?
15.00 -17.00 Merck Serono The future of fertility:
Androgens
individualised therapy
in women
17.20 -19.20 Follicular growth, oocyte quality, embrio Female sexuality
selection and endometrial receptivity: an
unsolved puzzle
19.20
Hall Affari 2
Hall Affari 1
Johnson &
Roundtable
Johnson Medical Discussion
Live reproductive The Hot Flush:
surgery session
Benign Annoyance
or Predictor of
Gyne surgery under Neurological
imaging conditions Vulnerability?
Hall Affari 3
Academy of Human Reproduction
The future trends of induction of
ovulation - dedicated to the late
dr. Sheldon Segal
Fertility preservation in woman with breast
cancer: a need for a global strategy
Breast cancer
Diagnostic tools for menopausal
symptoms
Bayer Schering Pharma
Young at heart
From nature for menopause
Hall Affari 4
Hall Onice
08.30 -10.00 Sociedad Argentina De Endocrinologia Bayer Italia
Ginecologica Y Reproductiva
Confronti clinici in contraccezione
Ovarian ageing: impact for fertility
ormonale
preservation
10.30 -11.00 New aspects of OHSS
Polish group of G.E. Fertility and
Hot topics in
pregnancy in 2010
gynecological
endocrinology
11.10 -13.10 Chronic anovulation
Hormones and
Patophysiology of
hormone receptors PCOS
14.10 -15.00 HRA PHARMA A new look at emergency Prevention of postmenopausal
contraception
osteoporosis: hormones or
bisphosphonates?
15.00 -17.00 Endometriosis: from the bench to the
Wyeth/Pfizer
bedside
Controversie clinico-terapeutiche
nell’ambulatorio del ginecologo
17.20 -19.20 Endometrial hyperplasia and cancer
Gynecological
cancers
Miscarriage and
abortion
Advances in
contraception
Clinical and
therapeutical
aspects of PCOS
Today’s picks
Roundtable Discussion
08.30/10.00 Hall Belvedere
The Hot Flush: Benign Annoyance or Predictor
of Neurological Vulnerability?
Roberta Diaz Brinton (USA), Andrea R. Genazzani (I),
Victor Henderson (USA), Pauline Maki (USA)
Social Evening
Arts in Florence
Guided visit and cocktail at the
Bargello museum. Please come to
the Social Events desk to get your
ticket with entrance and tour time.
Friday March 5th
Hall Auditorium
08.30 -10.00 Association Française pour l’étude
de la menopause
60
Friday March 5th
Friday March 5th
Hall AUDITORIUM
08.30/10.00
SYMPOSIUM ORGANIZED BY ASSOCIATION FRANÇAISE POUR L’ÉTUDE
DE LA MENOPAUSE
Chairpersons: Lachowsky Michèle (F), Scemama Lydia Marie (F)
Scemama Lydia Marie (F)
Premature ovarian failure and gynecology
Lachowsky Michèle (F)
Premature menopause and patients
Premature Menopause and metabolic alterations
10.30/11.00
PLENARY LECTURE
Genazzani Andrea R (I)
Estetrol; a fetal estrogen for clinical use
Chairpersons: Foidart Jean-Michel (B)
11.10/13.10
SPONSORED SYMPOSIUM - THERAMEX MERCK SERONO
A WOMAN’S JOURNEY: 3 MAIN PERIODS OF A WOMAN’S LIFE
THROUGH 3 THERAPEUTIC AREAS
Chairpersons: Benagiano Giuseppe (I), Kenemans Peter (NL)
Stevenson John (UK)
Menstrual cycle
Collins Peter (UK)
Cardiovascular issue
Graziottin Alessandra (I)
Quality of life and sexuality
14.10/15.00
DEBATE
Should there be an international limit on the
number of fertilized oocytes that are implanted
in a woman at one time?
Chairpersons: Frydman Réné (F), Polatti Franco (I)
Gianaroli Luca (I) — Tarlatzis Basil (GR)
15.00/17.00
SPONSORED SYMPOSIUM - MERCK SERONO
THE FUTURE OF FERTILITY: INDIVIDUALISED THERAPY
61
Friday March 5th
Chairpersons: Artini paolo Giovanni (I), Barri Pedro (E)
Welcome and Introduction
Carone Domenico (I)
The need of a tailored therapy
Revelli Alberto (I)
Mild stimulation protocols: from super ovulation to natural IVF
Alviggi Carlo (I)
How to treat Poor/Hypo/Slow responders efficiently
Ruvolo Giovanni (I)
New insights in oocytes, sperm and embryo selection
ECM
17.20/19.20
PLENARY SESSION
FOLLICULAR GROWTH, OOCYTE QUALITY, EMBRIO SELECTION
AND ENDOMETRIAL RECEPTIVITY: AN UNSOLVED PUZZLE
Chairpersons: Devoto Luigi (RCH), Di Lieto Andrea (I)
Horcajadas José (E)
Molecular Diagnosis of Endometrial Receptivity
Artini Paolo G (I)
Human oocyte cryopreservation by Vitrification technique
Picton Helen M (UK)
In vitro models for understanding follicular growth and maturation
Frydman Réné (F)
How to choose the good embryos ?
Ferraretti Anna Pia (I)
Oocyte competence: the role of LH
Hall BELVEDERE
08.30/10.00
Roundtable Discussion
The Hot Flush: Benign Annoyance or Predictor
of Neurological Vulnerability?
Discussants:
Roberta Diaz Brinton (USA), Andrea R. Genazzani (I),
Victor Henderson (USA), Pauline Maki (USA)
Hot flushes are the most frequently reported and recognizable symptom of menopause.
Worldwide, there are currently more than 470 million women aged 50-plus.
As the aging population expands, the occurrence of hot flashes and its health
consequences will continue to be of clinical relevance. Prevalence of hot flash ranges
from 60-82% of peri- to postmenopausal women in Western cultures whereas the
prevalence in oophorectomized women is 90%. While reported hot flash frequency varies
across cultures, a sizable proportion of women world wide can be anticipated to manifest
the hot flash as part of reproductive senescence. The Round Table Discussion on “The
Hot Flush: Benign Annoyance or Predictor of Neurological Vulnerability?” will consider
current views on the hot flush and implications for neurological health.
62
Hall VERDE
PLENARY LECTURE
Mettler Liselotte (D)
Gyne surgery under imaging conditions
LIVE SURGERY SESSION FROM PISA UNIVERSITY HOSPITAL
Angioni Stefano (I), Cela Vito (I), Freschi Letizia (I), Litta Pietro (I), Pluchino Nicola (I),
Tana Roberta (I), Teti Giancarlo (I)
Hysterectomy, Subtotal hysterectomy, Myomectomy, Single port laparoscopic surgery,
Office hysteroscopy
14.10/15.00
DEBATE
Is there a role for metformin in the treatment
of pcos women?
08.30/13.10
Friday March 5th
LIVE REPRODUCTIVE SURGERY SESSION SPONSORED
BY JOHNSON & JOHNSON MEDICAL
Chairpersons in Florence: Mettler Liselotte (D), Scarselli Gianfranco (I)
Chairperson in Pisa: Cela Vito (I)
Chairpersons: Barri Pedro (E), Tranquilli Andrea (I)
Dunaif Andrea (USA) — Genazzani Alessandro D (I)
15.00/17.00
PLENARY SESSION
ANDROGENS IN WOMEN
ECM
Chairpersons: Dunaif Andrea (USA), Piccione Emilio (I)
Sultan Charles (F)
Congenital adrenal hyperplasia: from clinic to gene, from gene to clinic
Ibáñez Lourdes (E)
Hyperandrogenism in adolescence
Milewicz Andrzej (PL)
Treatment of hyperandrogenism
Smetnik Vera (RUS)
The androgen-deficiency syndrome and related diseases
Androgen therapy in women: an unsolved puzzle
17.20/19.20
PLENARY SESSION
FEMALE SEXUALITY
Chairpersons: Colacurci Nicola (I), Lachowsky Michèle (F)
Nappi Rossella (I)
Brain control of female sexuality: neuroendocrine control
Birkhaeuser Martin (CH)
Sexual dysfunction after menopause: the place of androgen substitution
Valentino Valeria (I)
Assisted procreation and its impact on couple sexuality
How to promote the sexual health of the elderly couple
Caruso Salvatore (I)
Age and metabolic related structural changes in female clitoral cavernosal tissue
ECM
Hall AFFARI 1
THE FUTURE TRENDS OF INDUCTION OF OVULATION
DEDICATED TO THE LATE DR. SHELDON SEGAL
08.30/10.00
63
ACADEMY OF HUMAN REPRODUCTION
Friday March 5th
Chairpersons: Naftolin Frederick (USA), Schenker Joseph (IL)
The Exquisite Choreography of Follicle Development and ovulation by the
Hypothalamus, Pituitary and Ovary
Gonadotropins for Induction of Ovulation
Frydman Réné (F)
Can we identifie the so call good oocyte after ovarian stimulation for ART
Shoham Zeev (IL)
Luteal support in ART cycles: Why, with what, and for how long?
Schenker Joseph (IL)
Complications of Induction of Ovulation
10.30/11.00
PLENARY LECTURE
Uzan Serge (F)
Fertility preservation in woman with breast cancer:
a need for a global strategy
Chairpersons: Benedetti Panici Pierluigi (I), Mueck Alfred (D)
11.10/13.10
PLENARY SESSION
BREAST CANCER
Chairpersons: Panay Nicholas (UK), Zervoudis Stefanos (GR)
Simpson Evan (AUS)
Sex, aging, fat and breast cancer - an update
Mueck Alfred (D)
Role of estrogen metabolites in breast cancer
Santen Richard J (USA)
Aromatase and breast cancer
von Schoultz Bo (S)
Mammographic density to monitor the breast during hormone therapy
Sismondi Piero (I)
New frontiers in integrated therapy in breast cancer
14.10/15.00
DEBATE
Diagnostic tools for menopausal symptoms
Chairpersons: Brincat Mark (M), Capetta Piero (I)
Chedraui Peter (EC) — Nachtigall Lila E (USA)
ECM
64
15.00/17.00
SPONSORED SYMPOSIUM - BAYER SCHERING PHARMA
YOUNG AT HEART
Friday March 5th
Chairpersons: Blake Jennifer (CDN), Foidart Jean-Michel (B)
HRT Today – Recent Insights
Otto Christiane (D)
Effects of Drospirenone on Breast Tissue
Rosano Giuseppe (I)
Cardiovascular Aspects of Drospirenone
Collins Peter (UK)
Managing a Woman’s Cardiovascular Risk: a Gynecologists’ Guide
17.20/19.20
PLENARY SESSION
FROM NATURE FOR MENOPAUSE
Chairpersons: Facchinetti Fabio (I), Sjoberg Nils-Otto (S)
Jungbauer Alois (A)
Bioactive compounds recommended for nutrition of climacteric women
Cianci Antonio (I)
Isoflavones and lactobacilli for a natural approach to menopausal disorders
Huber Johannes (A)
Equol - an endogenous phytochemical for the menopause
Nachtigall Lila E (USA)
Clotting Issues in Oral Estrogen, Transdermal Estrogen and Femarelle
Neuroendocrine effects of DT56A (Femarelle™) administration
Hall AFFARI 2
OVARIAN AGEING: IMPACT FOR FERTILITY PRESERVATION
08.30/10.00
SYMPOSIUM ORGANIZED BY SOCIEDAD ARGENTINA DE ENDOCRINOLOGIA
GINECOLOGICA Y REPRODUCTIVA
Cortelezzi Marta (RA)
Marcadores endocrinos de reserva ovarica (Endocrine markers for ovarian reserve)
Nolting Manuel (RA)
FOP: consecuencias reproductivas y no reproductivas (POF: reproductive and non
reproductive consequences)
Lombardi E (RA)
Preservación de la fertilidad (Fertility preservation)
Moses Nora (RA)
Implicancias endocrino-metabolicas en mujeres mayores de 40 (Endocrine and metabolic
implications of ovarian aging)
10.30/11.00
PLENARY LECTURE
Schenker Joseph (IL)
New aspects of OHSS
Chairpersons: Nachtigall Lila E (USA), Venturini Pierluigi (I)
ECM
11.10/13.10
PLENARY SESSION
CHRONIC ANOVULATION
ECM
Friday March 5th
Chairpersons: Kiesel Ludwig (D), Metka Markus (a)
Hormonal control of ovulation
Meczekalski Blazej (PL)
Neuroendocrine and endocrine aspects of hypothalamic amenorrhea
Pathophysiology of chronic anovulatory syndromes
Lanzone Antonio (I)
Diagnosis and clinical management of menstrual irregularities and infertility
Nappi Carmine (I)
Long-term health consequences of chronic anovulation
14.10/15.00
SPONSORED SYMPOSIUM - HRA PHARMA
A NEW LOOK AT EMERGENCY CONTRACEPTION
Chairpersons: Baird David (UK)
Moreau Caroline (F)
Emergency contraception: A real need for a second chance - Epidemiological evidence
Glasier Anna (UK)
ellaOne® Ulipristal Acetate: Improved efficacy - Clinical evidence
15.00/17.00
PLENARY SESSION
ENDOMETRIOSIS: FROM THE BENCH TO THE BEDSIDE
Chairpersons: Bulun Serdar (USA), DEssole salvatore (I)
Scarselli Gianfranco (I)
Epigenetic alterations in endometriotic tissue : the role of hox genes
Kiesel Ludwig (D)
Stem cells in endometrium and endometriosis
Angioni Stefano (I)
Pain in endometriosis: central sensitization or peripheral mechanisms?
Schindler Adolf (D)
Dienogest – a novel progestogen for the treatment of endometriosis
Luisi Stefano (I)
New treatment of endometriosis-related pain
65
ECM
66
17.20/19.20
PLENARY SESSION
ENDOMETRIAL HYPERPLASIA AND CANCER
ECM
Friday March 5th
Chairpersons: Santen Richard J (USA), Sartori Enrico (I)
Prat Jaime (E)
From endometrial hyperplasia to endometrial cancer
Sturdee David (UK)
Hormonal control of endometrial hyperplasia
Pélissier-Langbort Clara, Nathalie Chabbert-Buffet (F)
Progestins treatment in premenopausal women
Baird David (UK)
Hormone treatment for the prevention and treatment of endometrial hyperplasia with
preservation of fertility
Hourvitz Ariel (IL)
In vitro fertilization after endometrial adenocarcinoma
Hall AFFARI 3
CONFRONTI CLINICI IN CONTRACCEZIONE ORMONALE prima sessione
08.30/10.30
EDUCATIONAL COURSE - BAYER ITALIA
Chairpersons: Bruni Vincenzina (I), Massobrio Marco (I)
Dei Metella (I)
Contraccezione nelle fasce di età estreme
Lello Stefano (I)
Estroprogestinici e iperandrogenismo
Paoletti Anna Maria (I)
Contraccezione e sintomi premestruali
Nappi Rossella (I)
Contraccezione e flussi mestruali abbondanti
11.00/13.00
EDUCATIONAL COURSE - BAYER ITALIA
CONFRONTI CLINICI IN CONTRACCEZIONE ORMONALE seconda sessione
Chairpersons: Fruzzetti Franca (I), Melis Gian Benedetto (I)
Candiani Massimo (I)
Contraccezione ed endometriosi
Caruso Salvatore (I)
Contraccezione e sessualità
Contraccezione oggi. Quali estrogeni e quali progestinici?
Personalizzazione della terapia contraccettiva
DEBATE
Prevention of postmenopausal osteoporosis:
hormones or bisphosphonates?
Chairpersons: Smetnik Vera (RUS), Surico Nicola (I)
gambacciani marco (I) — Christiansen Claus (DK)
15.00/19.20
EDUCATIONAL COURSE - WYETH/PFIZER
CONTROVERSIE CLINICO-TERAPEUTICHE
NELL’AMBULATORIO DEL GINECOLOGO
Chairpersons: Nappi Carmine (I), Scarselli Gianfranco (I)
Il cervello femminile e le sue vulnerabilità nell’ambulatorio del ginecologo
Nappi Rossella (I)
Le problematiche sessuali e la pratica clinica: come riconoscerle e affrontarle
Maffei Silvia (I)
Cuore vasi e terapia ormonale: l’importanza di un inizio precoce
Sismondi Piero (I)
La mammella nell’ambulatorio del ginecologo
Lello Stefano (I)
Perché l’osteoporosi post-menopausale è di gestione del ginecologo?
Perino Antonio (I)
Infezioni vaginali e flogosi pelvica: un binomio non ancora risolto
Hall AFFARI 4
HOT TOPICS IN GYNECOLOGICAL ENDOCRINOLOGY
08.30/10.00
SYMPOSIUM ORGANIZED BY POLISH GROUP OF GYNECOLOGICAL
ENDOCRINOLOGY
Czajkowski Krzysztof (PL)
The role of progesterone in early pregnancy
Jedrzejczak Piotr (PL)
Fertility in ageing male
Smolarczyk Roman (PL)
Practical solution of hyperprolactinaemia in gynecological practice
Meczekalski Blazej (PL)
Hypoestrogenism in young women and its influence on bone mass density
11.10/13.10
Oral Presentations
HORMONES AND HORMONE RECEPTORS
Chairpersons: Jungbauer Alois (A), Mannella Paolo (I)
Black SM, Sud N, Wiseman DA, (USA)
Development of a peptide that attenuates the plasma membrane translocation of
estrogen receptor alpha
Cork DMW, Lennard TWJ, Tyson-Capper AJ, (UK)
Alternatively Spliced Progesterone Receptor (PR) Expression in Breast Cancer
67
Friday March 5th
14.10/15.00
Giannini A, Cubeddu A, Bucci F, Russo M, Daino D, Russo N, Merlini S, Pluchino N,
Casarosa E, Luisi M, Genazzani AR, (I)
Progesterone counteracts estrogen-induced increases in central and peripheral BrainDerived Neurotrophic Factor in female ovx rats
68
Friday March 5th
Kechagioglou K, Kolibianakis EM, Venetis CA, Chatzimeletiou K, Loutradi K,
Tarlatzis BC, (GR)
Association of human progesterone receptor polymorphisms with the probability of
pregnancy: a systematic review
Leitao BB, Jones MC, Fusi L, Higham J, Lee Y, Takano M, Goto T, Christian M, Lam
EWF, Brosens JJ, (UK)
Silencing of the JNK pathway maintains progesterone receptor activity in decidualizing
human endometrial stromal cells exposed to oxidative stress signals
Lucas C, Thackery L, Gonzalez D, Hopkins L, Davies C, Joels L, White J, Conlan S, (UK)
The expression of the transcription factor WT1 (Wilms tumour suppressor gene) within
the human uterus during decidualization
Medjakovic S, Zoechling A, Vollmer G, Zierau O, Kretzschmar G, Moeller F, Kolba S,
Papke A, Opietnik M, Kosma P, Rosenau T, Jungbauer A (A)
Potent AhR agonist from sauerkraut modulates the ER pathway
Sanchez AM, Zullino S, Flamini MI, Genazzani AR, Simoncini T, (I)
Rapid signaling of estrogen to focal adhesion kinase in endothelial cells
Tyson-Capper A, Kirby J, (UK)
The role of endogenous ligands in modulating inflammation and TLR signalling events
associated with preterm birth
Tyson-Capper A, Robson S, (UK)
Non-classical pathways are responsible for the immunomodulatory and anti-inflammatory
action of progesterone in human myometrial and amnion cells
Vladic-Stjernholm Y, Vladic T, Blesson C, Ekman-Ordeberg G, Sahlin L, (S)
Prostaglandin treatment is followed by a withdrawal of progesterone and androgen in
the human uterine cervix
Wilhelm F, Kovacs KA, Menyhárt Cs, Lengyel F, Szabó I, (HR)
Estradiol activates Akt/protein kinase B in postmenopausal endometrium
15.00/17.00
Oral Presentations
GYNECOLOGICAL CANCERS
Chairpersons: Amunni Gianni (I), Gadducci Angiolo (I)
Bellati F, Gasparri ML, Pernice M, Musella A, Donfrancesco C, Ruscito I, Visconti V,
Benedetti Panici P, (I)
Improvement of QoL after hormone replacemet therapy in cervical cancer survivors
Benedetti Panici P, Napoletano C, Bellati F, Gasparri ML, Ruscito I, Pernice M,
Pastore M, Antonilli M, Maffucci D, Nuti M, (I)
Improvement of quality of life and immunological fitness targeting VEGF in platinum
refractory ovarian cancer patient
Cole LA, (USA)
Hyperglycosylated hCG in tumor invasion
Franchi V, Verrocchi F, (I)
Nutritional status in oncological gynaecology. Which importance?
Jadoon B, Sundar S, Kehoe S, Roamian K, (UK)
Analysis of outcome in women with borderline glandular change
Koutlaki N, Dimitraki M, Zervoudis S, Psillaki A, Sofiadou V, Nikas I, Grapsas X,
Galazios G, Liberis V, (GR)
Relation of body mass index and blood androgens levels to tumor prognostic factors
among premenopausal women with breast cancer
Laurelli G, Di Vagno G, Scaffa C, Iodice F, Gallo MS, Forleo F, Greggi S, (I)
Conservative treatment of early endometrial cancer: preliminary results of a pilot study
Puett D, Cui J, Eldredge JB, Miner BM, Warrenfeltz SW, Xu Y, (USA)
Gene expression profiling of ovarian cancer cells post-activation of the LH receptor
Wincewicz Andrzej, Sulkowska M, Kanczuga-Koda L, Koda M, Sulkowski S, (PL)
Eventual proapoptotic or anti-apoptotic impact of aberrantly expressed Cx43 and Cx26
can depend on ER-alpha overexpression in endometrioid adenocarcinoma
Wincewicz A, Wincewicz A, Sulkowska M, Koda M, Kanczuga-Koda L, Sulkowski S, (PL)
STAT3, E-cadherin and apoptosis regulators: Bak and Bcl-xL in endometrioid
adenocarcinomas of different ER-alpha immunoprofile
Zafran N, Goldman S, Shalev E, (IL)
Plexin B1 is differentially expressed in biopsies from normal and tumoral endometrium
having tissue specific effect on in-vitro invasion
17.20/19.20
Oral Presentations
MISCARRIAGE AND ABORTION
Chairpersons: Gambacciani Marco (I), Spinillo Arsenio (I)
Coccia ME, Spitaleri M, Riviello C, Rizzello F, Castellacci E, Caponi D, Mariani G,
Scarselli G, (I)
Recurrent Pregnancy Loss: the effectiveness of a new therapeutic approach
El Kamel-Lebbi I, Ayed W, Bhouri R, Kacem O, Kileni O, Bouayed Abdelmoula N,
Zhioua Fi, Amouri A, (TN)
Male chromosomal implication in recurrent spontaneous abortions
Essadi FM, Elmehashi MO, Elsaratie OA, (LAR)
Efficacy of Low dose Aspirin & Low-molecular-weight- heparin treatment in women with
recurrent first trimester pregnancy loss
Hedayat Z, Mohammadzade V, Javadi H, Sadeghi MR, Akhondi MM, Sadeghitabar
A, Zarnani AH, (IR)
Higher frequency of anti-thyroid antibodies in patients with recurrent spontaneous
abortion may stem from impaired vitamin D3 metabolism
Horie A, Fujiwara H, Suginami K, Takao Y, Fujii H, Sato Y, Konishi I, (JP)
Laeverin, a novel membrane-bound aminopeptidase, regulates early human placentation
Russu M, Stănculescu R, Păun M, Nastasia S, Mubarack N, Marin JA, Lachanas I, (RO)
Pregnancy outcome after preconceptional and during window of implantation Vaginal
Micronized Progesterone administration in recurrent pregnancy loss
Salvador S, Londero AP, D’Aietti V, Driul L, Fruscalzo A, Bertozzi S, Marchesoni D, (I)
Short-term follow-up of voluntary abortion in an Italian centre: a prospective analysis
of 186 cases
Friday March 5th
Karimi Zarchi M, Mousavi A, Behtash N, Modares Gilani M, Ghaemmaghami F, (IR)
Fertility sparing in infertile women with endometrial cancer or complex atypical
hyperplasia
69
70
Seremak-Mrozikiewicz A, Drews K, Barlik M, Kurzawińska G, Łukaszewski T,
Mrozikiewicz PM, (PL)
The Arg353Gln polymorphism of factor VII in women with recurrent miscarriages
Friday March 5th
Spitaleri M, Riviello C, Rizzello F, Castellacci E, Caponi D, Mariani G, Coccia ME, (I)
Antithyroid antibodies and Recurrent Pregnancy Loss
Toulis K, Dimitrios G, Goulis Christos A, Venetis Efstratios M, Kolibianakis V,
Harizopoulou RN, Tarlatzis BC, Papadimas I, (GR)
Risk of spontaneous miscarriage in euthyroid women with thyroid autoimmunity
undergoing in-vitro fertilization: a systematic review and a meta-analysis
Turp AB (TR)
Are We Missing Out Evaluation of Paternal Chromosomal Abnormality In Recurrent
Miscarriage? Varicocele and Sperm FISH
Tutchenko TN, Tatarchuk TF, Gorovenko NG, Podolskaya SV, Shakalo IN, (UA)
Glutathione S-transferase M1 and T1 Polymorphisms and the Risk of Recurrent Early
Pregnancy Loss in Women with High Perceived Stress
Hall ONICE
FERTILITY AND PREGNANCY IN 2010
08.30/10.00
Oral Presentations
Chairpersons: Ferraretti Anna Pia (I), Horcajadas José (E)
Carminati R, Giannice R, Patregnani C, Bertozzi R, Forloni G, Fogliani M, (I)
Vaginal Salpingectomy as Surgical Treatment for Extrauterine Tubal Pregnancy: a Pilot
Randomized Study
Klimov V (UA)
Autosensibilization to the progesterone and syndrome loss of pregnancy
Marin JA, Russu M, Ionescu-Tirgoviste C, (RO)
Diabetes and obesity as complex metabolic disorders, and pregnancy outcomes
Mohseni Meybodi A, Haratian K, Zari Moradi S, Mansouri Z, (IR)
Detection of different kind of human papillomavirus in normal pregnancy and in
pregnant women with insulin dependent diabetes mellitus
Riviello C, Mello G, Jovanovic L, (I)
Breastfeeding and Basal Insulin Requirement in Type 1 Diabetic Women
Takao Y, Fujiwara H, Ueda M, Fujii H, Horie A, Konishi I, (JP)
Human luteal cells express Monoamine oxidase-A during early pregnancy
Tica Oana Sorina, Tica A, Berceanu C, Georgescu C, (RO)
Abnormal pregnancies after clomiphene citrate
11.10/13.10
Oral Presentations
PATOPHYSIOLOGY OF PCOS
Chairpersons: Angioni Stefano (I), Pucci Enrico (I)
Benelli E, Bernini GP, Rinaldi E, Del Ghianda S, Cionini R, Burelli A, Monteleone P,
Vitti P, Pucci E, (I)
Aldosterone and renin plasma levels in young patients with Polycystic Ovary Syndrome
Davydova GN, Melnichenko GA, Chebotnikova TV, (RUS)
Clinical features of polycystic ovary syndrome
Domingues T, Serafini P, Monteiro Rocha A, Leme Alves da Motta E, Yadid I,
Coslovsky M, Fettback P, Domingues T, Homem de Mello Bianchi P, Carrilho E,
Baracat EC, (BR)
Polycystic ovarian disease does not enhance rescue of corpus luteum by administration
of recombinant (r)hCG on the first day of the menses
Falbo A, Materazzo C, Rocca M, Russo T, Zullo F, Palomba S, (I)
Effects of metformin with or without folate supplementation on homocysteine levels and
vascular endothelium of women with polycystic ovary syndrome
Georgopoulos NA, Piouka A, Katsikis I, Saltamavros AD, Bakatselou K, Decavalas G,
Panidis D, (GR)
The relationship of Antimüllerian hormone (AMH) to LH and FSH serum levels and the
impact of obesity, in young women with polycystic ovary syndrome (PCOS)
Lanzoni C, Chierchia E, Rattighieri E, Santagni S, Campedelli A, Casarosa E, Luisi M,
Genazzani AD, (I)
Metformin administration restores allopregnanolone response to ACTH stimulation in
overweight hyperinsulinemic PCOS patients
Matteo M, Scillitani G, Noviello A, De Rosario F, Liso A, Massenzio F, Picca G, Greco P, (I)
Reduced percentage of natural killer cells associated with impaired cytokine network in
the secretory endometrium of infertile PCOS women
Rinaldi E, Benelli E, Simoncini T, Del Ghianda S, Fiore E, Burelli A, Cionini R, Vitti P,
Pucci E, (I)
Glucose metabolism and adrenal activity
Shebl O, Sommergruber M, Ebner T, Sir A, Tews G (A)
Effect of ovarian drilling on serum AMH level in women with PCOS
Spettu F, Daga A, Orrù A, Melis GB, Fulghesu AM, (I)
AMH as a marker of ovarian activity in multifollicular ovaries
Tuck A, Tilley W, Hickey T, (AUS)
Increased kit ligand levels in human polycystic ovaries
15.00/17.00
Oral Presentations
ADVANCES IN CONTRACEPTION
Chairpersons: Blithe Diana (USA), Fruzzetti Franca (I)
Ågren U, Duijkers IJM, Sommer W, Grob P, Mommers E, Korver T, (FIN)
Impact of a Unique, Monophasic Combined Oral Contraceptive Containing Nomegestrol
Acetate/17 Beta-Estradiol on SHBG and Androgenic Markers in Two Open-Label,
Randomized, Comparative Studies
Brache V, Cochon L, Jesam C, Maldonado R, Salvatierra AM, Levy DP, Gainer E,
Croxatto HB, (DOM)
Immediate preovulatory administration of 30mg ulipristal acetate significantly delays
subsequent follicular rupture
71
Friday March 5th
Campagna G, Ricciardi L, Bompiani A, De Cicco S, Tagliaferri V, Romualdi D, Guido
M, Lanzone A, (I)
Ethinylestradiol-chlormadinone acetate combination for the treatment of hirsutism
and hormonal alterations of normal-weight women with polycystic ovary syndrome:
evalutation of metabolic impact
72
Duijkers IJM, Klipping C, Grob P, Korver T, (NL)
Effects of a Unique, Monophasic Combined Oral Contraceptive Containing Nomegestrol
Acetate/17 Beta-Estradiol on Ovarian Function
Friday March 5th
Gaussem P, Alhenc-Gelas M, Thomas JL, Remones V, Aiach M, Scarabin PY, (F)
Haemostatic effects of a new combined oral contraceptive, nomegestrol acetate/17ßestradiol, compared with those of levonorgestrel/ethinyl estradiol
Heliövaara-Peippo S, Aalto AM, Grenman S, Halmesmäki K, Hurskainen R, Kivelä A,
Teperi J, Tomas E, Tuppurainen M, Paavonen J, (FIN)
The effect of hysterectomy or levonorgestrel-releasing intrauterine system on quality of
life among women with menorrhagia: a 10-year randomised controlled trial
Pal D, Sabde S, Ray H, Pal BC, Mitra D, Kabir SN, (IND)
Acaciaside-B-enriched fraction of Acacia auriculiformis possesses spermicidal as well as
anti-HIV activity with wide margin of safety
Saha P, Pal BC, Kabir SN, (IND)
Puerarin, a selective estrogen receptor modulator, disrupts embryo-uterine
communication and inhibits implantation in rats
Saki G, Saki J, Kadkhodaei Elyaderani M, (IR)
In vivo study the effect of Oxamate on LDH-C4 activity of sperm in Rat
Sbano FM, Palomba S, Arduino B, Falbo A, Venturella R, Materazzo C, Annunziata
G, Zumpano A, Zullo F, (I)
Effectiveness of LNG-IUD in relation to FSH serum levels in patients with menorrhagia
Wildemeersch D, Andrade A, Janssens D, (B)
Review of clinical experience with the frameless LNG-IUS for contraception and
treatment of heavy menstrual bleeding
17.20/19.20
Oral Presentations
CLINICAL AND THERAPEUTICAL ASPECTS OF PCOS
Chairpersons: Dei Metella (I), Pluchino Nicola (I)
Capalbo A, Tiziano FD, Sagnella F, Morciano A, Martinez D, Moro F, Spettu F, Rienzi
LF, Ubaldi FM, Brahe C, Fulghesu A, Apa R, Lanzone A, (I)
The missense Ser312Asn variant of LHCGR gene is strongly associated with PCOS: a
case-control
Glinski L, Zuliani L, Bleve L, Azzolini S, Granzotto M, Ritunnano R, Maffei P, De Carlo
E, Martini C, Sicolo N, Vettor R, Mioni R, (I)
Insulin regulates both basal and stimulated gonadotropins secretion in PCOS patients:
different effect of metformin, hypocaloric and low glucidic diet
Huang W, Tao Y, Guo T, Li G, (PRC)
Association between serum adipocyte factor and insulin resistance in PCOS
Londero AP, Bertozzi S, Bernardi S, Driul L, Marchesoni S, (I)
Policystic ovary syndrome and benign breast disease: two aspects of the same
dysmetabolic condition
Perini D, Fruzzetti F, Lazzarini V, Gambacciani M, Parrini D, Genazzani AR, (I)
Comparison of effects of 3 mg drospirenone plus 20 mg ethinyl estradiol alone or
combined with metformin or cyproterone acetate on classic metabolic cardiovascular risk
factors in nonobese women with PCOS
Rice S, Pellatt L, Ramanthan K, Whitehead S, Mason H, (UK)
Metformin inhibits aromatase via an ERK-mediated pathway
Rinaldi E, Del Ghianda S, Benelli E, Mannella P, Burelli A, Cionini R, Latrofa F, Vitti P,
Pinchera A, Pucci E, (I)
Autoimmunity and Polycystic Ovary Syndrome
Sanna S, Angioni S, Melis GB, Fulghesu AM, (I)
Metformin effect in PCOS patients is not dose dependent
Signori C, Bonin C, Di Sarra D, Bettinazzi F, Forner S, Moghetti P, (I)
Metabolic features and uterine artery color doppler analysis in polycistic ovary syndrome
(PCOS) and control women
Talaei RZ, Pirkalani K, (IR)
Genetic predisposition of polycystic ovarian disease: Report of clusters within 10 large
families; inclusion of novel signs and describing male PCOD
73
Friday March 5th
Ricciardi L, Campagna G, Bompiani A, De Cicco S, Tagliaferri V, Romualdi D, Guido
M, Lanzone A, (I)
Follicular function and metabolic assessment in obese women with polycystic ovary
syndrome: Antimullerian hormone after insulin-sensitizing therapy
74
9
Scientific
Programme
Plenary Sessions
Post-traumatic stress disorder (ptsd after childbirth)
Where does it come from? Origin and development
(K. Wijma, S)
How can we understand it? Theoretical models
(S. Ayers, Sussex, UK)
How and where do we meet it? Clinical appearance
and prevalence (E-L. Ryding, S)
What can professionals do? Clinical care and treatment (P. Slade, UK)
Councelling for prenatal diagnosis
Decision making after fetal pathology (A. Rohde, D)
How to cope with uncertainty during pregnancy
(C. Luchi, I)
Prenatal counselling: Pregnant women‘s experiences
and needs (S. Tschudin, CH)
CongressParental
after the unexpected finding of a
International
tyreactions abnormality
chromosomal
in prenatal diagnoscie
tional Sosex
tic testing (J. Pieters, NL)
s
of the Interna
stetric
Caesarean section on demand
and mental disorders in obstetrics
atic ObAdaptive
som
cho
Pros and Cons from
a
medical
point
of
view
Depressive
symptoms
in Pregnancy and Puerperium
Psy
of
(A. Tranquilli, I)
(JF Navio, E)
gy
olo
nec
Should we follow the patient’sGy
Pregnant women and mental illnesses (J.Alder, CH)
and autonomy? (B. Maier, A) Oxytocin
Women choice of mode of delivery: a matter of
spray for post-partum depression
ly
Venezia, Ita 0, 2010
October 28-3
information (F. Facchinetti, I)
Practical steps in counseling (H. Kentenich, D)
Beyond somatic obstetrical complications
Psycho-social predictors of preterm delivery
(C. Benedetto, I)
Mother-baby intervention, a proven strategy in attachment between mothers and babies (N. Petilon NL)
Premature delivery and stress (C. Maggioni, I)
(R. Natale, I)
Attachment needs and disruptors in pregnancy and
puerperium (A. Graziottin, I)
Early detection of psychopathology in pregnant
women; a new strategy to prevent worse
(M. van den Berg, NL)
Surgery
E of female genitals
MMdesign
RY PROGRA“Designer Vagina”: Consensual declaration in referPRELIMINA 0.com ence to intimate surgery and its psychosomatic
aspects (B. Wimmer-Puchinger, A)
www.ispog201
Should we follow the patient’s wish? (A. Borkenhagen, D)
Labiohypertrophy and Labioplastic Surgery; Psychosomatic implications (H. Wienerroither, A)
Guidelines for gynaecologists and surgeons
(M. Paarlberg, NL)
“San Giovanni Evangelista”
Jacopo Guarana 1762,
Scuola Grande San Giovanni Evangelista
new preliminary programme
available
Venezia, Italy
October 28-31, 2010
www.ispog2010.com
Saturday March 6
75
th
Hall Auditorium
Hall Affari 1
Sobrage Health benefits of the
extended use of oral contraceptives
IMS
Unanswered questions on HRT
11.10 - 13.10 Bayer Schering Pharma
Innovation in endometriosis therapy
14.10 - 15.00 Is pcos a disease or an adaptation?
Art: from basic science to clinical
application
Are progestins always needed to
counteract effects of estrogens after
menopause?
Progesterone and progestins: their
targets
Dydrogesterone in HRT - New ultra -low
dose regimen to come
Woman’s health through menopause
and ageing
15.10 - 17.10 50 Years of ovarian stimulation with
human gonadotropins
17.10 - 19.30 Poster session in Poster Area
Hall Affari 2
08.30 -10.00 Ispog Psychosomatic Obstetrics and
Gynaecology at patient’s side
Hall Affari 3
Hall Affari 5/4
Hall Onice
Guidotti “Sindrome metabolica ed
insulino-resistenza nella donna”
-
Ethicon Women’s &
Urology - Johnson
& Johnson medical
- Karl Storz
8.30/13.00
AFFARI 5
See and Treat
Theoretical Part
14.00/17.00
AFFARI 4
See and Treat
Practical activities
(special registration
needed)
Gynecological
endocrinology and
infertility
10.30 - 11.00 Medical ethics – who writes the rules?
11.10 - 13.10 SERMS
14.10 - 15.00 Amgen in collaboration with GSK
New concept for the treatment of
postmenopausal
15.10 - 17.10 Endocrine control of bone metabolism
Today’s picks
Poster Session
17.10/19.30
Palazzo Affari
-1 floor
Hormones and female brain ageing
12.40-13.10
Assemblea generale isge italia
Are progestins effective for
threatened abortion?
Post-menarchal disorders and
reproductive tract anomalies
Frontiers in
pregnancy research
Advances in imaging
and surgery
Saturday March 6th
Hall Verde
08.30 -10.00 Esg/Seg Polycystic ovarian-metabolic
syndrome (pcos) from birth to postmenopause
10.30 - 11.00 Inflammation and endometriosis
76
Saturday March 6th
Saturday March 6th
Hall AUDITORIUM
POLYCYSTIC OVARIAN-METABOLIC SYNDROME (PCOS) FROM
BIRTH TO POST-MENOPAUSE
08.30/10.00
SYMPOSIUM ORGANIZED BY EUROPEAN SOCIETY OF GYNECOLOGY
Chairpersons: Bouchard Philippe (F), Pélissier-Langbort ClarA (F)
Sultan Charles (F)
Pediatric origins of adult PCOS
Palomba Stefano (I)
Efficacy predictors for metformin and clomiphene citrate treatment in anovulatory
infertile patients with polycystic ovary syndrome
Barri Pedro (E)
The IVF associated risks
Chabbert Buffet Nathalie (F)
PCOS in menopause
Fauser Bart (NL)
Cardio-vascular and metabolic risks
10.30/11.00
PLENARY LECTURE
Taylor Robert (USA)
Inflammation and endometriosis
Chairpersons: Maia Hugo (BR), Volpe Annibale (I)
11.10/13.10
SPONSORED SYMPOSIUM - BAYER SCHERING PHARMA
INNOVATION IN ENDOMETRIOSIS THERAPY
Chairpersons: Blake Jennifer (CDN), Maruo Takeshi (JP)
Hummelshoj Lone (UK)
Challenges faced by the woman with endometriosis
Evidence-based medicine in endometriosis
Mueck Alfred (D)
Progestins - beyond a class effect: The special role of Dienogest
Strowitzki Thomas (D)
New evidence for a special progestin: Clinical data for Dienogest
14.10/15.00
DEBATE
Is pcos a disease or an adaptation?
Chairpersons: Bacchi Modena Alberto (I), Sultan Charles (F)
Berga Sarah (USA) — Dunaif Andrea (USA)
ECM
15.10/17.10
JUBILEE SESSION IN HONOR OF BRUNO LUNENFELD
77
Saturday March 6th
50 YEARS OF OVARIAN STIMULATION WITH HUMAN
GONADOTROPINS
Chairpersons: Buhler Klaus (D), Genazzani Andrea R (I)
Fauser Bart (NL)
Ovulation induction from the Fifties to the 21st century
Schindler Adolf (D)
Measuring hormone levels - in the Seventies and today
Hackelöer Jochen (D)
Controlling gonadotropin stimulation treatment in the 70’s and today
Gonadotropin stimulation for ART: from urinary hMG to “pure” recombinant human
(FSH-LH) preparations
Lerner Liat (IL)
Ovarian stimulation and cancer
Closing remarks
Hall VERDE
HEALTH BENEFITS OF THE EXTENDED USE OF ORAL
CONTRACEPTIVES
08.30/10.00
SYMPOSIUM ORGANIZED BY SOCIEDADE BRASILEIRA DE GINECOLOGIA ENDÓCRINA
Maia Hugo (BR)
Progestins and blockade of menstrual-related inflammation
Bonassi Rogerio (BR)
Clinical trials with extended regimens in Brazil
Maia Hugo (BR)
Extended regimens for the treatment of endometriosis
10.30/11.00
PLENARY LECTURE
Ng Ernest (UK)
Chairpersons: Gil Sanchis Claudia (E), Zullo Fulvio (I)
11.10/13.10
PLENARY SESSION
ART: FROM BASIC SCIENCE TO CLINICAL APPLICATION
Chairpersons: LERNER Liat (IL), Martinelli Pasquale (I)
Magli Maria Cristina (I)
Non-invasive assessment of oocyte quality and embryo viability
Florio Pasquale (I)
Growth factors and implantation: from basic research to clinical applications
Gurgan Timur (TR)
Is there any impact of different gonadotrophins on the success rates for IUI cycles?
Shoham Zeev (IL)
The role of LH in the stimulation protocols
Volpe Annibale (I)
Indications for the mild ovarian stimulation
ECM
78
Saturday March 6th
14.10/15.00
DEBATE
Are progestins always needed to counteract effects
of estrogens after menopause?
Chairpersons: Palacios Santiago (E), Pelusi Giuseppe (I)
Schindler Adolf (D) — Sturdee David (UK)
15.10/17.10
PLENARY SESSION
PROGESTERONE AND PROGESTINS: THEIR TARGETS
Chairpersons: Carta Gaspare (I), Schindler Adolf (D)
Soderqvist Gunnar (S)
Progesterone and progestins effects on breast tissue proliferation and breast cancer risk
markers
Schumacher Michael (F)
Progesterone, new insights in Trauma Brain Injury
Gaspard Ulysse (F)
Management options of bleeding disorders in users of Progestin-only contraception
Vascular effects of progestins
De Ziegler Dominique (F)
A new subcutaneous progesterone in aqueous solution passed the ‘acid test’ of donoregg IVF
Hall AFFARI 1
08.30/10.00
SYMPOSIUM ORGANIZED BY INTERNATIONAL MENOPAUSE SOCIETY
UNANSWERED QUESTIONS ON HRT
Chairpersons: de villiers tobie (za), Sturdee david (UK)
Archer David (USA)
The role of SERMs in gynecology
Skouby Sven (DK)
Is there justification for the widespread fear about the dangers of HRT?
Villaseca Paulina (RCH)
Treating urogenital atrophy: are local estrogens safe?
Are all progestins created equal?
10.30/11.00
PLENARY LECTURE
Mueck Alfred (D)
Dydrogesterone in HRT - New ultra-low dose
regimen to come
Chairpersons: Bolis Pierfrancesco (I), Pines Amos (IL)
11.10/13.10
PLENARY SESSION
WOMAN’S HEALTH THROUGH MENOPAUSE AND AGEING
ECM
Saturday March 6th
Chairpersons: Ferrazzi Enrico (I), Siseles Nestor (RA)
Panay Nicholas (UK)
Long-term hormonal treatment in patients with POF
Collins Peter (UK)
Cardiovascular Risk assessment in Women - A European Perspective
Pérez-López Faustino (E)
Vitamin D and cardiovascular risk
Pines Amos (IL)
The cardiologic and metabolic aspects of HRT
Studd John (UK)
Why are physicians and psychiatrists unwilling to prescribe estrogens to women?
14.10/15.00
DEBATE
Chairpersons: Melcangi Roberto C (I), Studd John (UK)
Henderson Victor W (USA) — Maki Pauline (USA)
15.10/17.10
PLENARY SESSION
HORMONES AND FEMALE BRAIN AGEING
ECM
Chairpersons: Berga Sarah (USA), Garcia Segura Luis Miguel (E)
Maki Pauline (USA)
Effects of hormone therapy and botanical menopausal therapies on cognition in midlife
women
Henderson Victor W (USA)
Hormones and female brain aging
Melcangi Roberto C (I)
Sex difference in neuroactive steroid levels of nervous system
Pluchino Nicola (I)
Gonadal steroid effects on brain neurosteroids and β-Endorphin
Depression and menopause: why antidepressant are not enough
79
80
Hall AFFARI 2
Psychosomatic Obstetrics and Gynaecology
at patient’s side
08.30/10.00
Saturday March 6th
SYMPOSIUM ORGANIZED BY INTERNATIONAL SOCIETY OF PSYCHOSOMATIC
OBSTETRICS AND GYNECOLOGY
Lachowsky Michèle (F)
After breast cancer?
Patients with personality disorders in obstetrics and gynecology or Vulvodynia - a
diagnostic and therapeutic challenge
Facchinetti Fabio (I)
Supporting the choice of mode of delivery
Principles of communicating poor intrapartum events to parents and family
Placebo and nocebo effects: the psychosomatic perspective and clinical meaning
10.30/11.00
PLENARY LECTURE
Pickar James (USA)
Medical ethics – who writes the rules?
ECM
Chairpersons: Ng Ernest (HK), Rizzo Nicola (I)
11.10/13.10
PLENARY SESSION
SERMs
ECM
Chairpersons: Birkhaeuser Martin (CH), Nardelli Giovanni Battista (I)
Palacios Santiago (E)
Target organs for new SERMs
De Villiers Tobie (ZA)
SERMs and bone health
Cano Antonio (E)
Raloxifene action on the endothelium
Goldstein Steven (USA)
SERMs effects on the endometrium
Panay Nicholas (UK)
PhytoSERMS - maintaining benefits, minimising risks
14.10/15.00
SPONSORED PLENARY LECTURE - AMGEN IN COLLABORATION WITH GSK
Gambacciani Marco
new concept for the treatment of postmenopausal
osteoporosis
Chairpersons: Christiansen Claus (DK)
15.10/17.10
PLENARY SESSION
ENDOCRINE CONTROL OF BONE METABOLISM
ECM
Saggese Giuseppe (I)
Acquisition of bone mass during childhood and adolescence. Physiological and clinical
aspects
Huang Ko-En (PRC)
Clinical relevance and molecular mechanism of androgen/androgen receptor actions on
bone growth
Brandi Maria Luisa (I)
Can we prevent fragility fractures in pregnancy?
Christiansen Claus (DK)
The evolution of the use of markers of bone resorption and formation in clinical practice
Yoles Israel (IL)
Osteopenia, osteoporosis, fracture: when and how should we initiate treatment?
Hall AFFARI 3
SINDROME METABOLICA ED INSULINO-RESISTENZA
NELLA DONNA
8.30/12.30
EDUCATIONAL COURSE BY GUIDOTTI
Chairpersons: Loverro Giuseppe (I), Mastrantonio Pasquale (I)
Obesità: aspetti clinici e terapeutici nella donna
Santini Ferruccio (I)
Diabete tipo II e obesità
Palomba Stefano (I)
Metformina e sindrome metabolica in post menopausa
Lanzone Antonio (I)
Aumentata resistenza insulinica e gravidanza
Fulghesu Anna Maria (I)
The analysis of dose /response in Metformin treatment of adolescent PCOS subjects
14.10/15.00
DEBATE
Are progestins effective for threatened abortion?
Chairpersons: Arck Petra (D), Greco Pantaleo (I)
Carp Howard (IL) — Facchinetti Fabio (I)
Saturday March 6th
Chairpersons: Marchesoni Diego (I), Pérez-López Faustino (E)
81
82
ECM
PLENARY SESSION
POST-MENARCHAL DISORDERS AND REPRODUCTIVE TRACT
ANOMALIES
Saturday March 6th
15.10/17.10
Chairpersons: Fedele Luigi (I), Sultan Charles (F)
Deligeoroglou Efthimios (GR)
Post menarchal menorrhagia
Weight loss-associated amenorrhea
Paoletti Anna Maria (I)
Therapies for acne and androgen excesses
Creatsas George (GR)
Hormonal contraception in adolescence
Jasonni Valerio (I)
Surgical strategies for the correction of vaginal agenesis
Hall AFFARI 5
“See and Treat” – THEORETICAL PART (130 PARTICIPANTS)
8.30/13.00
EDUCATIONAL COURSE SPONSORED BY ETHICON WOMEN’S&UROLOGY
JOHNSON&JOHNSON MEDICAL - OFFICE OPERATIVE HYSTEROSCOPY
AND KARL STORZ ENDOSCOPIA ITALIA
Bettocchi Stefano (I)
Approching the “see and treat” phylosophy
Angioni Stefano (I), Cela Vito (I), Di Spiezio Sardo Attilio (I)
Experiencies in office hysteroscopy
Discussants:
Calzolari Stefano (I), Florio Pasquale (I), Franchini Mario (I), Luisi Stefano (I),
Pluchino Nicola (I)
Live Office procedures from University of Bari
Hands on: Instrumentation
Build up hysteroscopes, electronical controlled irrigation and suction device, bipolar
generator; mechanical instruments and bipolar electrodes
14.00 - 17.00
Hall AFFARI 4
EDUCATIONAL COURSE SPONSORED BY ETHICON WOMEN’S&UROLOGY
JOHNSON&JOHNSON MEDICAL - OFFICE OPERATIVE HYSTEROSCOPY
AND KARL STORZ ENDOSCOPIA ITALIA
“See and Treat” – PRACTICAL ACTIVITIES
ONLY 30 PARTICIPANTS - SPECIAL REGISTRATION needed
Tutors
Angioni Stefano (I), Achilarre Maria Teresa (I), Calzolari Stefano (I), Cela Vito (I),
Coppola Carmela (I), Dispiezio Sardo Attilio (I), Florio Pasquale (I),
Franchini Mario (I), Luisi Stefano (I), Maricosu Giovanni (I), Pinto Lauro (I),
Pluchino Nicola (I), Simi Giovanna (I), Spinelli Maria Luigia (I), Viana Gersia (I)
Hands on: Hystero Trainer
Vaginoscopy, technique of endometrial biopsy, technique of polipectomy, myomectomy
and metroplasty with mechanical instruments and bipolar electrodes.
Hall ONICE
GYNECOLOGICAL ENDOCRINOLOGY AND INFERTILITY
8.30/10.00
83
Oral Presentations
Bucci F, Giannini A, Cubeddu A, Russo N, Daino D, Russo M, Merlini S, Casarosa E,
Luisi M, Genazzani AR, (I)
Polycystic Ovary Syndrome: plasma and follicular fluid Brain-Derived Neurotrophic Factor
(BDNF) levels
Davydova Dedov II, Melnichenko GA, Chebotnikova TV, Davydova GN, Ilin AV, (RUS)
Natural history and long-term consequences of PCOS
Fuchs LFP, Maganhin CC, dos Santos Simões R, Soares Jr JM, Baracat EC, de Jesus
Simões M, (BR)
Melatonin affect adrenal of adult female pinealectomized rats: histomorphological and
imunohistochemical aspects
Grodnitskaya EE, Kurtser MA, (RUS)
The homocysteine levels in women of reproductive period with polycystic ovary
syndrome
Muhaxhiri F, Kotori A, Hoxha M, Muhaxhiri A, Republic of Kosova
Our experiences with the TRH-testing in infertile patients
Ritunnano R, Cosma C, Zuliani L, Glinski L, Azzolini S, Bleve L, Granzotto M, Maffei
P, Faggian D, Sicolo N, Vettor R, Mioni R, (I)
Acute GnRH-analogue administration does not influence AMH secretion in PCOS
patients
Scagliola P, Gambera A, Turrina S, Bugari G, Iacobello C, Pecorelli S, Sartori E, (I)
Anti-mullerian hormone evaluation in women with polycystic ovary syndrome
Suturina L, Labygina A, Kolesnikova L, Grebenkina L, Popova L, Lazareva L,
Atalyan A, (RUS)
Antioxidant insufficiency in women with endocrine infertility
11.10/13.10
Oral Presentations
FRONTIERS IN PREGNANCY RESEARCH
Chairpersons: Challis John (CDN), Luchi Carlo (I)
Borowicz PP, Grazul-Bilska AT, Johnson ML, Redmer DA, Reynolds LP, (USA)
Expression of mRNA for placental growth factor (PlGF) and hypoxia inducible factor
(HIF1α) in placental tissues during early pregnancy in sheep
Calleja-Agius J, Muttukrishna S, Brincat M, Jauniaux E, (M)
The Role of Tumour Necrosis Factor Alpha in Early Pregnancy
Camilleri Agius R, Muscat Baron Y, Brincat M, (M)
The effect of Dexamethasone on the Pre-eclamptic Process - a brief reprieve up to Day 4
post-dexamethasone?
Cañete P, Monllor A, Pineda A, Cano A, (E)
The levels of placental hsp27, a modulator of intracellular estrogen availability, are
reduced in deliveries of small fetuses
De Cata AP, Bonin C, Bettinazzi F, Signori C, Forner S, Travagliati V, Bonora E,
Bonadonna R, Moghetti P, (I)
Predictors of birth weight in babies of women with gestational diabetes
Saturday March 6th
Chairpersons: Baldi Elisabetta (I), Simi giovanna (i)
Klimov V, (UA)
Abnormality processes angiogenezise in pathogenesis of preeclampsia
84
Saturday March 6th
Mandò C, Tabano S, Colapietro P, Marino A, Pileri P, Miozzo M, Cetin I, (I)
Sodium coupled Neutral Aminoacid Transporter 2 (SNAT2) Intron1 methylation levels
and Single Nucleotide Polymorphism in IUGR placentas
Matsuzawa Y, Keiji S, Mitsutoshi I, (JP)
Improvement of insulin sensitivity to trophoblast cells improves trophoblast cell
migration stimulated by insulin-like growth factor
Mparmpakas D, Goumenou A, Harvey A, Karteris E, Gidron Y, (UK)
Environment and genetics: How GR polymorhism and maternal attitudes predict low
birth weight
Poopalapillai J, Tennekoon KH, Karunanayake EH, Kumarasiri JM, Wijesundere
APDeS, (CL)
Insulin-Like Growth Factor (IGF)-I , IGF Binding Protein-1 and Dinucleotide (CT) Repeat
Polymorphism of the intron 2 of IGF-I Gene and Their Association with Birth Indices
Reynolds LP, Borowicz PP, Redmer DA, Grazul-Bilska AT, Vonnahme KA, Caton JS, (USA)
‘Placental Programming’ and Fetal Growth Restriction
Sato Y, Fujiwara H, Konishi I, (JP)
Maternal platelets and placental vascular remodeling
15.10/17.10
Oral Presentations
ADVANCES IN IMAGING AND SURGERY
Chairpersons: Severi Filiberto (I), Strigini Francesca (I)
Alvarez Nieto JM, (YV)
Swab Test and Transperineal Ultrasound in the evaluation of the Urinary Incontinence
Brienza L, Amoroso C, Di Giovanni A, Romeo V, Exacoustos C, Arduini D, (I)
Two and Three-dimensional ultrasound evaluation of adenomyosis: correlation of
sonographic findings to histology
Del Ghianda S, Pucci A, Talini E, Giannini C, Benelli E, Burelli A, Rinaldi E, Vitti P,
Pucci E, Di Bello V, (I)
Analysis of left ventricular systolic and diastolic function in patients with polycistic ovary
syndrome: an echocardiographic study
Di Giovanni A, Exacoustos C, Szabolcs B, Romanini ME, Amoroso C, Romeo V, Zupi
E, Arduini D, (I)
Three-dimensional Coded Contrast Imaging : a new approach for automated
sonographic tubal patency evaluation.
Nanini C, Valentino V, Donati E, Genazzani AR, (I)
Women Pelvic Floor: management and rehabilitation
Oppedisano R, Venturella R, Materazzo C, Rocca M, Palomba S, Zullo F, (I)
Colposuspension versus tension free vaginal tape during laparoscopic sacralcolpopexy: a
retrospective study
Shahinaj R, Manoku N, (AL)
The value of the middle-cerebral-to-umbilical-artery pulsatility index ratio in the
prediction of adverse neonatal outcome in the fetuses with IUGR and preeclampsia
Simi G, Ruggiero M, Di Berardino OM, Artini PG, Angioni S, Pluchino N, Genazzani
AR, Cela V, (I)
Laparoscopy single-port surgery in gynecology: our experiences
Stangel-Wójcikiewicz K, Wojtyś A, Migdał M, (PL)
Laparoscopic modification of colpopexy technique performed with LSH, TLH, and after
open hysterectomy
Taavoni S, Haghani H, Fekrat M, (IR)
Postoperative pain management in gynecology and postpartum wards in main referral
hospirtal, Iran University of Medical Sciences
Venturella R, Oppedisano R, Rocca M, Materazzo C, Zullo F, Palomba S, (I)
Treatment of urinary stress incontinence during or following correction of pelvic organ
prolapse
Saturday March 6th
Stoykova V, Markov D, Karagjozova J, Ivanov S, (BG)
Second trimester Uterine Artery Doppler evaluation as predictor of hypertensive
disorders in late pregnancy
85
86
Sunday March 7th
Sunday March 7th
Hall Affari 1
08.30 - 10.30 New mechanisms of steroid
receptor signaling
Hall Affari 2
Hall Affari 3
Hall Affari 4
Benign Gynecological
disorders
Fiog “Somministrazione
di estro progestinici:
controvewrsie e clinical
evidence”
Menopause and
cardiovascular disease
Early pregnancy diagnosis
and treatment
Menopause, quality of life and
osteoporosis
10.30 - 11.00 Testosterone and male sexual
attitudes
and behaviours
11.00 - 13.00 Contraception in 2010
Diseases of pregnancy
13.00 - 13.30 Closing Ceremony
and Poster Awards
Today’s picks
Closing Ceremony
and Poster Awards
13.00/13.30 Hall Affari 1
Chairpersons:
Genazzani Andrea R (I) simoncini Tommaso (I)
87
Hall AFFARI 1
NEW MECHANISMS OF STEROID RECEPTOR SIGNALLING
08.30/10.30
PLENARY SESSION
ECM
Chairpersons: Huber Johannes (A), Schumacher Michael (F)
Marino Maria (I)
Steroid receptors at the cell membrane: what are they for?
Simoncini Tommaso (I)
Rapid signalling mechanisms of steroids on the cytoskeleton
Vegeto Elisabetta (I)
Sex steroids and inflammatory pathways in the brain
Gravanis Achilleas (GR)
Neurosteroid membrane signalling in neuronal survival
García Segura Luis Miguel (E)
Interactions of Estrogen Receptor ERα with IGF-I Signalling in the Brain
10.30/11.00
PLENARY LECTURE
Maggi Mario (I)
Testosterone and male sexual attitudes
and behaviours
11.00/13.00
Chairpersons: Caruso Salvatore (I), Lunenfeld Bruno (IL)
PLENARY SESSION
CONTRACEPTION IN 2010
Chairpersons: Gaspard Ulysse (F), Patella Alfredo (I)
Huber Johannes (A)
Non-contraceptive effects of hormonal contraceptives: the ovary and the uterus
Effects of hormonal contraceptives on the breast
De Melo Nilson Roberto (BR)
Contraception in Women with Cardiac Diseases
Melis Gian Benedetto (I)
Hormonal Contraception and premenstrual symptoms
13.00/13.30
Closing ceremony and poster awards
Chairpersons: Genazzani Andrea R. (I), simoncini Tommaso (I)
ECM
ECM
Sunday March 7th
88
Hall AFFARI 2
Sunday March 7th
08.30/10.30
ORAL PRESENTATIONS
BENIGN GYNECOLOGICAL DISORDERS
Chairpersons: Milani rodolfo (I), Penna Carlo (I)
Ajaya Maharajan P, Nicholls, (UK)
Is there a correlation between symptoms and clinical assessment with endometriosis?
Al-Jefout M, Dezarnaulds G, Cooper M, Tokushige N, Luscombe G, Markham R,
Fraser IS, (HKJ)
Endometrial biopsy for diagnosis of endometriosis: a double blind study
Annunziata M, Duràn-Prado M, Luque R, Grande C, Deltetto F, Delpiano E, Camanni
M, Ghigo E, Castaño J, Granata R, (I)
Somatostatin, cortistatin and their receptors are expressed in endometriotic tissues and
cells and inhibit PDGF-induced endometrial cell proliferation and motility
Caponi D, Rizzello F, Mariani G, Riviello C, Coccia ME, (I)
IVF-ET after laparoscopy for moderate-severe endometriosis. A case-control study
Fritsch M, Keator C, Möller C, Slayden OD, (D)
Survival and growth of human leiomyoma in a SCID mouse model
Gori I, Staedler D, Matskevich AA, Hohlfeld P, Canny GO, (CH)
Crosstalk between Tumor Necrosis Factor-alpha and Estrogen signaling pathways in
endometrial epithelial cells
Harirchian P, Kirchhoff D, Koch M, Zollner TM, Gashaw I, (D)
Estrogen effects lesion composition and persistence in a syngeneic transplantation
endometriosis mouse model
Konrad L, Omwando CA, von Hobe AK, Sui C, Kloeppels K, Hersemeyer K,
Tinneberg HR, (D)
Are cell lines a suitable model for studying endometriosis
Milewski L, Wojtowicz K, Roszkowski P, Kaminski P, Barcz E, Malejczyk J, (PL)
Expression of ghrelin and its receptor in endometriotic lesions
Ruggiero M, Viana G, Di Berardino OM, Papini F, Carletti E, Artini PG, Cela V,
Genazzani AR, (I)
Comparison between GnRH agonist and antagonist protocols for severe endometriosis
in vitro fertilization cycles
Seeber B, Faserl K, Sarg B, Kremser L, Golderer G, Lindner H, Wildt L, (A)
Reduced ability to activate macrophages via Vitamin-D-Binding Protein may contribute
to the pathogenesis of endometriosis
Seitz C, Gerlinger C, Faustmann T, (D)
The safety profile of dienogest in endometriosis: pooled analyses from the clinical
study program
11.00/13.00
ORAL PRESENTATIONS
DISEASES OF PREGNANCY
Armeni E, Lambrinoudaki I, Rizos D, Pliatsika P, Leonardou A, Sygelou A, Argeitis J,
Spentzou G, Hasiakos D, Zervas I, Papadias C, (GR)
Thyroid function and postpartum mood disturbances in Greek women
Ćetković A, Popović V, Miljić D, Đurović M, Pekić S, Doknić M, Micić J, (SRB - MNE)
Kisspeptin in pregnancies with hypertensive syndrome as a potential predictor of adverse
perinatal outcome
Fernández-Alonso AM, Ferrando-Marco P, Dionis-Sánchez EC, Salmerón-González
MD, Fernández-Alonso IM, Cuadros-López JL, Pérez-López FR, (E)
Serum 25-hydroxyvitamin levels in first trimester pregnant women living in a sunny
Spanish region
Hazi GM, Procopciuc LM, Caracostea G, Iordache G, Dragatoiu Gh, Olteanu I,
Stamatian F, (RO)
Correlation between the TSHRc-Asp727Glu polymorphism and plasma TSH levels in
Romanian preeclamptic women
Kalogeropoulos SG, Papantoniou N, Koutroumanis P, Chatzi E, Daskalakis G,
Mesogitis S, Antsaklis A, (GR)
How does Gestational Weight Gain Affect Pregnancy Outcome in Obese Women?
Luchi C, Schifano M, Nanini C, Sceusa F, Capriello P, Genazzani AR, (I)
Detailed fetal anatomy assessment in the first trimester at 11, 12 and 13 weeks of
gestation
Naver KV, Lundbye-Christensen S, Gorst-Rasmussen A, Nilas L, Secher NJ,
Rasmussen S, Ovesen P, (DK)
Parity and Diabetes in a Danish Cohort
Petrilli G, Blom JMC, (I)
Psychopathology during pregnancy and postpartum: the importance of prenatal
screening
Pisaneschi S, Sanchez MA, Begliuomini S, Strigini FAL, Ghirri P, Boldrini A,
Genazzani AR, Coceani F, Simoncini T, (I)
Functional and molecular analysis of umbilical vessels endothelial cells of fetuses with
normal growth and intrauterine growth restriction
Veltman SM, van Haeften TW, Eijkemans MJC, de Valk HW, Fauser BCJM,
Goverde AJ, (NL)
In PCOS preconceptional HOMA index identifies women at risk for gestational diabetes
Sunday March 7th
Chairpersons: Florio Pasquale (I), Mello Giorgio (I)
89
90
Hall AFFARI 3
SOMMINISTRAZIONE DI ESTROPROGESTINIci:
CONTROVERSIE E CLINICAL EVIDENCE
08.30/10.30
Sunday March 7th
SYMPOSIUM ORGANIZED BY FEDERAZIONE ITALIANA DI OSTETRICIA E
GINECOLOGIA
Chairpersons: Bologna Maurizio (I), Cersosimo Luigi (I), Zinno Giulia (I)
Scarselli Gianfranco (I)
Introduzione
Giorgino Francesco (I)
Contraccettivi ormonali: effetto teratogeno nella gravidanza iniziale
Lisi Franco (I)
Progestinici e prevenzione dell’aborto spontaneo
Del Pup Lino (I)
Estroprogestinici e Carcinoma mammario
Serra Giovan Battista (I)
Appropriatezza prescrittivi e responsabilità professionale
11.00/13.00
PLENARY SESSION
EARLY PREGNANCY DIAGNOSIS AND TREATMENT
ECM
Chairpersons: Arduini Domenico (I), Shoham Zeev (IL)
Luchi Carlo (I)
Early Health: new Advanced Technology in Embriology using very high frequency probes
3D/4D
Migliore Lucia (I)
Abnormal folate metabolism and chromosomal segregation in mothers with Down
syndrome offspring
Facchinetti Fabio (I)
Progesterone in threatened abortion and recurrent miscarriage prevention
Simi Paolo (I)
Prenatal diagnosis: past, present and future
Carp Howard (IL)
Biochemical and recurrent biochemical pregnancies: definition and management
Hall AFFARI 4
MENOPAUSE AND CARDIOVASCULAR DISEASE
08.30/10.30
Oral Presentations
Chairpersons: Fulghesu Anna Maria (I), Maffei Silvia (I)
Black SM, Kumar S, Sharma S, Sun X, Mintz JD, Hoyer PB, Stepp DW, (USA)
Follicle depletion induced by 4-vinylcyclohexene diepoxide leads to endothelial
dysfunction secondary to the uncoupling of NOSIII
Boz N, Gulerman C, Guray Y, Korkmaz S, (TR)
Is there any association between mild hypertension and hot flash experience among women?
Clapauch R, Mecenas AS, Maranhão PA, Bouskela E, (BR)
Impaired Microvascular Endothelial Function and Wall Stiffness in simultaneously
diabetic and hypertensive postmenopausal women compared to controls: responses to
acute Estradiol
Fu S, Low Choy N, Nitz J, (AUS)
Looking for the right balance - consideration of exercise approaches in the menopause
transition, healthy ageing and early falls prevention
Gorlato G, Nuzzo A, Chiurlia E, Origliani G, Battistini NC, Fantini G, Rossi R,
Modena MG, (I)
Effect of lifestyle on vascular function and metabolism in post menopausal hypertensive
and obese women
Hermenegildo C, Sobrino A, Oviedo PJ, Laguna-Fernández A, Bueno C, Monsalve E,
Novella S, (E)
Prostanoids release induced by estradiol differs in endothelial cells from vein and arterial
origin
Morales Alvarado L, Sanjuán A, Castelo-Branco C, (E)
Effect of Androgenic and Antiandrogenic Acting Compounds in Macrophage
Accumulation and Cell Replication in the Aorta of Oophorectomized
Hypercholesterolemic Rabbits
Novensà Casas L, Novella S, Castillo N, Medina P, Segarra G, Hermenegildo C,
Dantas AP, (E)
Aging plays a detrimental role on cardiovascular protection by estrogen
Vélez M, Godoy-Izquierdo D, Mendoza N, Andrés CP, Pérez-Fortis A, González I,
Marín L, Salamanca A, de Teresa C, Godoy JF, (E)
Predictors of exercise outcomes among initiators and regular exercisers menopausal
women
Zang H, Moritz T, Lundgren K, Norstedt G, Hirschberg AL, Tollet-Egnell P, (PRC)
Effects of Estrogen and Testosterone Therapy on Serum Metabolites in Postmenopausal
Women
Zelenina TA, Vorokhobina N, Mamontov O, (RUS)
Cardiac autonomic neuropathy in diabetic postmenopausal women
11.00/13.00
Oral Presentations
MENOPAUSE, QUALITY OF LIFE AND OSTEOPOROSIS
Chairpersons: Serra Giovan Battista (I), Stomati Massimo (I)
Adami S, Cummings SR, McClung MR, Christiansen C, Siris E, Eastell R, Kutilek S,
Reid IR, Zanchetta JR, San Martin J, Libanati C, Siddhanti S, Franchimont N, Wang
A, Austin M, Boonen S, (I)
The Effects of Denosumab on Risk of Fracture Over 3 Years Among Postmenopausal
Women: The FREEDOM Trial
Cubeddu A, Bucci F, Giannini A, Merlini S, Russo M, Daino D, Russo N, Casarosa E,
Luisi M, Genazzani AR, (I)
HRT and paroxetine: the efficacy of the two treatments on brain-derived neurotrophic
factor (BDNF) plasma levels in menopausal women
Del Pup L, (I)
Treatment of menopausal symptoms in estrogen sensitive gynaecological cancer
patients
91
Sunday March 7th
de Oliveira Belo N, Nery de Andrade E, Kelle Neves Gonçalves G, Caldeira de
Oliveira TH, Silva Santos C, Leal Silva e Souza C, Mendes de Magalhães AC, de
Jesus Soares T, (BR)
Development of postmenopausal hypertension in a rat model of diet-induced obesity: a
link between cardiac endocrine function and fat mass
92
Sunday March 7th
Della Martina M, Magrini F, Rinuncini D, Vogrig E, Xodo S, Maurigh A, Ganzitti L,
Fabiani G, Marchesoni D, (I)
Identification of patients with a high risk for osteoporosis: analysis by FRAX® and
phalangeal ultrasonography in a female population in North East Italy
Fu S, Kuys S, Isles R, Nitz J, Australia
Wii Fit: the new generation tool for improving balance, health and well-being for
women?
Godoy-Izquierdo D, Vélez M, Mendoza N, Pérez-Fortis A, Andrés CP, González I,
Marín L, Salamanca A, de Teresa C, Godoy JF, (E)
Exercise and quality of life in menopause: physical, medical and psychological findings of
a monitorized physical exercise programme
Mendoza N, Presa J, Santalla A, Malde J, Ruiz J, Sánchez Borrego R, Quereda F,
Gonzalez I, Salamanca A, (E)
Food customs in the development of the hip osteroporosis: the importance of
Mediterranean diet
Moruzzi C, Leoni F, Di Florio C, Minisola G, D’erasmo E, Falaschi P, Lanzone A, Villa P, (I)
Osteoporosis rate in menopausal female population by a bone mineral density diagnosis
test after a prescription of glucocorticoid therapy for other disease: the EGEO study
Sciacchitano SG, Savoca S, Rubino C, Ventura B, Panella M, (I)
Hormonal alterations and Osteoporosis in women with Coeliac Desease
Seifert-Klauss V, Wimmer T, Müller D, Schuster T, Goppel K, (D)
Do elevated FSH-levels during perimenopause increase loss of bone density?
Sisó Raber C, Castelo Branco C, (E)
A poblational study of menopause and quality of life
List of Posters
Palazzo Affari
Poster Session - Saturday March 6th 17.10/19.30
5
0 Ground Floor
-1 Floor
5
5 Poster Area
BASIC SCIENCE
1
Effective methods in diagnostics of ovarian tumours Abdullaeva LM, Babadjanova GS, Nazarova
DB, Republic of Uzbekistan
2
Review on the molecular mechanisms implicated
in bladder cancer development and their association to treatment response Augoulea A, Maipa S,
Boutzouvis S, Greece
3
The HLA Ancestral Haplotype AH8.1: from good
intrauterine life to autoimmune diseases Capittini
C, Bergamaschi P, Tinelli C, Martinetti M, Salvaneschi L, Cuccia M, Italy
4
Derivation of mesenchymal stem cells from human
endometrial polyps Chen P-C, Ding DC, Taiwan
5
Characterisation of Osteopontin Function in the
Human Endometrium De Mello N, Gonzalez D,
Joels L, Conlan S, White J, UK
6
Real-time impedance analysis as a new tool for
measuring hormonal and toxicological effects on
human endometrial cell lines Deppert W, Fischer L,
Nöthling C, Zahradnik HP, Schäfer W, Germany
7
The human endometrial Ishikawa cell line as model for detecting tissue-specific estrogenic effects
Fischer L, Deppert WR, Nöthling C, AustermannHesse H, Zahradnik HP, Schäfer WR, Germany
8
A multigenic combination of polymorphisms
within ESR1, ESR2, FSHR, CYP19A1, NRIP1
and BMP15 genes are associated with the duration
of fertility age in a Spanish population Galliano
D, González I, Mendoza N, Eloy Ruíz J, SánchezBorrego R, Salamanca A, Malde J, Godoy D, Vélez
M, Spain
9
Estradiol reverses the ovariectomy-increased contractile effect of thromboxane A2 in aorta from
senescence-accelerated mice Hermenegildo C,
Novella S, Medina P, Dantas AP, Díaz A, Bueno C,
Segarra G, Spain
10 Omental and subcutaneous adipose tissue steroid
hormone level in women Kinoshita T, Watanabe Y,
Honma S, Japan
11 Estradiol activates the Akt pathway in human uterine leiomyoma and promotes survival Kovács KA,
Wilhelm F, Lengyel F, Bódis J, Hungary
12 Maternal and placental pathology as main predictors in the quality of umbilical cord stem cells and
the success of sampling and cryopreservation
Marin JA, Calomfirescu M, Bohiltea R, Horhoianu I, Horhoianu V, Russu M, Nastasia S, Ionescu-Tirgoviste C, Romania
13 Thiazolidiones reduce the concentration of proinflammatory cytokines, IL-6 and IL-8, secreted
from cultured primary endometrial stromal cells
McKinnon B, Bersinger NA, Mueller MD, Switzerland
14 Effects of simvastatin on the proliferation and apoptosis of human endometrial stromal cells from
women with endometriosis Na Y-J, Moon SH, Joo
JK, Kim HG, Lee KS, Republic of Korea
15 The importance of oncomarker CA-125 in diagnostics and treatment of patients with tumours
of ovary Nazarova DB, Abdullaeva LM, Ashurova
UA, Republic of Uzbekistan
93
94
16 Effect of Estradiol and Progesterone on Urocortins
mRNA Expression in Cultured Endometrial Stromal Cells Novembri R, Bloise E, Aiello AC, De
Pascalis F, Florio P, Petraglia F, Italy
17 Role of CRH-Receptors During in vitro Decidualization Process Novembri R, Borges LE, Bloise E,
Aiello AC, De Pascalis F, Florio P, Petraglia F, Italy
18 CD40, CD40L and ADAM8 expression in endometriosis Panoulis K, Nieri E, Kaparos G,
Augoulea A, Logothetis E, Creatsa M, Fotiou S,
Greece
19 Extra-nuclear signaling of estrogen to wave1 controls neuronal spine formation through the actin
cytoskeleton Sanchez AM, Flamini MI, Genazzani
AR, Simoncini T, Italy
20 Effects of estrogen on breast cancer cell migration and invasion through focal adhesion kinase
Sanchez AM, Flamini MI, Genazzani AR, Simoncini T, Italy
21 Heparin modulates effects of TNF-a in human endometrial stromal cells by interference with NF-kB
Spratte J, Fluhr H, Zygmunt M, Germany
22 The influence of obesity on the sexual life of the
menopausal women Tancic Gajic M, Nenezic A,
Stojanovic M, Ivovic M, Marina L, Barac M, Arizanovic Z, Vujovic S, Serbia and Montenegro
25 Correction of insulin resistance in polycystic ovary
syndrome Andreeva EN, Karpova EA, Derkach
DA, Sheremetyeva EV, Russia
26 Features of psychological status and quality of life
in patients with the syndrome PCOS Andreeva
EN, Karpova EA, Sheremetyeva EV, Surkova EV,
Derkach DA, Russia
27 Quality of life in menopause: outcomes derived
from adhering to a monitorized physical exercise
programme Andrés PC, Godoy-Izquierdo D, Vélez
M, Pérez-Fortis A, Mendoza N, Salamanca A, de
Teresa C, Godoy JF, Spain
28 Gynaecological correlators of health status, perceived health status and quality of life in menopause Andrés PC, Godoy-Izquierdo D, Vélez M,
Pérez-Fortis A, Mendoza N, Salamanca A, de Teresa C, Godoy JF, Spain
29 Premenstrual syndrome in women with cushing
syndrome Barac MM, Ivovic M, Tancic M, Marina L, Ivanisevic M, Arizanovic Z, Vujovic SZ,
Serbia
30 Follow-up of hyperprolactinemic women with macroprolactinemia Barmina II, Dzeranova LK, Russia
31 Glucose tolerance abnormalities in Greek women with PCOS Basios G, Trakakis E, Peppa M,
Chrelias C, Boutati E, Simeonidis G, Creatsa M,
Salamalekis G, Skarpas P, Panagopoulos P, Kassanos D, Greece
GYNECOLOGICAL ENDOCRINOLOGY 32 Frequency of anticardiolipin antibody in patients
23 An Open-Label, Comparative Study of the Unique,
Monophasic Combined Oral Contraceptive Nomegestrol Acetate/17 Beta-Estradiol: Impact on
Adrenal and Thyroid Function Ågren U, Anttila
M, Mäenpää-Liukko K, Rantala ML, Rautiainen
H, Sommer W, Mommers E, Finland
24 Endometrial vessel characterisation in a mouse
model of human endometrial transplantation exposed to levonorgestrel and a MMP inhibitor
Alvarez Gonzalez M-L, Frankenne F, Beliard A,
Evrard B, Jerome C, Galand C, Marbaix E, Foidart
JM, Nisolle M, Belgium
with SLE and it s correlation with clinical manifestation Basiri Z, Faridnia M, Gholyani M, Iran
33 Effects of glucosamine alone and in association
with chondroitin sulphate in epiphyseal growth
plate on ovariectomized rats Bastos Wolff R, Teixeira Gomes RC, Simões MJ, dos Santos Simões R,
Ferraz Carbonel AA, Verna C, Baracat EC, Soares
Júnior JM, Brazil
34 Hormone replacement therapy and calcitonin for
postmenopausal women with bone mass loss
Bazarra-Fernandez A, Spain
95
96
35 HPV and contraception Bazarra-Fernandez A, Spain
36 In female osteoporosis oestrogens are not the only
cause Bazarra-Fernandez A, Spain
37 Turner syndrome and osteoporosis Bazarra-Fernandez A, Spain
38 Relationship between lipid profile and other cardiovascular risk markers and hormonal treatment
in female-to-male transsexuals Becerra-Fernandez
A, Menacho-Roman M, Perez-Lopez G, Lucio-Perez
MJ, Asenjo-Araque N, Rodriguez-Molina JM, Spain
39 Natural and synthetic oestrogens and its benefits
in breast formation in girls with primary estrogen
deficient (PED) Belokon IP, Ozerova OE, Surcova
LV, Uvarova EV, Russia
40 Bone mineral density markers in girls with primary
estrogen deficiency (PED) Belokon IP, Kiseleva IA,
Uvarova EV, Zaidiev KU, Russia
41 Sertoli-Leydig cell tumor - a rare androgen secreting ovarian tumor in postmenopausal women: case
report and review of literature
Benelli E, Rinaldi E, Del Ghianda S, Cionini R,
Burelli A, Cela V, Caruso A, Vitti P, Pucci E, Italy
42 Effect of adipose tissue transplantation on fertility
restoration in obese anovulating mice ovaries
Berguio Vidotti D, Pereira Júnior M, Dale Cotrim
Guerreiro da Silva I, Silva I, de Jesus Simões M,
Haidar MA, Brazil
47 Reproduction: immune response and dna integrity
Brufman AS, Orellano EG, Garcia Rosasco MME,
Argentina
48 Relation among BDNF, cortisol and estradiol in
hypothalamic amenorrhoea Bucci F, Cubeddu A,
Giannini A, Russo N, Russo M, Daino D, Merlini
S, Casarosa E, Luisi M, Genazzani AR, Italy
49 Weight loss impact on hypernadrogenism in overweight PCOS patients Bucuras DL, Anastasiu D,
Craina M, Grigoras D, Romania
50 Fitoestrogens and breast tightness in menopause
women on hrt Bulajic E, Serbia and Montenegro
51 Etiopathogenesis and treatment of hyperprolactinemia (HPRL) Bylykbashi E, Bylykbashi I,
Zhaka A, Janushaj O, Albania
52 Profille of fats to women in menopause Bylykbashi
E, Qafa I, Bylykbashi I, Janushaj O, Albania
53 Could LH/FSH Ratio After GnRH Stimulation
Be Useful In the Diagnosis of Polycystic Ovary
Syndrome? Cajdler-Luba A, Lewandowski KC, Bienkiewicz M, Salata I, Lewinski A, Poland
54 A case of primary hyperparathyroidism in pregnancy Camilleri Agius R, Muscat Baron Y, Brincat
M, Craus J, Attard A, Cachia M, Malta
43 The usage of oral hormonal contraceptives among
adolescent population Berisavac M, Sparic R, Gudovic A, Markovic N, Serbia
55 Effects of metoclopramide-induced hyperprolactinemia on the gene expression of hyaluronan
synthases I, II and III in mouse uterine Carozi
Cristofani GC, Teixeira Gomes RC, Verna C, Malva Silva AI, dos Santos Simões R, Ferraz Carbonel
AA, Bonciani Nader H, Soares Júnior JM, Brazil
44 Level of total testosterone (TT) and wide spectrum
of steroids measured by mass spectrometry in adolescent girls with hirsutism and polycystic ovarian
morphology Bogdanova PS, Kareva MA, Russia
56 New born weight´s predictability for body mass
index and waist circumference in adolescents
Carpintero P, Litterio G, Fusaro D, Campostrini
B, Franchina M, Argentina
45 Menstrual Irregularity in Adolescents with Risk
Factors for Metabolic Syndrome Bouzas I, Braga
C, Leao L, Bouzas D, Brazil
57 Prevalence of HPV among Maltese women with
abnormal Smear Tests Cassar OA, Spiteri D, Brincat M, UK
46 Polycystic Ovarian Syndrome (POS) in Adolescence: Clinical and Laboratorial Alterations Bouzas
I, Braga C, Leoao L, Rodeiro D, Brazil
www.ivf-worldwide.com Be part of our global network...
97
THE WORLD'S LARGEST IVF DIRECTORY
including national and international sperm banks
WWW.IVF-WORLDWIDE.COM
IVF-Worldwide.com is the largest and most comprehensive IVF-focused website for doctors, embryologists,
nurses and social workers. We offer free and exclusive information to both the professional field and
the general public.
IVF-Worldwide.com is built with the vision to give to its members the ability to locate
IVF units anywhere in the world and to communicate directly with the unit. In addition
IVF-Worldwide.com will be home to a large section of educational material including
recent publications, abstracts, PowerPoint presentations and newsletters.
98
58 Clinical phenotypes of polycystic ovary syndrome
in population of Moscow Chebotnikova T, Melnichenko GA, Davydova GN, Russia
59 Assessing perceived control over hot flushes in climacteric women Chedraui P, Leimberg ML, PérezLópez FR, Mendoza M, Martínez MA, Vallarino
V, Hidalgo L, Ecuador
60 Use of venlafaxine in climacteric syndrome Ciani
V, Luisi S, Lazzeri L, Dores D, Dottarelli P, Castrogiovanni A, De Capua A, Petraglia F, Italy
61 The effect of different treatment modalities in post
menopausal women suffering from osteoporosis in
the Maltese population Cini Custò R, Cini C, Felice N, Muscat Baron Y, Brincat M, Malta
62 Treatment of hyperandrogenism by myo-inositol
Ciotta L, Iozza I, Rubbino G, Iemmola A, Lizzio
I, Teodoro MC, Palumbo M, Italy
63 Brain-derived neurotrophic factor (BDNF) and
allopregnanolone in the different phases of the
menstrual cycles of women with premenstrual syndrome Cubeddu A, Giannini A, Bucci F, Daino D,
Russo M, Russo N, Casarosa E, Luisi M, Genazzani AR, Italy
64 The effect of smoking on inhibin B levels in normal fertile women Dafopoulos A, Dafopoulos K,
Koutlaki N, Georgoulias P, Galazios G, Maroulis
G, Liatsikos S, Zografou C, Tsikouras P, Limberis
V, Greece
65 Salivary BDNF levels during menstrual cycle
Daino D, Giannini A, Cubeddu A, Bucci F, Russo N, Russo M, Casarosa E, Merlini S, Luisi M,
Genazzani AR, Italy
66 Manifestations of somatic disturbances in early
post menopause in women after physiological and
surgical menopause Daneva-Markova A, Antovska
V, Stefanija A, Kiproska G, Republic of Macedonia
67 Calciuria and bone loss in premenopausal female
patients with glomerulopathies and receive longterm immunosuppression de Deus RB, Nogueira
Ferraz RR, Brazil
68 Efficacy of red yeast and berberin in women with
altered lipid metabolism using hormonal contraceptives De Leo V, Morgante G, Musacchio MC,
Disabatino A, Benvenuti C, Italy
69 TSH levels in Polycystic Ovarian Syndrome according to body mass index de Paula Guedes Neto
E, Silva de Moraes G, do Amaral Cristovam R, von
Eye Corleta H, Francalacci Savaris R, Brazil
70 Comparisons of SF-12 and cervantes scales findings
as indicators of outcomes on quality of life derived
from a monitorized physical exercise programme in
menopause de Teresa C, Godoy-Izquierdo D, Andrés CP, Vélez M, Pérez-Fortis A, González I, Marín
L, Salamanca A, Mendoza N, Godoy JF, Spain
71 POF presenting as primary amenorrhoea Del Ghianda S, Rinaldi E, Benelli E, Giretti MS, Burelli A,
Cionini R, Vitti P, Pucci E, Italy
72 Giant prolactinomas in women Delgrange E, Gustin T, Raftopoulos C, Maiter D, Belgium
73 Insulin resistance in the polycystic ovary syndrome:
summary of current theories Delimpalta C, Zampetaki C, Greece
74 Myo-inositol administration in PCOS patients after IVF Di Berardino OM, Monteleone P, Valentino V, Ruggiero M, Papini F, Cela V, Artini PG,
Genazzani AR, Italy
75 Postmenopausal hyperandrogenism in a woman
with adrenal gland incidentaloma Di Sarra D,
Bonin C, Piazzola E, Tosi F, Moghetti P, Italy
76 Premenstrual Syndrome: therapeutic impact of
GnRH analogues and add-back therapy Dimitraki M, Koutlaki N, Zervoudis S, Psillaki A, Sofiadou V, Nikas I, Grapsas X, Galazios G, Liberis V,
Greece
77 Combination therapy with spironolactone and
metformin as compared to metformin alone in
PCOS patients D’Orrico B, Fava A, Fico F, Fruci
B, Mazza A, Belfiore A, Italy
78 Endometrial and Cervical Mucus Responses to a
Unique, Monophasic Combined Oral Contraceptive Containing Nomegestrol Acetate/17 Beta-Estradiol Duijkers IJM, Klipping C, Grob P, Korver
T, The Netherlands
79 Primary Amenorrhea and 46 XY Kariotype - 2
cases report Dumitrescu C, Chirita C, Carsote M,
Ene C, Dumitrascu A, Vasilescu F, Terzea D, Poiana C, Romania
80 Correlation between body weight (epididymal
fat) and permeaetion rate of serum leptin through
the blood-brain barrier (BBB) in male rats aged 8
months Ebrahimian F, Ebrahimian F, Sarkaki A,
Amozegari Z, Iran
81 Prevalence of polycystic ovary syndrome amongst
female first degree relatives: a common finding
Edelstein S, van der Spuy ZM, Republic of South
Africa
82 Etonogestrel implant in adolescents: bleeding
pattern, efficacy and discontinuation rate Falbo
Guazzelli CA, Teixeira de Queiroz F, Barbieri M,
Torloni MR, Gasparoto LM, de Araujo FF, Brazil
83 LNG-IUS, effective contraception with health
benefits Farris M, Bastianelli C, Italy
84 Intervertebral disc height in premenopausal women, treated and untreated postmenopausal women
and postmenopausal women with osteoporotic
vertebral fractures Felice N, Muscat Baron Y, Brincat M, Galea R, Calleja N, Malta
85 Metabolic syndrome factors in Caucasian Spanish
postmenopausal women with severe climacteric
symptoms Fernández-Alonso AM, Cuadros JL,
Ándres-Nuñez CP, Pérez-López FR, López-Baena MT, Cuadros AM, Sabatel RM, García-León
P, González-Carvajal FJ, Fernández Alonso IM,
Spain
86 Are vigorous walking and keep-fit activities sufficient to improve strength, balance and mobility
for middle-aged women? Fu S, Choy NL, Nitz J,
Australia
87 Hemodynamic evaluation of healthy young women
during use of an oral contraceptive containing 20
mcg of ethinyl estradiol plus 3mg of drospirenone
Galvão Giribela CR, de Melo NR, Nieselbaum
M, Guerra GM, Baracat EC, Marciano ConsolimColombo F, Brazil
88 Effects of a low dose combined oral contraceptive
containing drospirenone (in a 24/4 regimen) on
body mass index (BMI), insulin resistance (IR),
and lipid metabolism of healthy young women
Galvão Giribela CR, de Melo NR, Nisenbaum
MG, Galvão Giribela AH, Machado Barbosa Neto
C, Baracat EC, Marciano Consolim-Colombo F,
Brazil
89 Evaluation and role of serum anti-mullerian hormone in women with premature ovarian failure
Gambera A, Trussardi E, Fratus C, Bugari G, Iacobello C, Scagliola P, Pecorelli S, Sartori E, Italy
90 Subclinical hypothyroidism as ethiological factor
of female infertility: our experience Giampietro
A, Grande G, Milardi D, Astorri AL, Merola AM,
Pompa G, Pontecorvi A, Lanzone A, De Marinis
L, Marana R, Italy
91 Changes in central and peripheral content of
Brain-Derived Neurotrophic Factor (BDNF) in
female ovx rats treated with androgens Giannini
A, Cubeddu A, Bucci F, Russo M, Daino D, Russo
N, Merlini S, Pluchino N, Casarosa E, Luisi M,
Genazzani AR, Italy
92 Perceived health status in menopause: objective
health indicators and health-related behaviors as
contributors Godoy-Izquierdo D, Vélez M, Andrés
CP, Pérez-Fortis A, Mendoza N, Salamanca A, de
Teresa C, Godoy JF, Spain
93 Correlacion entre el volumen ovarico y el perfil
reproductivo de pacientes con SOP Gonzalez N,
Caceres M, Pizzi R, Centeno I, Venezuela
94 Side- view of users of emergency contraception in
a health community area in the south of Granada
(Spain) González Vanegas O, Andrés Nuñez P,
Romero Espinar Y, Torrado Bardasano E, Caliendo C, Spain
95 Efficasy of metformin in hyperinsulinemic PCOS
Greek adolescences Grammatikakis I, Trakakis E,
Salamalekis G, Chrelias C, Patsouras C, Kassanos
D, Greece
96 Effects of human chorionic gonadotropin administration on follicular growth and ovulation in OB/
OB and DB/DB mice Habay N, Alvarez Gonzalez
ML, Monget P, Foidart JM, Pintiaux A, Belgium
99
100
97 Cerebral ventriculomegaly and secondary amenorrhea: therapeutic approach Habay N, Legros JJ,
Schoenen J, Mouchamps M, Foidart JM, Pintiaux
A, Belgium
98 Lipid changes associated with hypogonadotropic
amenorrhea and effect of HRT Ilovayskaya IA,
Zektser VY, Ilyin AV, Donina EY, Goncharov NP,
Melnichenko GA, Dedov II, Russia
99 Effects of chlormadinone acetate (CMA)-containing oral contraceptive on premenstrual depressive
mood Iozza I, Andò A, Ciotta L, Giunta G, Iemmola A, Rubbino G, Palumbo M, Italy
100Helping in low-calory treatment of overweight
women with PCOS but without meaningful insulin-resistance Iozza I, Andò A, Ciotta L, Rubbino
G, Canicola MC, Palumbo M, Italy
101Premature ovarian failure and bone density
Ivanisevic M, Barac M, Sljivancanin D, Vujovic S,
Serbia and Montenegro
102In vivo study the effect of oxamate on spermatogenesis and LDH-C4 activity in mouse
Kadkhodaei Elyaderani M, Saki J, Saki G, Iran
103Overweight and oligomenorrhea in adolescence - a
preliminary study Kedikova S, Sirakov M, Pavlova
E, Boyadzhieva M, Bulgaria
104Parental administration of natural progesterone for
hormonal replacement therapy (HRT) Lambos G,
Dimitraki M, Koutlaki N, Zervoudis S, Nikas I,
Mandratzi J, Sofiadou V, Grapsas X, Galazios G,
Liberis V, Greece
105Serum Anti-Müllerian hormone and inhibins levels in women with secondary amenorrhea Lazzeri
L, Luisi S, Ciani V, Podfigurna-Stopa A, De Pascalis F, Bellucci F, Meczekalski B, Petraglia F, Italy
106Vitamin D serum levels and vitamin D receptor
gene polymorphisms in uruguayan people more
than 50 years old Lima S, Vaglio A, Chijani V,
Hernández J, Martino I, Calegari M, Suárez R,
Aleman A, Pagano S, Albanese M, Uruguay
107Chronic anemia and menstrual cycle abnormalities by nutritional behaviour disorders Londero
AP, Bertozzi S, Fruscalzo A, Driul L, Marchesoni
D, Italy
108Effects of melatonin on the ovarian gene expression of pinealectomized rats Maganhin CC, de
Jesus Simões M, Cavalcante Fonseca M, Rennó
Guimarães C, Mendes Akiau D, Gasparini Fernandes LH, da Silva Ferreira C, Santos Alves MM,
dos Santos Simões R, Castello Girão MJB, Haidar
MA, Baracat EC, Soares Jr JM, Brazil
109Melatonin decrease the proliferation of ovarian internal tecae cells of pinealectomized rats Maganhin
CC, Cavalcante Fonseca M, Rennó Guimarães C,
Mendes Akiau D, Gasparini Fernandes LH, dos
Santos Simões R, Haidar M, Baracat EC, Soares
JM Jr, Brazil
110Obesity related lipid profile and altered insulin
incretion in adolescent with PCOS Magnini R,
Fulghesu AM, Portoghese E, Angioni S, Minerba,
Melis GB, Italy
111Metformin may ameliorate the fast insulin of female rats with estrous permanent Mahamed RR,
de Jesus Simões M, dos Santos Simões R, Maganhin CC, Haidar MA, Leme Alves da Motta E, Cavalcante Fonseca M, Rennó Guimarães C, Mendes
Akiau D, da Silva Ferreira C, Baracat EC, Soares Jr
JM, Brazil
112Metformin may induce the emergence of luteal
body in andronized rats Mahamed RR, Maganhin
CC, Haidar MA, Gasparini Fernandes LH, Santos
Alves MM, Rodrigues Armijo P, da Silva Ferreira
C, dos Santos Simões R, Baracat EC, Soares JM
Júnior, Brazil
113Transferrin Receptor 1 protein expression and localization in human Intrauterine Growth Restriction placentas Mandò C, Tabano S, Colapietro P,
Marino A, Pileri P, Parisi F, Avagliano L, Bulfamante G, Miozzo M, Cetin I, Italy
114Effects of metformin on menstrual irregularity
and pregnancy rate in lean and obese women with
polycystic ovary syndrome Maragno L, Calienno
C, Trio C, Marra C, Ferrari L, Mignini Renzini M,
Milani R, Italy
115Sexual function and different types of sexual desire
in women with premature ovarian failure Martini
E, Terreno E, Pisani C, Albani F, Tonani S, Santamaria V, Polatti F, Nappi RE, Italy
116Effects of natural dietary antioxidants on insulin
secretion in obese female patients Martorana GE,
Di Donna V, Leone E, Magini M, Raimondo S,
Silvestrini A, Meucci E, Mele C, Pontecorvi A,
Mancini A, Italy
117Multilocus analysis of estrogen-related genes in
Spanish postmenopausal women suggests an interactive role of ESR2, NRIP1 and BMP15 genes in
the pathogenesis of the hip osteoporosis Mendoza
N, Presa J, Santalla A, Malde J, Ruiz J, Marín L,
Sánchez Borrego R, Vázquez F, Martinez-Astorquiza T, Spain
124What is Werner Syndrome? Nölting M, Blanco G,
Pérez Lana MB, Onetto C, Straminsky V, Galluzzo
L, Argentina
125Hypogonadotropic hypogonadism male infertility
- a local mini case-series Ong X, Hendricks MS,
Loh SF, Singapore
126Effect of standard therapeutic regimens on adipose
tissue hormones, clinical and metabolic characteristics in women with polycystic ovary syndrome
(PCOS) Orbetzova M, Mitkov M, Pehlivanov B,
Atanassova I, Bulgaria
127Genetic polymorphisms affect the lipidaimic profile of healthy postmenopausal women Papadimitriou D, Kaparos G, Rizos D, Armeni E, Christantoni E, Tsakonas E, Creatsa M, Alexandrou A,
Christodoulakos G, Lambrinoudaki I, Greece
128Physical exercise and psychological variables related to health in menopausal women Pérez-Fortis A,
Godoy-Izquierdo D, Vélez M, Mendoza N, Salamanca A, de Teresa C, Godoy JF, Spain
118Functional hypothalamic amenorrhoea in adolescents. Is too much stress to blame? Michala L,
Sotiropoulou M, Michopoulos I, Drakakis P, Antsaklis A, Greece
129Metabolic variables after ten years of hormonal
treatment in Spanish postmenopausal women
Pérez-López FR, Fernández-Alonso AM, Cuadros
JL,Cuadros AM, Sabatel RM, Chedraui P, Spain
119Ghrelin in insulin resistant women with pcos and
diabetes mellitus type 2 Mitkov M, Orbetzova M,
Nonchev B, Bulgaria
130Hyperandrogenism (HA) and metabolic syndrome
(MS) in male transsexuals (FMT) patients
Perez-Lopez GB, Becerra-Fernandez A, RodriguezMolina JM, Asenjo-Araque N, Lucio-Perez MJ, Spain
120High- Density Lipoprotein cholesterol (HDL) less
than 50 mg/dl as a significant component of metabolic syndrome in Polycystic Ovarian Syndrome
(PCOS) Moini A, Javanmard F, Eslami B, Iran
121Prevalence of gynaecological pathology among adolescents admitted at Guillermo Rawson General
Hospital, San Juan, Argentina Molina S, Mazzanti
Agustina Yanzón C, Argentina
122Classic Congenital Adrenal Hyperplasia: from birth
to adult life Myriokefalitaki E, Iavazzo C, Ntziora
F, Bozemberg T, Paschalinopoulos D, Greece
123Correlation between genotype and hormonal levels
in carriers and non carriers of 21-OH-deficiency
Napolitano E, Manieri C, Restivo F, Composto E,
Lanfranco F, Repici M, Pasini B, Einaudi S, Menegatti E, Italy
131Umbilical endometriosis with silent pelvic localizations in a young woman: surgical treatment and
laparoscopic assistance Peruzzi E, Mannini L, Bruscoli G, Dini M, Bruni V, Scarselli GF, Italy
132Polycystic ovary syndrome, adiposity and inflammation Pignatelli D, Beires J, Portugal
133Polycystic Ovarian Disease: A Threshold model for
the development and symptomatic progression
Pirkalani KK, Talaei Rad Z, Iran
101
102
134Evaluation of functional hyperprolactinemia after
Cabergoline in patients with breast disorders
Poalelungi C, Jercălău S, Dobrescu R, Caragheorgheopol A, Badiu C, Romania
135Management in a case of male pseudohermaphroditism Poiana C, Carsote M, Virtej I, Gruia A,
Grigoriu C, Chirita C, Terzea D, Banceanu G, Romania
136Effect of zolendronic acid in treatment of postmenopausal women with osteoporosis Povoroznyuk V, Grygorieva NV, Vaóda VM, Dzerovych NI,
Balatska NI, Ukraine
137Bone mineral density in postmenopausal women
with osteoporotic fractures Povoroznyuk V, Vayda
VM, Dzerovych NI, Ukraine
138Interrelation between bone mineral density and
lipid profile in postmenopausal women Povoroznyuk V, Nishkumay OI, Ukraine
139Structural-functional state of bone in older women
living in mountain region of Zakarpattya region
Povoroznyuk V, Vayda VM, Vayda VV, Povoroznyuk VV, Ukraine
140Sex hormone- binding globulin (SHBG) and indices of insulin resistance in women with polycystic
ovary syndrome Pradier SM, Leiderman S, Carbone S, Bonsergent S, Mongitore MR, Dicugno
M, Maya AG, Moguilevsky J, Argentina
141Metformin effects on obese anovulating mice:
genetic and protein evaluation Prado Correa LE,
Azevedo M, de Jesus Simões M, Dale Cotrim
Guerreiro da Silva I, Berguio Vidotti D, Haidar
MA, Brazil
142The assessment of tolerance and effectiveness in reducing menopausal symptoms hormonal treatment
containing 1 mg estradiol and 2 mg drospirenone
Radowicki S, Skórska J, Kunicki M, Poland
143Retinol-binding protein 4 levels in postmenopausal women relationship with glyco-insulinemic and
lipid metabolism Ricciardi L, Miceli F, De Cicco
S,Tagliaferri V, Di Florio C, Lanzone A, Villa P, Italy
144Metformin & insulin signalling in the human ovary
Rice S, Pellatt L, Bryan S, Whitehead SA, Mason
HD, UK
145Relationship between Lipid profile, insulin-resistance and BMI in PCOS patients Ros Cerro C,
Steinvarcel Valerga F, Castelo-Branco C, Spain
146Prevalence of high tsh levels and its association
with lipoprotein alterations in the menopausal
transition Rosales M, Siseles N, Berg G, Mesch V,
Argentina
147Analysis of candidate genes for primary ovarian
insufficiency in a large cohort of women with primary or secondary amenorrhea Rossetti R, Cacciatore C, Marozzi A, Persani L, NIDO (Network
Italiano per lo studio dei Difetti Ovarici), Italy
148Juvenile gigantomastia associated to pseudoangiomatous stromal hyperplasia of the breast:
Tamoxifen Rossini G, Amato A, Bobbio L, Maciel
A, Cabaleiro C, Argentina
149Hypogonadotropic hypogonadism and ovulation
induction: Case Report Rubbino G, Iemmola A,
Giuffrida L, Iozza I, Ciotta L, Palumbo MA, Italy
150PCOS and PCOM: differences in human plasma
Brain-Derived Neurotrophic Factor Russo M, Giannini A, Cubeddu A, Daino D, Russo N, Casarosa E, Merlini S, Luisi M, Genazzani AR, Italy
151Brain-derived neurotrophic factor (BDNF) in
amenorrhoeic women Russo N, Giannini A, Bucci F, Russo M, Daino D, Cubeddu A, Merlini S,
Casarosa E, Luisi M, Genazzani AR, Italy
152Treatment of labial adhesion in prepubertal girls with
topical estrogen therapy Rusu L, Republic of Moldova
153Association of gestational diabetes and macrosomia
in women who refer to mother and child clinics of
Ahvaz Sadeghi S, Afshari P, Hekmat K, Iran
154Transdermal Hormone Replacement Therapy: the
cardiovascular and breast cancer risk Salvagno F,
Pertusio A, Gallo M, Massobrio M, Italy
155The effect of soy isoflavones over mood and menopausal symptoms in mid-aged women with increased body mass index San Miguel G, Schwager
G, Chedraui P, Ecuador
156The Management of Patients with Premature Ovarian Failure (POF) Sarbu Z, Republic of Moldova
157Ovulation and loss of bone density during the
perimenopausal transition: the PEKNO study
Seifert-Klauss V, Wimmer T, Müller D, Schuster
T, Goppel K, Germany
158Melatonin effects on the VEGF on the ovaries of
the pinealectomized rats Soares JM Júnior, Maganhin CC, dos Santos Simões R, Haidar MA, Baracat EC, Fonseca MC, de Jesus Simões M, Brazil
159Decrease of ovarian function in infertile clinic patients Sobek jr A, Tkadlec E, Hladikova B, Sobek
A, Czech Republic
160In vitro assays for assessing anti-inflammatory effects of chlormadinone acetate in dysmenorrhoea
Stuckenschneider J, Fischer L, Schaefer WR, Deppert WR, Seebacher L, Hanjalic-Beck A, Zahradnik HP, Germany
164The effects of hyperprolactinemia on the glycosaminoglycan content in the uterus of the female
mouse along the different phases of the estrous cycle
Teixeira Gomes RC, Verna C, dos Santos Simões
R, de Jesus Simões M, Bonciani Nader H, Baracat
EC, Soares Júnior JM, Brazil
165Amenorrhea in schizophrenic women - Correlation with the pharmacodynamic particularities of
both “typical” and “atypical” antipsychotics
Tica OS, Chirita A, Tica A, Barbu M, Berceanu C,
Romania
166Correlation between Genotype and Phenotype /
Hormonal Levels in Nonclassical Adrenal Hyperplasia Tuli G, Napolitano E, Menegatti E, Restivo
F, Baldi M, Einaudi S, Grosso E, Migone N, Motta
G, Manieri C, Italy
167Endocrinlogical, metabolic and clinic features of a
six-cycle treatment with estroprogestin oral contraceptive monophasic formulation (OC) containing
30 mcg of ethinylestradiol (EE) plus2 mg of chlormadinone acetate (CMA) in non obese women
with polycystic ovay syndrome Uras R, Orrù M,
Molin Pradel NA, Marotto MF, Pilloni M, Guerriero S, Etzi R, Zedda P, Sorge R, Lello S, Melis
GB, Paoletti AM, Italy
168Experience with LNG IUS Mirena in routine clinical practice Vasaraudze I, Rezeberga D, Latvia
161Iranian Midwives’ Role in Menopause Consultation
Taavoni S, Iran
169The effect of foot-reflexology on hot flash in menopausal women Vasegh Rahim-Parvar FS, Shafee A, Iran
162Twenty four hours urinary Prolactin is the best
marker for Prolactinoma with differentiating
microadenoma from macroadenoma in terms of
total Prolactin output
Talaei RZ, Pirkalani K, Iran
170Levonorgestrel only emergency contraceptive pill.
Evolution of use between 2001- 2009 period in
the south of Granada health community area
Vega Cañadas J, Andres Nunez PC, Teva García
MJ, Cruz Martínez M, Rodriguez I, Spain
163Effects of metoclopramide-induced hyperprolactinemia on the hyaluronanic in mouse uterine
along the different phases of the estrous cycle
Teixeira Gomes RC, Verna C, dos Santos Simões
R, Bonciani Nader H, de Jesus Simões M, Baracat
EC, Soares Júnior JM, Brazil
171Establishment of an electronic registered system for
users of emergency contraception Vega Cañadas J,
Andrés Nuñez P, García León P, Teva García MJ,
Cruz Martínez M, González Vanegas O, Spain
172Exercise and quality of life in menopause: comparisons between long-term active, initiaters, nonadhering and sedentary women Vélez M, GodoyIzquierdo D, Andrés CP, Pérez-Fortis A, Mendoza
N, Salamanca A, de Teresa C, Godoy JF, Spain
103
104
173Immunohistochemical study of prolactin in lacrimal gland of female mice with hyperprolactinemia induced by metoclopramide during proestous
Verna C, Teixeira Gomes RC, Bastos Wolff R,
Soares Júnior JM, de Jesus Simões M, dos Santos
Simões R, Baracat EC, Brazil
174The impact of an oral contraceptive containing
35mg ethinyl estradiol+2mg cyproterone acetate
on plasma viscosity levels, insulin resistance and
lipid profile in young women with polycystic ovary syndrome (PCOS) Vervita V, Saltamavros AD,
Karela A, Markantes G, Armeni A, Adonakis G,
Decavalas G, Georgopoulos NA, Greece
175Relationship between TSH (thyroid stimulating
hormone) and postmenopausal osteopenic or osteoporotic patients Vilariño ASI, Lioy G, Vilariño
C,Urthiaghe M-E, Dotto J, Contreras Ortiz O,
Argentina
176Human sperm morphometry after swim-up processing: a pilot study Vladić T, Kvist U, Sweden
177Treatment of menopausal disorders Voichenko N,
Kuznetsova I, Mychka V, Kirillova M, Russia
178Clinical predictors of the development of postmenopausal osteoporosis Yermolenko T, Ignatyev
O, Batsulya L, Ukraine
179Safety and Efficacy of Femarelle (DT56a) for the
Management of Menopause Yoles I, Israel
180Comparison of oral Metranidazole and methanol
extracts of Myrtus Communis Yousefinezhad F,
Afshari P, Dabagh M, Iran
181Zoledronic acid in the treatment of postmenopausal osteoporosis in Russia Yureneva SV, Yakushevskaya OV, Gavisova AA, Smetnik VP, Sukchich
GT, Russia
182Pilot study of using quinagolide in normoprolactinemiant patients with galactorrhea Zervoudis
S, Iatrakis G, Galazios G, Liberis V, Tsikouras P,
Koutlaki N, Navrozoglou I, Mastorakos G, Badiu
C, Greece
183Plasma homocysteine levels in woman with polycystic ovary syndrome Atanasova E, Atanasova A,
Dimitrov GI, Republic of Macedonia
183bis Efficacy, tolerability and anti-androgenic effects
of an oral contraceptive containing Ethinylestradiol 0.03 mg and Chlormadinone acetate 2 mg
(Belara®) Giuffrida L, Tomaselli I, Placenti NC,
Valenti O, Garofalo G, Napoli C, Italy
184 Lipid and lipoprotein profile and insulin-resistence
in polycystic ovary syndrome (PCOS) Cortelezzi
M, Fenili C, Kozak A, Boero L, Schreier L, Berg
G, Argentina
GYNECOLOGY
184bis Vaginal lactic acid bacteria in B.V treated with
oral and vaginal metronidazole and clindamaycin
vaginal cream Afshari P, Nadaran Tahan M, Iran
185The analysis of clinical and angiogenic characteristics of patients with external genital endometriosis and infertility: restoration of fertility after the
combined treatment Burlev VA, Shorohova MA, Ilyasova NA, Kulakova EV, Onishchenko AS, Russia
186Management of intermenstrual bleeding in women
with the levonorgestrel intrauterine system Craus
J, Agius R, Muscat Baron Y, Malta
187Amibimiasis extragenital Escobar M, Pérez MM,
Mendoza D, Plata J, Venezuela
188Urogenital symptoms and risk factor among of postmenopausal women in sabzevar Iran Fazel N, Iran
189Isolated prepubertal ovarian cysts: an atypical form
of McCune-Albright syndrome? Gaspari L, Paris F,
Sultan C, France
190Peripheral precocious puberty in a newborn girl:
a consequence of pesticide exposure? Gaspari L,
Paris F, Sultan C, France
191Effects of VA111913, an orally available vasopressin V1a receptor antagonist in clinical development for the treatment of dysmenorrhoea, on
vasopressin-induced human uterine artery contractions Igidbashian S, Hampton S, Handy R,
Akerlund M, Sweden
192The effects of electromagnetic field (EMF) on
ovary in rat(A light microscopic study) Khaki AA,
Khaki A, Ozsezer Y, Iran
193Newear approaches for the treatment of uterine
myomas Lapotka M, Belarus
194Complex without atypia endometrial hyperplasia in a
13-years-old woman Maglione A, Petruzzelli F, Italy
195Pyomyoma after spontaneous labor with purulent pelviperitonitis with E. Coli, without bacteremia, from the same bacterial agents Maglione A,
Petruzzelli F, Italy
196Role of Cytokines and Oxyproline in the Progressing
of Endometriotic Disease Makhmudova G, Russia
197Clinical outcome of transobturator tape procedure,
one single centre experience Mihai D, Dumitrascu MC, Badea G, Albu R, Nichitelea R, Albu S,
Mardare C, Horhoianu VV, Vartej P, Romania
198Vascular Endothelial Growth Factor and Ultrasonography Doppler Index in Ovarian Tumors
Malignancy Prediction Moszynski R, Szpurek D,
Michalak S, Krygowska J, Szubert S, Sajdak S, Poland
204Biologic Interpretation of Da Vinci’s Love Child
Turp AB, Turkey
205Is history of previous Multiload 375 IUD expulsion a risk factor for levonorgestrel-releasing intrauterine device users?
Ayrim AA, Öztürk Turhan N, Turkey
205bis Out Break treatment of H1N1 Influenza virus by
propolis in women Ali Farid Mohamed Ali, Egypt
REPRODUCTION
206hCG: a pregnancy-related hormone stimulating
angiogenesis and pericyte recruitment Berndt S,
Blacher S, Perrier d’Hauterive S, Thiry M, Tsampalas M, Cruz A, Péqueux C, Lorquet S, Munaut
C, Noël A, Foidart JM, Belgium
207Adiponectin isoform distribution in serum and in
follicular fluid of women undergoing IVF/ICSI treatment Bersinger NA, Wunder DM, Switzerland
208Human oocyte vitrification: our experience
Carletti E, Casarosa E, Valentino V, Ruggiero M,
Monteleone P, Cela V, Genazzani AR, Artini PG,
Italy
199The first mPCR for detection of U. urealyticum,
M. hominis and M. genitalium in sexually active
women in Sofia, Bulgaria Ouzounova V, Ouzounova I, Mitov I, Bulgaria
209A pilot study of premature ovarian failure patients
with infertility: intracytoplasmic sperm injection
with their own oocyte Chen S, Chen X, Luo C,
China
200Hysteroscopic diagnosis in abnormal uterine
bleeding Papadia LS, Fiorentino N, Italy
210The role of androgen supplementation in ovulation
induction in older women Claessens AE, Blanco
Mejia S, Maroleanu M, Ryan EAJ, Canada
201Hysteroscopic treatment of ectopic pregnancyin
the cesarean section scar Rubattu A, Rosas N, Cossu G, Nocco C, Italy
202Estimation of serum endoglin concentration in
women with ovarian tumors Szpurek D, Moszyński
R, Szubert S, Krygowska J, Michalak S, Sajdak S,
Poland
203Pelvic Pain and Endometriosis Taavoni S, Iran
205 bis Sex chromosomal mosaicism in ovarian tissue
in women with premature ovarian insufficiency
and polycystic ovary syndrome Chernukha GE,
Marchenko LA, Jahour NA, Butareva LB, Karseladze AI, Russia
211Role of hyperprolactinemia in fertility Demaliaj E,
Cerekja A, Albania
212Ovary hyperstimulation syndrome in women
undergoing IVF and ET procedures Dervishi Z,
Krasniqi M, Shala S, Pllana T, Republic of Kosova
213Ovary hyperstimulation syndrome in women
undergoing IVF and ET procedures- case report
Dervishi Z, Krasniqi M, Pllana T, Shala S, Republic of Kosova
214FSHR: polymorphism in 307 and outcome in IVF
Dolfin E, Guani B, Lussiana C, Restagno G, Mari
C, Revelli A, Massobrio M, Italy
105
106
215The probiotic Lactobacillus rhamnosus, in the
diet, increase fecundity in Danio rerio Gioacchini
G, Maradonna F, Bizzaro D, Carnevali O, Italy
225Combined approach to fertility preservation in
cancer patients Oriol B, Goppel K, Seifert-Klauss
V, Kiechle M, Popovici RM, Germany
216The effect of GnRH antagonist usage in addition to
gonadotropins on clinical pregnancy rates in ovulation
induction protocols with IUI therapy Gonenc AI,
Dansuk R, Kayaalti ES, Yucel O, Turkey
226Fertility preservation in patients with cancer Ortiz
Murillo E, Cañete P, Crespo J, Cano A, Pellicer A,
Sanchez M, Spain
217Expansion of trophoblastic spheroids is promoted
by coculture with decidualized endometrial stromal cells and enhanced by HB-EGF and IL-1ß
González M, Reimann K, Bamberger AM, Gellersen B, Germany
218Pregnancy-rate of frozen-thawed embryo transfer artificial versus spontaneous cycle
Hancke K, Isachenko I, Kreienberg R, Weiss JM,
Germany
219Knowledge, Attitude and Performance of couples
Referred to an Infertility Treatment Centers of Tehran toward use of Herbal Medicine Heidari M,
Maleki H, Tayebi M, Akhondi MM, Sadeghi MR,
Akhondzadeh S, Ramezanzadeh F, Iran
220Tecnique of embryo transfer using a syringeless
catheter: optimal US visibility and easy-to-use
Inaudi P, Petrilli S, Italy
221Review of Consecutive 1046 IUI Cases at Lahore
Institute of Fertility and Endocrinology (LIFE),
PAKISTANIrfan S, Khan YL, Pakistan
222 Recurrent Spontaneous Ovarian Hyperstimulation
Syndrome (OHSS) in a single patient: case report
Korneeva IE, Kholnov AI, Ivanets TYu, Barkalina
NV, Nazarenko TA, Russia
223Does the prevention of corpus luteum rescue
caused by administration of hcg at early follicular
phase improve IVF outcome? Messias Gomes C,
Serafini P, Monteiro Rocha A, Leme Alves da Motta
E, Yadid I, Coslovsky M, Fettback P, Domingues T,
Homem de Mello Bianchi P, Carrilho E, Baracat
EC, Brazil
224Cytogenetics of couples with recurrent ART failure
and spontaneous abortions Mozdarani S, Mohseni
Meybodi A, Mozdarani H, Iran
227Effectiveness of highly purified hMG versus recombinant FSH in patients with moderate male
factor infertility undergoing in vitro fertilization/
intracytoplasmic sperm injection Öztürk TN,
Pekel A, Ayrim AA, Bayrak O, Turkey
228ICSI outcome in severe oligoasthenozoospermic
patients and its relationship to prewash progressive
sperm motility Öztürk TN, Pekel A, Ayrim AA,
Bayrak O, Turkey
229Sub-endometrial wave-like activity in infertile patients
Parisen Toldin MR, Ruggiero M, Viana G, Di Berardino OM, Valentino V, Genazzani AR, Cela V,
Artini PG, Italy
230Use of LH supplementation in IVF cycle Rubbino
G, Iemmola A, Gulino FA, Giuffrida E, Leonardi E,
Lenzi L, Iozza I, Ciotta L, Palumbo MA, Italy
231IVF pregnancy complications after severe ovarian hyperstimulation syndrome (OHSS) Saroyan
TT, Krechetova LV, Ziganshina MM, Korneeva IE,
Nazarenko TA, Sukhikh GT, Russia
232Effect of body mass index on in vitro fertilization
outcomes in women Sathya A, Sathya B, Varma
TR, India
233Is FSH day 3 a reliable marker of ovarian response?
Spadoni V, Sagnella F, Martinez D, Moro F, Morciano A, Paolelli S, Gangale MF, Tropea A, Lanzone
A, Apa R, Italy
234Long GnRH agonist vs. GnRH antagonist protocol in randomized controlled trial in unselected
patients -hormonal and cycle characteristics- pilot
study Streda R, Mardesic T, Sobotka V, Tosner J,
Czech Republic
235The outcomes of pregnancy in different ways of
conception in the infertility women Vishnevskaya
M, Vasileva L, Belarus
OBSTETRICS
236Diabetes insipidus and two consecutive pregnancies Adonakis GL, Kyriazopoulou V, Androutsopoulos G, Papadopoulos V, Decavalas G, Kourounis
G, Georgopoulos NA, Greece
237 Is Ultrasound a sensitive tool in diagnosing ectopic
pregnancy? Ajaya Maharajan P, Beaumont M, Nicholls, UK
238Management of Reccurent Pregnancy Loss
Albu AR, Dumitrascu M, Mihai D, Mardare C,
Horhoianu I, Albu S, Horhoianu V, Vartej P, Romania
239Glycoprotein IIIa polymorphism and spontaneous
abortion Armeni E, Kaparos GJ, Sergentanis TN,
Alexandrou A, Damaskos C, Christodoulakos GE,
Dendrinos S, Lambrinoudaki I, Greece
240Serum interleukin-10 in patients with threatened
preterm labour Asnawi AA, Variantono AA, Ansyori MH, Effendi KYT, Indonesia
241Human chorionic gonadotropin AUC as a new parameter to predict the success of single-dose methotrexate in the treatment of ectopic pregnancy Aybatli A, Balkanli Kaplan P, Sut N, Yuce MA, Cenk
Sayin N, Varol FG, Turkey
242Optimization of diagnostics of varicose expansion
of veins of the small basin at pregnant women and
methods of its treatment Babadjanova GS, Habibullaeva MF, Eshonkhodjaeva ND, Republic of
Uzbekistan
243The relation between labor pain and religious beliefs Bakhtyar M, Afshari P, Sadeghi S, Iran
244Heat-Killed Lactobacillus Rhamnosus GG Increases IL-4 and IL-10 and Reverses LPS-Induced
TNF-α Release in Term Primary Trophoblast Cells
Bloise E, Torricelli M, Novembri R, Borges LE, Imperatore A, Reis FM, Petraglia F, Italy
245Comparison of two diagnostic models for assessment of gestational diabetes mellitus Boyadzhieva
M, Atanasova I, Tankova Tz, Bulgaria
246Screening for gestational diabetes mellitus in Bulgaria - preliminary results Boyadzhieva M, Atanasova I, Tankova Tz, Dimitrova V, Markov D, Stoykova
V, Todorova K, Kedikova S, Bulgaria
247Thymol affects mature Gardnerella vaginalis biofilm Braga PC, Dal Sasso M, Culici M, Spallino A,
Italy
248Activity of thymol on the genesis of Gardnerella
vaginalis biofilm Braga PC, Dal Sasso M, Culici M,
Spallino A, Italy
249Risk of gestational diabetes in pregnant women
with thyroid dysfunction Brufman AS, Umansky
Z, Mirian R, Argentina
250Is pre-eclampsia the end-stage of a systemic inflammatory response to various inflammatory triggers in the
presence of a placental circulation? A new hypothesis
on pre-eclampsia - the disease of theories Camilleri
Agius R, Muscat Baron Y, Brincat M, Malta
251Clinical efficacy of a vaginal gel formulation based
on thymol and eugenol in bacterial vaginosis Cianci A, De Leo V, Italy
252Recurrent Pregnancy Loss: a precocious defeat
Coccia ME, Spitaleri M, Riviello C, Rizzello F, Castellacci E, Caponi D, Mariani G, Italy
253The knowledge and opinion of the women about
legal abortion in Iran Daemi F, Daemi N, Vasegh
Rahim-Parvar SF, Iran
254 The service providers’ opinion about the legal abortion in Iran Daemi N, Daemi F, Vasegh Rahim-Parvar SF, Iran
255Adiponectin and gestational diabetes Daher S,
Gueuvoghlanian-Silva BY, Oliveira LS, Scomparini
FB, Torloni MR, Mattar R, Guazzelli CAF, Brazil
256Pregnancy and Epilepsy Diaz L, Zambrano B,
Chacon G, Venezuela
107
108
257Thyroid disorders and pregnancy Djurica S,
Vuksanović M, Zerajić B, Pečinović N, Serbia and
Montenegro
258Screening,prevention and treatment of hypothyroidism in pregnancy Dorogoi V, Republic of
Moldova
259Evaluation of maternal and neonatal complication
in diabetic pregnant at the Imam Hospital during
5 year Ebrahimian F, Zargar M, Afshari P, Iran
260Efficacy of Progestogens Supplementation in First
Trimester Threatened Miscarriages Essadi FM,
Elmehashi MO, Libya
261Utility of Universal Screening of Thyroid Dysfunction in Early Pregnancy Faraj G, Saban M, Quevedo V, Martinez C, Nuñez M, Calé J, Argentina
262Effect of glucocorticoid treatment for foetal lung
maturation on maternal capillary glycemia and
ketonemia Firquet A, Degée S, Pintiaux A, Foidart
JM, Belgium
263Changes of level of some sexual steroid hormones
after the antibacterial therapy in preconceptional
period among the patients with pregnancy loss Fofanova Iyu, Russia
269Role of endothelial dysfunction in development of
premature birth and antenatal pour out of natal
waters Khodjaeva HZ, Babadjanova GS, Komarin
AS, Eshonkhodjaeva ND, Mavlonov OV, Republic
of Uzbekistan
270Circulating levels of adiponectin in preeclamptic
patients Khosrowbeygi A, Lorzadeh N, Ahmadvand H, Birjandi M, Iran
271Obstetric complications cluster in women with
endometriosis among IVF pregnancies KuivasaariPirinen P, Hippeläinen M, Heinonen S, Finland
272Pathogenethic antithrombotic and haemostatic therapy in women with chorion abruption
Kuneshko NF, Makatsariya AD, Bitsadze VO,
Baimuradova SV, Akinshina SV, Russia
273Current trends of the medical management and
prevention of genital infections Kuzmin V, Russia
274Recurrent early preeclampsia. Diet, as only therapy,
could change outcome Lauro V, Pisani C, Mora G,
Italy
275Is there a good time for Nuchal Translucency measurement? Luchi C, Schifano M, Nanini C, Sceusa
F, Capriello P, Genazzani AR, Italy
264Differential expression of mammalian target of rapamycin (mTOR) in human myometrium Foster
H, Goumenou A, Karteris E, UK
276The assessment of fetal heart failure with respect to
the severity of fetal anaemia Luterek K, Wielgos M,
Szymusik I, Bartkowiak R, Filipiak KJ, Poland
265Pro-inflammatory cytokine gene polymorphisms
and genetic thrombophilia in pregnant women
with metabolic syndrome Gadaeva Z, Bitsadze V,
Russia
277Thrombophilia and preeclampsia Makatsariya AD,
Bitsadze VO, Baimuradova SV, Akinshina SV, Russia
266Hippocratic “Aphorisms” describing pregnancy
endocrine disorders Grammatikakis I, Trakakis E,
Salamalekis G, Hintipas E, Kassanos D, Greece
278Pathogenetic prophylaxis of obstetrics complications and reccurent thrombosis in women with
history of stroke or venous thromboembolic complications Makatsariya AD, Akinshina SV, Bitsadze
VO, Baimuradova SM, Russia
267Foetuses of the hypothyroid mothers Gudovic A,
Spremovic-Radjenovic S, Lazovic G, Milicevic S,
Sparic R, Serbia and Montenegro
279Recurrent abortion with subclinical autoimmune
thyroiditis (Hashimoto’s disease) Mashadiyeva S,
Azerbaijan
268 The frequency of resorted to abortion in women
who refer to private clinics of Ahwaz Karimi L, Afshari P, Iran
280Bacteriological findings in pregnant women with
Gram stain smear and culture from vaginal discharge Mehdinejad M, Yazdizadeh H, Iran
281To determine the risk of prematurity in subject
with diabetes throughout pregnancy Mersini B,
Petrela E, Bimbashi A, Gega M, Albania
282Cervical pregnancy, a rare but dramatic case Mocuta D, Pop T, Craiut D, Herczegh R, Szasz F, Veres
M, Romania
283Arterial hypertension can force a too early delivery
Mocuta D, Pop T, Herczegh R, Lacziko S, Noja C,
Bodog A, Romania
284The effect of male involvement in prenatal care on
pregnancy outcome Mortazavi F, Bodaghabadi M,
Akaberi A, Iran
285Clinical activity and safety of a hydrating intimate
hygiene cleanser Mucci M, Mancini R, Italy
286The importance in hydrating intimate hygiene in
vulvar dermatoses Murina F, Benvenuti C, Italy
287In prenatal diagnosis how much is important informed choise? Nanini C, Luchi C, Schifano M,
Sceusa F, Capriello P, Genazzani AR, Italy
288Successful medical management of an intramural
ectopic pregnancy Ong Aihui C, Lin SL, Chia D,
Choolani M, Biswas A, Singapore
294Control of gestational diabetes with the newly
described instillation of insulin into the auditory
channel via a piezoelectric pump: A comprehensive approach and a novel option Pirkalani KK,
Talaei Rad Z, Iran
295Role of the nitric oxide system related to fetal
growth, mechanism of delivery, and peri-natal adaptation Pisaneschi S, Sanchez MA, Begliuomini
S, Strigini FAL, Ghirri P, Boldrini A, Genazzani
AR, Coceani F, Simoncini T, Italy
296The survey of maternal health`s problems and their
help behavioral after delivery in women reffering
to health centers Radmehr M, Gachpaz A, Mahdi
SB, Iran
297Metabolic syndrome and vascular risk Radulovich
T, Perederyaeva E, Makatsaria A, Russia
298Celiac disease and Recurrent Pregnancy Loss
Riviello C, Spitaleri M, Rizzello F, Castellacci E,
Caponi D, Mariani G, Coccia ME, Italy
299Differences between primigravidae and multigravidae mothers in postpartum depression and fatigue
Rouhi M, Usefi H, Iran
289Hysteroscopy in diagnosis and treatment in recurrent abortion Papadia LS, Fiorentino N, Italy
300Recurrent pregnancy loss (RPL) in women with
nonautoimmune (NATD) and autoimmune thyroid diseases (ATD) Santaguida MG, Del Duca S,
Virili C, Gargano L, Centanni M, Italy
290Cesarean scar pregnancy successfully treated with
systemic methotrexate administration and sac aspiration Patsouras K, Sioulas V, Salamalekis G,
Chrelias C, Grapsas S, Kassanos D, Greece
301Role of genetic factors and oxidative stress in recurrent pregnancy loss Shamsi MB, Venkatesh S,
Kumar K, Talwar P, Kumar R, Mittal S, Dada R,
India
291Exposure of rat pups to medical intensity ultrasound
waves Pečlin P, Rozman J, Republic of Slovenia
302Placental and maternal serum inhibin A in patients
of pre-eclampsia and intrauterine fetal growth restriction Shen Z, Cai LY, Suprapto I-S, Shenoy P,
Zhou X, China
292Antibiotic therapy and gluten free diet may prevent preeclampsia Pelotti D, Italy
293Childbearing women affected by psychopathology: results from a selected-high risk sample Petrilli
G, Rizzi G, Anniverno R, Mencacci C, Blom JMC,
Italy
303Polymerization of Insulin-like Growth Factor
Binding Protein-1 (IGFBP-1) Potentiates IGF-I
Actions in Placenta Shibuya H, Keiji S, Mitsutoshi
I, Japan
304Prenatal care of twin related Terasaka O, Meleti D,
Andrade CMA, Nowak P, Guazzelli C, Moron AF,
Brazil
109
110
305The effect of epidural analgesia on caesarean section using Robson’s classification Triunfo S, Ferrazzani S, Draisci G, Scambia G, Italy
316Polycystic ovary syndrome and pregnancy complications in patients from Macedonia Dzikova E,
Dimitrov G, Andonova I, Republic of Macedonia
306Effect of partogram use on caesarean section using Robson’s classification Triunfo S, Ferrazzani S,
Scambia G, Italy
316 bis Laparoscopic bipolar coagulation of hypogastric artery in post-partum haemorrhage: a case report Volpi E, Panuccio E, Ferrero A, Sismondi P,
Italy
307Aesthetic Transvaginal Folliculometry According
to Da Vinci’s Vitruvian Man: A Different Perspective to IVF Failure Due to Oocyte Aging Turp AB,
Turkey
308Evaluation of maternal obesity during pregnancy
Valenti O, Barbagallo V, Giuffrida L, Rugolo S,
Roccasalva LS, Italy
309 Pregnancy outcome in treated recurrent miscarriers
affected with subclinical hypothyroidism Vaquero
E, Lazzarin N, Di Giovanni A, Romeo V, Moretti
C, Italy
310Reproductive history in postmenopausal women
with type II diabetes mellitus Virtej I, Vartej P,
Zervoudis S, Navrozoglou I, Poiana C, Greece
311Combined conservative approach in early diagnosed tubar pregnancy Virtej P, Grigoriu C, Grigoras M, Cezar C, Horhoianu I, Horhoianu VV,
Romania
312Level of proteinases in cervical mucus in women
with risk of miscarriage Zabolotnov V, Rybalka A,
Kuznetsova T, Palamarchuk M, Ukraine
316tris Treatment of repeated implantation failure by
Autologus eye tears Ali Farid Mohamed Ali Egypt
316quater Inherited Thrombophilia in mother and fetus Federica Bellussi
ONCOLOGY
317Research of balance of the cores cytocines in blood
of patients with good-quality tumours of ovary
Abdullaeva LM, Ashurova UA, Republic of Uzbekistan
318Effectiveness of treatment for cervical intraepithelial neoplasia with leep and predicting factors Ahmeti F, Hoxha S, Republic of Kosovo
319The estrogen metabolism disorders in premenopausal
women with endometrial hyperplasia Artymuk N,
Kcharenkova E, Gulyaeva L, Russia
320Mammographically confirmed microcalcifications and their association with P53, C-erbB2 and
hormone receptors in breast cancer Augoulea A,
Mourouti G, Chondrodimou Z, Maipa S, Karameris A, Boutzouvis S, Greece
313Cell growth is differentially modulated by IL-1beta
and progesterone in human choriocarcinoma cells
Zachariades E, Foster H, Mparmpakas D, RandWeaver M, Goumenou A, Karteris E, UK
321Regulation of cyclin G2 degradation in ovarian cancer cells Bernaudo S, Rosman D, Peng C, Canada
314Serum interleukin-10 and progesterone level in
patients with threatened abortions and normal
pregnancy Zulkarnain O, Abadi A, Zulqarnain I,
Novaliani A, Budi Azhar M, Indonesia
322Cervix carcinosarcoma in an 80-year- old woman
Blàzquez Ventura A, Gonzalez Bosquet E,Valladares
Pérez E, Rovira Zurriaga C, Lailla Vicens JM,
Spain
315PCOS and Spontaneous Pregnancy Loss: Etiology, Diagnosis and Therapy Albu AR, Dumitrascu
M, Mardare C, Mihai D, Horhoianu I, Albu S,
Horhoianu VV, Vartej P, Romania
323How healthy food helped me with my breast cancer - a female gynecologist testimony Bocchi de
Souza LM, Brazil
324WWP1, TGFβ and KLF gene expression levels as
prognostic factors in cervical oncogenesis Botezatu
A, Socolov D, Goia CD, Iancu IV, Huica I, Plesa
A, Anton G, Romania
325Interaction between effects of estrogen receptor
(RE) (ER) and human epidermal growth factor receptor 2 (HER-2) on hormone treatment of breast
cancer (BC) Buda F, Italy
336Rapid Signals from Estrogens and SERMs involved
in endometrial cell migration and invasion Flamini
MI, Sanchez AM, Genazzani AR, Simoncini T,
Italy
326Female sexual function after loop electrosurgical
excisional procedure for cervical intraepithelial lesions Cattoni E, Serati M, Salvatore S, Zanirato
M, Mauri S, Bolis P, Italy
337Estrogen receptor enhances endometrial cell motility and invasion via extra-nuclear activation of
focal adhesion kinase Flamini MI, Sanchez AM,
Genazzani AR, Simoncini T, Italy
327Prevention of vulvo-vaginal signs and symptoms
induced by pelvic radiotherapy with a topical Calendula preparation Corallo A, Cartia G, D’Emilio
V, Pedalino A, Rabito A, Barone V, Italy
338Effectiveness of raloxifene (SERMs) in reduction
of uterine leiomyomas growth in premenopausal
women: our experience Giuffrida L, Rubbino G,
Garofalo G, Tomaselli I, Placenti NC, Napoli C,
Italy
328Risk factors in relation to endometrial adenocarcinoma diagnosis features Daneva-Markova A, Antovska V, Stefanija A, Dimitrov G, Kiprovska G,
Republic of Macedonia
329Characterisation of Mutations and Sequence
Variants in Breast Cancer Susceptibility Gene 2
(BRCA2) in a Group of Breast Cancer Patients in
Sri Lanka De Silva S, Tennekoon KH, Karunanayake EH, De Silva JWN, Amarasinghe I, Angunawala P, Sri Lanka
330How to give lifestyle advices after gynecologic cancer treatment Del Pup L, Italy
331Clinical, laboratory and pathological anatomy
characterization of ovarian cancer Diaz L, Zambrano B, Santos M, Omaña D, Venezuela
332Labor stress and lactation Dimitraki M, Koutlaki
N, Zervoudis S, Gourovanidis V, Mandratzi J,
Konstandou E, Grapsas X, Galazios G, Liberis V,
Greece
333Gastro-intestinal symptoms in women diagnosed
with pelvic endometriosis Dingli M, Muscat Baron Y, Agius R, Brincat M, Malta
334Does endometrium in women with breast cancer
has malignant potential? Drljevic K, Mehmedbasic
S, Drljevic I, Bosnia and Herzegovina
335Gene expression in endometriosis is similar to the
peritoneum rather than to the human endometrium Fettback P, Mendes Alves Pereira R, Monteiro
da Rocha A, Serafini P, Leme Alves da Motta E,
Zanatta A, Bianchi P, Assad Hassun P, Baracat EC,
Smith G, Brazil
339George Papanicolaou: exfoliative cytology and
pre tumoral lesions Grammatikakis I, Trakakis E,
Salamalekis G, Spanou F, Kassanos D, Greece
340Adipocyte fatty acid-binding protein as a novel
prognostic factor in obese breast cancer patients
Hancke K, Grubeck D, Hauser N, Kreienberg R,
Weiss JM, Germany
341Type distribution of Human Papillomaviruses in
non-familial breast cancer patients in Iran Haratian K, Mohseni Meybodi A, Iran
342Disturbed estrogen metabolism in endometrial
cancer Hevir N, Smuc T, Vouk K, Sinkovec J, Lanisnik Rizner T, Slovenia
343The effects of oestrogen on alternative splicing
regulators in breast cancer cells Hong E, Elliott D,
Tyson-Capper A, UK
344System-based changes of angiogenic growth factors in patients with external genital endometriosis
against the combined treatment Kulakova EV, Burlev VA, Shorohova MA, Ilyasova NA, Shchetinina
NS, Russia
345HLA-G gene polymorphism in breast cancer
Lorite Martínez P, Martínez Martos JM, Ramírez
Expósito MJ, Palomeque Messía T, Mayas MD,
Carrera P and Torres López MI, Spain
111
112
346Clinical management of patients with positive excision margin after cervical conization Malenkovic
G, Rajovic J, Mandic A, Novakovic P, Zivaljevic
M, Nincic D, Serbia and Montenegro
347Unusual morphologic pattern of endometrial cancer diagnosed by Transvaginal-Ultrasound Mariani
G, Rizzello F, Di Dato R, Caponi D, Riviello C,
Castellacci E, Coccia ME, Italy
348Altered endogenous oxytocin/oxytocinase system
modifies hypothalamus-pituitary-thyroid axis in
rats with breast cancer Martínez-Martos JM, Carrera MP, García MJ, Mayas MD, Ramírez Expósito
Mj, Spain
349Neoadjuvant chemotherapy modifies serum angiotensinase activities in women with breast cancer
Martínez-Martos JM, Lorite P, Torres MI, Carrera
P, Mayas MD, Ramírez Expósito MJ, Spain
350Serum beta HCG in cervical poorly differentiated
adenocarcinoma with dominant choriocarcinomatous pattern Nikolic B, Kuzmanovic I, DragojevicDikic S, Serbia and Montenegro
356Laparoscopic treatment of endometriosis and fecundity Ramos Rivas YVS, Pachero Romero J, Peru
357Medical treatment of Deep pelvic endometriosis:
effect on natural history and symptomatology
Rizzello F, Caponi D, Mariani G, Spitaleri M,
Castellacci E, Coccia ME, Italy
358Concept for centres of excellence for endometriosis
Schweppe K-W, Germany
359Changes In Bone Turnover Markers, Serum Lipids, Endometrium And Clinical Tolerability Of
Raloxifene In Estabilished Postmenopausal Osteoporosis In Indian women Singh M, India
360Estrogenic/progestogenic-regulated endometrial
responses to bisphenol a during decidual development in rats Spencer F, Thompson M, Qi L, USA
361Diagnostic markers of endometrial hyperplasia and
cancer Tikhonovskaya IV, Kuznetsova I, Nemtsova
M, Russia
362Menopause and malignancies Varisco EM, Livello
L, Stomati M, Pellegrino A, Italy
351Association the PCOS and endometrial carcinoma in young women Nölting M, Blanco G, Pérez
Lana MB, Onetto C, Straminsky V, Galluzzo L,
Argentina
363Hypoxia induces estrogen receptor mRNA repression in MCF-7 human breast cancer cells You K,
Bahn JJ, Jang S, Lee YJ, Korea
352Medroxyprogesterone acetate for surgically unresectable granulosa cell tumor Ota H, Oyama N,
Sato H, Japan
364Experience on the treatment of advanced ovarian
cancer Zambrano B, Diaz L, Santos M, Omaña D,
Venezuela
353Vaginal estriol to overcome side effects of aromatase inhibitors in adjuvant treated breast cancer
patients Pfeiler G, Glatz C, Königsberg R, Geisendorfer T, Fink-Retter A, Kubista E, Singer C, Seifert M, Austria
365Breast cancer and pregnancy: theories and guidelines Zampetaki C, Delimpalta C, Greece
354Pyrrolidone carboxypeptidase activity is related
to circulating levels of GnRH and FSH but not
LH in postmenopausal women with breast cancer
Ramírez-Expósito MJ, Torres MI, Lorite P, Carrera
P, Mayas MD, Martínez-Martos JM, Spain
355Mammary angiotensinase activities are modified
in rats with breast cancer induced by N-MethylNitrosourea Ramírez-Expósito MJ, Carrera MP,
García MJ, Mayas MD, Martínez Martos JM,
Spain
editing and copyright
Biomedical Technologies
art direction
Biomedical Technologies - Stefano Berti
photography
Alessandro Genazzani
printer
Istituto Arti Grafiche Mengarelli
www.iagmengarelli.it
Interaction with other drugs and other forms of interaction
No serious clinical interaction of Fostimon with other medicines has been reported.
A combination of Fostimon and other substances used for stimulation of ovulation,
can cause an increased follicular response, while concomitant therapy with GnRH
antagonist, which causes hypophyseal desensitiveness, may require an increased
dose of Fostimon, in order to obtain a satisfactory follicular response.
Incompatibilities of Fostimon with other drugs have not been reported.
Fostimon should not be mixed with other drugs in the same syringe.
Pregnancy and lactation
Fostimon must not be administered during pregnancy and lactation.
Effects on ability to drive and use machines
Fostimon does not cause any modification of these abilities.
Undesirable effects
Cases of headache have been reported following the administration of urofollitropin.
Rare cases of local reactions at the site of injection may occur.
Women: Fever and joint pain have been reported following the administration of urofollitropin. During a treatment with Fostimon, the likelihood of ovarian hyperstimulation should be taken into account. The first symptoms of ovarian hyperstimulation
are: pain in the lower abdomen, possibly in connection with nausea, vomit and
weight gain. In severe but rare cases, ovarian hyperstimulation syndrome with
enlargement of ovaries can be accompanied with an accumulation of fluid in the peritoneal cavity or thorax, as well as with more serious thromboembolic complications,
which can take place independently from ovarian hyperstimulation syndrome. In such
cases a thorough medical examination is recommended. Furthermore, a treatment
with Fostimon should be interrupted and the hCG administration withheld. The risk
of multiple pregnancy is increased with Fostimon, as well as with other substances
which are used for the stimulation of ovulation. The majority of multiple pregnancies
results in twin births: in IVF it is related with the number of replaced embryos. In rare
cases arterial thromboembolism has been associated with menotropin/hCG treatment, which could also occur during a treatment with Fostimon/hCG. The incidence
of miscarriage is comparable with that observed in women with other fertility problems. Ectopic pregnancy may occur in women with a history of tubal disorders.
Men: Occasionally gynecomastia (enlargement of breast), acne and weight gain during therapy with Fostimon/hCG can be observed.
These are known reactions observed during therapy with hCG.
Overdosage
The consequences of overdose with Fostimon are not known; nevertheless ovarian
hyperstimulation syndrome cannot be ruled out, as described in section “Special
warnings and Precautions”.
PHARMACOLOGICAL PROPERTIES
Pharmacodynamic properties
Pharmaco-therapeutic category: gonadotrophins and other drugs for ovulation
stimulation: urofollitropin. ATC Code: G03GA04.
Women: Fostimon contains urofollitropin, a hormone with sole follicle-stimulating
(FSH) activity, which is highly purified and extracted from human postmenopausal
gonadotrophin (hMG). The most significant result following parenteral administration
of FSH, is the development of mature Graaf follicles.
Men: Fostimon given in conjunction with hCG for a period of at least 4 months, can
produce spermatogenesis in men with FSH insufficiency.
Pharmacokinetic properties
Following single i.m. administration of 150 IU of urofollitropin to healthy volunteers
the highest level of FSH in serum was achieved within 10 ± 4 h. An increase of 4.0 ±
2 IU/L FSH above the basal values is obtained. The FSH levels in serum after 72 h
were still significantly higher than the basal values. The elimination half-time of FSH
has been estimated between 30-40 hours.
Preclinical safety data
In toxicological studies and studies performed in animals, no significant findings were
observed. Acute toxicity studies were performed in rats and mice, at doses above
than 1500 IU/kg. Sub-acute toxicity studies performed in rats and monkeys, included doses up to 100 IU/kg/day, for 13 weeks.
In mutagenesis studies urofollitropin did not reveal any mutagenic effects.
PHARMACEUTICAL PARTICULARS
List of excipients:
The powder vial contains: lactose
The solvent ampoule of 1 ml: contains: physiological solution
Incompatibilities:
There are not known chemical incompatibilities with Fostimon, however it is advisable not to mix this medicine with other products in the same syringe.
Shelf life:
24 months.
Special precautions for storage:
Protect from light and at a temperature below 25°C.
Nature and contents of the container:
Containers: vials with lyophilised powder and solvent ampoules (physiological solution) are made of transparent neutral glass (class I).
Packs: Fostimon 75 IU/1ml powder and solvent for solution for injection for intramuscular or subcutaneous use:
pack with 1 vial of lyophilized powder 75 IU + 1 ampoule of solvent,
pack with 5 vials of lyophilized powder 75 IU + 5 ampoules of solvent,
Fostimon 150 IU/1ml powder and solvent for solution for injection for intramuscular or subcutaneous use:
Instructions for use, handling
In order to avoid FSH waste due to adherence to the vial internal surface, Fostimon
should be administered immediately after reconstitution. The degree of absorption
that can take place has no significant effect on the dose required for clinical efficacy.
MARKETING AUTHORIZATION HOLDER
IBSA Farmaceutici Italia S.r.l. – Via Emilia 99, 26900 Lodi – Fraz. San Grato
MARKETING AUTHORIZATION NUMBER
Fostimon 75 IU/1ml powder and solvent for solution for injection for intramuscular
or subcutaneous use:
AIC n. 032921013
AIC n. 032921037,
AIC n. 032921049
AIC n. 032921025
AIC n. 032921052
AIC n. 032921064
DATE OF FIRST AUTHORIZATION / RENEWAL OF AUTHORIZATION
Fostimon 75 IU/1ml powder and solvent for solution for injection for intramuscular
or subcutaneous use:
pack with 1/5/10 vial of lyophilized powder 75 IU + 1/5/10 ampoule of solvent,
12/2003
pack with 1/5/10 vial of lyophilized powder 75 IU + 1/5/10 ampoule of solvent,
12/2003
DATE OF (PARTIAL) REVISION OF THE TEXT: 21 July 2006
113
Fostimon
Fostimon
TRADE NAME OF THE MEDICINAL PRODUCT
Fostimon 75 IU/ 1 ml powder and solvent for solution for injection for intramuscular
or subcutaneous use Fostimon 150 IU/ 1 ml powder and solvent for solution for
injection for intramuscular or subcutaneous use
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each vial contains:
75 IU vial
150 IU vial
Urofollitropin, corresponding to
Highly purified human urinary
Follicle stimulating hormone (FSH)
75 IU
150 IU
PHARMACEUTICAL FORM
Powder and solvent for solution for injection.
CLINICAL PARTICULARS
Therapeutic indications
Female sterility
Ovulation induction, in association with chorionic gonadotropin in patients suffering
from polycystic ovary disease; amenorrhoea or anovulatory conditions due to insufficient follicular phase; other infertility conditions associated with an increased
LH/FSH ratio.
Fostimon is indicated for the stimulation of multiple follicular development in women
undergoing ovulation induction during in-vitro fertilization programs (IVF) or other
Assisted Reproductive Techniques (FIVET-GIFT-ZIFT).
Male sterility
Induction of spermatogenesis in men suffering from hypogonadotropic hypogonadism, in association with human chorionic gonadotropin (hCG).
Dosage and method of administration
Women with hypothalamic-pituitary dysfunction associated with oligomenorrhea
or amenorrhea
The aim of the treatment is the development of a mature Graaf follicle from which
the ovule will be released, following the administration of chorionic gonadotrophin
(hCG). The therapy must start within the first 7 days of the menstrual cycle and can
be administered by daily injections. The dosage must be adjusted individually
depending on individual patient response, i.e. the follicle size, assessed by ultrasound and/or oestrogen secretion.
As a guideline, the following dosages are recommended: Daily administration of 75150 IU of Fostimon, which may be increased or decreased if required by stages of
37.5 IU (up to 75 IU) with intervals of 7 or 14 days in order to achieve a satisfactory
but not excessive response. If the patients response is not satisfactory after 4 weeks
of therapy, the cycle should be abandoned. Once a favourable response is obtained,
24-48 h following the last Fostimon injection, the administration of 10000 IU of hCG
is required. The patient should be advised to have sexual intercourse on the day of
the administration of hCG and on the following day. If there is an excessive response,
the therapy should be interrupted and the administration of hCG should be withheld
(see section “Precautions”). The therapy should continue with a cycle at a lower
dosage. Therapy should start the next cycle, with doses smaller than those during
the previous cycle.
Women undergoing superovulation treatment for IVF or other assisted reproductive techniques
Administer 150-225 IU of Fostimon daily starting on the 2nd or 3rd day of the cycle.
The dosage can be adjusted depending on individual response up to a maximum of
450 IU daily until the required follicular development is obtained, assessing it by
monitoring of oestrogen concentration and/or ultrasonography. As a general rule,
down-regulation is induced by administration of GnRH agonists in order to suppress
the surge of endogenous LH and to control the tonic levels. The most commonly
used protocol involves the use of Fostimon about 2 weeks after the onset of the
therapy with GnRH agonists: both treatments are continued until the required follicle development is achieved. A suggested treatment is to administer 225 IU of
Fostimon (s.c. or i.m.) during the first 7 days and subsequently adjust the dose
according to the ovarian response.
Men suffering from hypogonadotrophic hypogonadism
Pre-treatment: 2000 IU of hCG i.m. or s.c. twice a week (can be adapted to each case)
until normalization of testosterone blood levels.
Treatment: one vial of Fostimon 150 IU i.m. or s.c. three times a week in combination
with hCG 2000 IU i.m. or s.c. twice a week (or the dosage required for normalization
of testosterone blood levels) for 4 months, to be continued for up to 18 months,
depending on the physician decision in case of failed response.
Directions for use: Fostimon can be administered either intramuscularly, or subcutaneously. The injectable solution must be prepared by dissolving the freeze-dried
powder with the solvent provided in the pack. Fostimon must be administered
immediately after reconstitution. In order to avoid administration of large volumes, it
is possible to dissolve up to 5 vials of product in 1 ml of solvent.
Contraindications
Hypersensitivity to the active ingredient or one of the excipient in the formulation.
Women: Fostimon is contraindicated during pregnancy and lactation, ovarian
enlargement or cysts not due to polycystic ovarian syndrome; gynaecological bleeding of unknown origin, ovarian, uterus or breast tumors, hypothalamus and
hypophysis tumors.
Fostimon is contraindicated in women also in cases where no adequate response is
achievable, such as: primary ovarian failure; malformations of the genital organs
incompatible with pregnancy; uterus fibrinous tumors incompatible with pregnancy.
Men: Fostimon is contraindicated in men when a satisfactory response cannot be
achieved, e.g. in cases of primary insufficiency of the testis.
Special warnings and special precautions for use
Fostimon can cause local reactions at the site of injection. Allergic type reactions
have been reported occasionally, and lactose intolerance was assumed, although not
proven to be the problem. It is important to take into account the lactose reaction
when administering the product to patients with lactose intolerance.
Women: Before starting a treatment with Fostimon the couple infertility should be
assessed and any contraindications to pregnancy should be ruled out. Specifically,
patients should be examined to assess the potential presence of hypothyroidism,
adrenocortical insufficiency, hyperprolactinaemia and hypothalamic tumours or
tumours of hypophysis and appropriate specific treatment should be given. Although
the strict adherence to the recommended Fostimon dosage scheme minimizes the
risk of ovarian hyperstimulation, the likelihood of hyperstimulation and multiple ovulation should be taken into account and monitored during treatment. This syndrome
can progressively become a serious medical problem, which is characterized by
enlarged ovarian cysts which have a tendency for rupture. Severe hyperstimulation
due to excessive oestrogen response can be avoided by not administering hCG for
the induction of ovulation. In these cases it is wise to avoid the administration of hCG
and the patient should be advised not to have any sexual intercourse for at least 4
days. Patients with superovulation have an higher risk of developing hyperstimulation due to excessive oestrogen response and multi follicles development. The aspiration of all the follicles before the ovulation, may limit the onset of hyperstimulation.
The risk of multiple pregnancy following Assisted Reproductive Technologies is related with the number of oocytes/embryos that are transferred. In other patients the
risk of multiple deliveries and pregnancy is increased by the administration of
Fostimon, similarly to other products for the stimulation of ovulation, however, the
majority of multiple pregnancies results in the birth of twins.
The rate of miscarriage is higher than in the normal population, but comparable with
the one of women having other fertility disorders. In patients not submitted to superovulation the presence of smaller secondary follicles together with a predominant
follicle, which can be detected by ultrasonography, is related with the increased
onset of hyperstimulation.
Men: Increased levels of endogenous FSH are indicative of primary insufficiency
of testis.
These patients are unresponsive to a therapy with Fostimon/hCG. Sperm analysis is
advisable 4 to 6 months following the initiation of treatment, in order to determine the
response to therapy. Although no cases of viral contamination have ever been reported in association with the administration of human urinary gonadotrophins, the risk of
transmission of known or unknown pathogenic agents cannot be totally ruled out.
Cod. ZI.09.014
ta il punto di interazione tra folati e cobalamina.
5.2 Proprietà farmacocinetiche
Per le sue caratteristiche di molecola fisiologica il 5-MTHF viene utilizzato
dall’organismo come tale, senza cioè subire ulteriori processi di biotrasformazione. Esso costituisce la forma fisiologica di trasporto dell’acido
folico nel plasma, dove rappresenta la quasi totalità dei folati circolanti. È
prontamente assorbito dal tratto digestivo e, quindi, si distribuisce a tutti i
tessuti compreso il SNC; esso è infatti captato dai plessi corioidei nel liquido cefalorachidiano ove la sua concentrazione è pari a tre volte quella del
sangue. Il t½ del 5-MTHF per via endovenosa è di circa 2 ore, per via orale
di circa 2-3 ore. Viene eliminato per via renale ed intestinale.
6. INFORMAZIONI FARMACEUTICHE
6.1 Lista degli eccipienti
• PREFOLIC 15 Compresse Amido di mais, lattosio, magnesio stearato,
polietilenglicole 6000, polimetacrilati, polisorbato 80, simeticone, sodio
idrossido, talco.
• PREFOLIC 15 mg/3 ml polvere e solvente per soluzione iniettabile
Acido citrico, glutatione, mannite, metile p-idrossibenzoato, sodio idrossido.
Una fiala di solvente contiene: acqua per preparazioni iniettabili.
• PREFOLIC 50 mg/3 ml polvere e solvente per soluzione iniettabile Acido citrico, glutatione, mannite, metile p-idrossibenzoato, sodio idrossido. Una fiala di solvente contiene: acqua per preparazioni iniettabili. 6.2
Incompatibilità Non va addizionato a soluzioni contenenti bicarbonato.
6.3 Validità
• PREFOLIC 15 Compresse: 36 mesi
• PREFOLIC 15 mg/3 ml e PREFOLIC 50 mg/3 ml, polvere e solvente per soluzione iniettabile:
30 mesi - Il prodotto ricostituito rimane stabile per 10 ore.
6.4 Speciali precauzioni per la conservazione
Tenere al riparo dalla luce e conservare le compresse a una temperatura
inferiore ai 30°C.
6.5 Natura e capacità del contenitore
− Astuccio contenente 3 blister (alluminio-politene) da 10 compresse di 15 mg
− Astuccio contenente 5 flaconcini di vetro scuro a chiusura ermetica (tappo di gomma e ghiera metallica in alluminio) da 15 mg + 5 fiale di vetro
contenenti 3 ml di solvente
− Astuccio contenente 6 flaconcini di vetro scuro a chiusura ermetica (tappo di gomma e ghiera metallica in alluminio) da 50 mg + 6 fiale di vetro
contenenti 3 ml di solvente
6.6 Istruzioni per l’uso Modalità di apertura della fiala di solvente:
− posizionare la fiala come indicato nella
figura 1;
− esercitare una pressione con il pollice posto sopra il punto colorato come indicato
Figura 1
Figura 2
nella figura 2.
7. TITOLARE DELL’AUTORIZZAZIONE ALL’IMMISSIONE IN COMMERCIO
ZAMBON ITALIA s.r.l. - Via Lillo del Duca, 10 - 20091 Bresso (MI)
8. NUMERO DELL’AUTORIZZAZIONE
ALL’IMMISSIONE IN COMMERCIO
− 30 compresse di 15 mg - A.I.C. n. 024703124
− 5 flaconcini di polvere da 15 mg + 5 fiale di solvente da 3 ml - A.I.C. n.
024703098
− 6 flaconcini di polvere da 50 mg + 6 fiale di solvente da 3 ml - A.I.C. n.
024703112
9. DATA DI PRIMA AUTORIZZAZIONE/RINNOVO DELL’AUTORIZZAZIONE
− 30 compresse di 15 mg: 20.07.1989
− 5 flaconcini di polvere da 15 mg + 5 fiale di solvente da 3 ml:
30.04.1982
− 6 flaconcini di polvere da 50 mg + 6 fiale di solvente da 3 ml:
21.02.1985
Rinnovo autorizzazione: 01.06.2005
10. DATA DI (PARZIALE) REVISIONE DEL TESTO
27 gennaio 2009 Informazioni fornite ai sensi del Decreto Legislativo
n.219, Art 119, comma 3: Medicinale soggetto a prescrizione medica
• PREFOLIC 15 mg, 30 compresse – euro 19,90
• PREFOLIC 15 mg/3 ml, 5 flaconcini di polvere da 15 mg + 5 fiale di
solvente da 3 ml – euro 10,40
• PREFOLIC 50 mg/3 ml, 6 flaconcini di polvere da 50 mg + 6 fiale di
solvente da 3 ml – euro 21,20
Depositato presso AIFA in data 1/04/2009
RIASSUNTO DELLE CARATTERISTICHE DEL PRODOTTO
114 1. DENOMINAZIONE DEL MEDICINALE
PREFOLIC 15 Compresse
PREFOLIC 15 mg/3 ml polvere e solvente per soluzione iniettabile
PREFOLIC 50 mg/3 ml polvere e solvente per soluzione iniettabile
2. COMPOSIZIONE QUALITATIVA E QUANTITATIVA
• PREFOLIC 15 Compresse
Una compressa gastroresistente contiene:
Principio attivo: N5-metiltetraidrofolato di calcio pentaidrato - 19,18 mg
pari ad acido 15 mg
Un flaconcino di polvere contiene:
pari ad acido 15 mg
Un flaconcino di polvere contiene:
pari ad acido 50 mg
3. FORMA FARMACEUTICA
Compresse gastroresistenti - Flaconcini di polvere + fiale di solvente
4. INFORMAZIONI CLINICHE
4.1 Indicazioni terapeutiche In tutte le forme da carenza di folati dovute ad
aumentata richiesta, ridotto assorbimento, insufficiente apporto dietetico. Nella
terapia antidotica di dosi eccessive di antagonisti dell’acido folico e per combattere gli effetti collaterali indotti da aminopterina e da metotrexate.
4.2 Posologia e modo di somministrazione Dopo somministrazione orale
di PREFOLIC si ottiene un picco ematico a 2-3 ore che decade poi lentamente
nel tempo. La posologia media di PREFOLIC sia per via orale che per via parenterale intramuscolare o endovenosa può essere indicata in 15 mg al dì o a
giorni alterni secondo prescrizione medica. Il trattamento con PREFOLIC deve
essere prolungato fino a completa remissione dei sintomi della carenza folica
e ricostituzione del patrimonio endogeno. In casi eccezionali o nell’impiego
del PREFOLIC per l’antidotismo dei farmaci citotossici antifolici (ad esempio
nel caso di somministrazione di metotrexate ad alta dose), la posologia può
comportare l’uso di dosi più elevate, somministrate ad intervalli di poche ore:
15 mg per os ogni 6-8 ore oppure 50-100 mg per endovena ogni 3-8 ore per
qualche giorno in base ai parametri del “rescue”.
4.3 Controindicazioni Ipersensibilità nota verso i componenti.
4.4 Speciali avvertenze e precauzioni per l’uso Nel caso si faccia
ricorso alla somministrazione endovenosa si raccomanda di praticare l’iniezione lentamente. Nei soggetti epilettici i farmaci anticonvulsivanti possono
provocare un abbassamento della folatemia; la somministrazione di PREFOLIC, pur controbilanciando tale effetto, può aumentare la frequenza degli accessi. Le compresse sono gastroresistenti, liberano cioè il principio
attivo nell’intestino prossimale; esse non vanno masticate, ma debbono
essere deglutite intere, preferibilmente al mattino. In presenza di anemia
perniciosa è buona norma associare al PREFOLIC anche la vitamina B12 per
prevenire le complicazioni neurologiche della malattia.
4.5 Interazioni con altri medicinali e altre forme di interazione Non
sono note.
4.6 Gravidanza e allattamento Trattasi di composto vitaminico, normale
componente del nostro organismo, privo di effetti sulla madre e sul feto.
4.7 Effetti sulla capacità di guidare e di usare macchinari Non interferisce sulla capacità di guidare veicoli e sull’uso di macchinari.
4.8 Effetti indesiderati Con l’uso del prodotto sono possibili manifestazioni di ipersensibilizzazione (febbre, orticaria, ipotensione arteriosa, tachicardia, broncospasmo, shock anafilattico).
4.9 Sovradosaggio Non sono noti fino ad ora casi clinici di sovradosaggio.
5. PROPRIETÀ FARMACOLOGICHE
5.1 Proprietà farmacodinamiche
N5-metiltetraidrofolato di calcio (5-MTHF), molecola fisiologica di natura vitaminica, è un principio attivo che interviene negli organismi animali in una
serie di reazioni importanti, dal punto di vista biochimico-metabolico, finalizzate a realizzare il trasferimento dell’unità monocarboniosa. Tra queste
reazioni vanno in particolare ricordate le seguenti:
− a. la sintesi delle purine e del timidilato, tappa indispensabile per la biosintesi degli acidi nucleici;
− b. la sintesi ex-novo dei metili labili a partire da serina, glicina, istidina,
formiato;
− c. la sintesi della metionina a partire dall’omocisteina, reazione che richiede la presenza della vitamina B12 come cofattore e che pertanto rappresen-
best
A selection of the the courses
g
lessons held durin School
al
of the Internation
of Gynecological
Endocrinology
and Reproductive
rom
Abstracts f al
Gynecologic gy
Endocrinolo
News on hot topics
in science
and clinical practice
n°
The interview
3 questions to the editorial's Author...
1. What would be the most important determinations to
assess these risk factors for CVD in patients?
2. What do you consider the main variables that lead to
increased risk of cardiovascular disease?
3. What conduct should be taken to reverse the risk of
cardiovascular disease?
continue reading.
33 May 2009
The congress on-line
Lectures and simposya from
the 13th world congress on
human reproduction
News in science
and clinical practice
Abstracts
from Gynecological Endocrinology
And much more on www.gynendonews.com
13
GynEndo News
at ISGE 14th world congress
ROOM 13
13
Palazzo
dei Congressi
Entrance9to
Congressi
Ground Floor
Innovating
choices in
women’s health
The art of women’s health

Final Programme

Transcript

Documenti analoghi

percentuale di immobili venduti per fascia prezzo in Pinellas County

INGLESE - Mistretta Susanna - 2015-16

The Author and his Double

Stop Surrogacy Now Statement with Signatories LOCKED

Migrant Women For Development in Africa

Pantera rosa spartito

FlyOneluglioagosto08

Daniela Pedrini, SIAIS

Nickname per msn shqip

LA DOTE - Casa Internazionale delle Donne di Trieste